CN117500543A - Drug delivery device with balancing weights - Google Patents
Drug delivery device with balancing weights Download PDFInfo
- Publication number
- CN117500543A CN117500543A CN202280041055.XA CN202280041055A CN117500543A CN 117500543 A CN117500543 A CN 117500543A CN 202280041055 A CN202280041055 A CN 202280041055A CN 117500543 A CN117500543 A CN 117500543A
- Authority
- CN
- China
- Prior art keywords
- drug delivery
- delivery device
- housing
- dose
- longitudinal axis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000012377 drug delivery Methods 0.000 title claims abstract description 548
- 230000007246 mechanism Effects 0.000 claims description 216
- 239000003814 drug Substances 0.000 claims description 66
- 229940079593 drug Drugs 0.000 claims description 52
- 238000002347 injection Methods 0.000 claims description 22
- 239000007924 injection Substances 0.000 claims description 22
- 230000003287 optical effect Effects 0.000 claims description 22
- 239000000463 material Substances 0.000 claims description 12
- 230000000295 complement effect Effects 0.000 claims description 9
- 239000003550 marker Substances 0.000 claims description 7
- 239000002184 metal Substances 0.000 claims description 6
- 230000008878 coupling Effects 0.000 description 108
- 238000010168 coupling process Methods 0.000 description 108
- 238000005859 coupling reaction Methods 0.000 description 108
- 230000000670 limiting effect Effects 0.000 description 56
- 239000011295 pitch Substances 0.000 description 39
- 238000003780 insertion Methods 0.000 description 19
- 230000037431 insertion Effects 0.000 description 19
- 239000008186 active pharmaceutical agent Substances 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 230000013011 mating Effects 0.000 description 8
- 230000008901 benefit Effects 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000005096 rolling process Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 238000007789 sealing Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000006835 compression Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002783 friction material Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000001746 injection moulding Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000004323 axial length Effects 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
Landscapes
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
A drug delivery device comprising: an elongated, e.g., generally cylindrical, housing extending along a longitudinal axis between a distal end and a proximal end; and a balance weight located within the housing, wherein a centroid of the drug delivery device is positioned radially offset in a radial direction from the longitudinal axis towards the balance weight.
Description
Technical Field
The present disclosure relates to a drug delivery device.
Background
To date, drug delivery devices that may be used for self-administration of a medicament by non-medically trained persons, such as for example patients, have become more and more complex in view of their dose setting mechanism and/or their dose delivery mechanism. Uses of such devices may include, for example, diabetics, where drug management (i.e., the extent to which a patient adheres to medical instructions and procedures that may originate from a medically trained person such as a doctor) is often extremely important. Among the known types of drug delivery devices that can be manually, semi-automatically or automatically actuated to expel a drug from a drug compartment, pen-type devices have become very popular.
For drug delivery devices in general, and in particular for drug delivery devices designed for use by medically untrained persons, it is desirable that the design of such devices allows for easy and safe use. In particular, the design should be adapted to prevent injury from potentially harmful components of the device (e.g. the needle) and ensure that the part of the device in contact with the patient and/or the drug to be administered remains sterile during use of the device.
For devices that include an elongated, substantially cylindrical housing, such as a pen-type device, potentially dangerous situations that may lead to injury or contamination of the device include situations where a user places such a device on a flat surface, such as a surface of a table or the like. These situations may occur, for example, when the user relaxes after injection with the device. The device may then start rolling over the surface and eventually fall off the surface, e.g. towards the patient or the floor.
The rolling of the generally cylindrical drug delivery device is typically prevented by an asymmetric feature provided on the outer surface of the device, such as a protruding element of the housing or an asymmetric shape. Such features may be incorporated, for example, into a cap placed on one end of the device, or into an actuation member disposed at the other end of the device. The features incorporated into the cap have in particular the disadvantage that they are not effective when the cap is removed during use of the device, for example immediately after medicament delivery. Features, such as actuation members, provided at other portions of the housing may interfere with a user during use of the device.
Accordingly, there is a need to improve the safety during use of the drug delivery device in a way that does not interfere with the user using the device. In particular, there is a need to thereby improve safety by preventing the drug delivery device from rolling off a flat surface.
Disclosure of Invention
The present disclosure provides a drug delivery device according to the independent claims. Embodiments are given in the dependent claims, the description and the drawings.
In one aspect, the present disclosure relates to a drug delivery device, such as an injection device, like a pen-type injector, having an elongated, e.g. substantially cylindrical, housing extending along a longitudinal axis between a distal end and a proximal end, wherein the drug delivery device comprises a balancing weight located within the housing, and wherein a centre of mass of the drug delivery device is positioned radially offset from the longitudinal axis towards the balancing weight in a radial direction.
By providing a balancing weight within the housing and thereby moving the centre of mass of the drug delivery device away from the longitudinal axis, the drug delivery device is effectively prevented from rolling on a flat surface. Conversely, when placed in such a surface, the drug delivery device will orient itself in such a way that the centroid lies substantially between the surface and the longitudinal axis. By positioning the balancing weight within the elongated housing in a suitable manner, the drug delivery device may be forced to assume a well-defined rotational position when it is placed on a flat surface.
The housing may be configured as an outer housing of the device such that the outer surface of the housing also forms the outer surface of the drug delivery device. The drug delivery device may comprise an additional housing element which is rotationally and axially fixed relative to the housing. Such additional housing element may be, for example, an inner housing located within the housing or a piston guide defining an opening for receiving a piston rod of the device. The balancing weight may then be located outside one, more or all of the additional housing elements, for example outside the inner housing, so as to be located between the outer housing and the inner housing.
The drug delivery device may have a substantially cylindrical housing, e.g. a cylindrical housing.
The balance weight may be configured as a separate component. For example, the balancing weight may be configured as a separate component from the housing of the device. The balancing weight may also be configured to be separate from all functional components of the drug delivery device.
For example, the balance weight may be configured as a single unitary member. The balance weight may be made of a single material, such as a casting, molded member, milled member, or lathed member. For example, the balance weight may be configured as a sheet metal component.
The balancing weight may also be configured as a member integral with the housing of the device. For example, the balance weight and the housing portion of the apparatus may be configured as a single unitary and/or monolithic member, such as a single cast, molded, milled, or machined member. For example, the balance weight and the outer or inner housing of the device may be configured as a single integral and/or monolithic member. Typically, the balancing weight may be integrated with a functional component of the drug delivery device, such as a housing, a dose setting member, a dosing member or the like.
The balancing weights may be configured as flat and/or thin components. As a thin component, the balancing weight has a height that is less than its length, for example 1/2, 1/5 or 1/10 of its length, and also less than its width, for example 1/2, 1/5 or 1/10 of its width. The balance weight may be oriented within the housing with its height radially away from the longitudinal axis. For example, the balance weight may be configured as a thin member that is curved.
The balancing weight may have a bottom surface facing the longitudinal axis and/or a top surface facing away from the longitudinal axis. The bottom surface and the top surface may be oriented parallel to each other. The bottom surface may be configured as a curved and/or concave surface. Additionally or alternatively, the top surface may be configured as a curved and/or convex surface.
Typically, the balance weight may be curved about a longitudinal axis. For example, the bottom surface and/or the top surface may be curved about a longitudinal axis. The bottom surface and/or the top surface may form part of a cylindrical surface having a central axis coinciding with the longitudinal axis.
The shape of the balance weight may be symmetrical with respect to a central plane of the balance weight oriented perpendicular to the longitudinal axis.
The contact surface of the drug delivery device may be defined substantially by all surface elements of the drug delivery device which contact a flat surface when the device is rolled over said surface. Thus, in case the drug delivery device is in a drug administration state and ready for drug delivery, e.g. after the cap of the device has been removed, the first contact surface may be provided by all surface elements contacting the planar surface. Additionally or alternatively, the second contact surface may be formed by all surface elements contacting the planar surface when the drug delivery device is in a storage state, e.g. when the cap is attached to the device. The second contact surface in the storage state may be different from the first contact surface in the administration state, or it may be the same as the first contact surface in the administration state.
The contact surface, e.g. the first and/or the second contact surface, may be entirely within a cylindrical surface about the longitudinal axis. For example, the first contact surface may be located entirely within the cylindrical surface, while the second contact surface may be offset from the cylindrical surface about the longitudinal axis. For example, the second contact surface may have a protrusion, e.g. a protrusion provided at the cap of the device. Such a projection may be produced, for example, by a clip of the device.
The contact surface, e.g. the first contact surface, may be provided by an outer surface of the housing of the device. The contact surface and/or the outer surface may have holes, such as windows and/or recesses, etc.
Generally, the housing of the device may have a smooth outer surface. For example, the outer surface may be free of protrusions or the like. The outer surface may be, for example, a cylindrical surface about a longitudinal axis.
While the centre of mass of the drug delivery device is radially offset in a radial direction from the longitudinal axis towards the balancing weight, it may also not be located between the balancing weight and the longitudinal axis. Instead, the center of mass may be moved away from the balance weight along the longitudinal axis and may be positioned axially beside the balance weight in the distal direction or in the proximal direction.
The balancing weight may be placed within an angular region of at least 180 °, at least 120 °, at least 90 °, at least 80 °, or at least 60 ° about the longitudinal axis. The angular region may be at most 60 °, at most 70 °, at most 90 °, or at most 120 °.
According to an embodiment, the distance between the radial position of the balancing weight and the radial position of the centroid is greater than the distance between the radial position of the centroid and the longitudinal axis. Locating the centroid at a smaller distance from the longitudinal axis than the balancing weight allows for the use of a relatively small balancing weight while still moving the centroid away from the longitudinal axis.
According to an embodiment, the balancing weight and the housing window for displaying the optical indicia indicative of the set dose are located at different angular positions with respect to the longitudinal axis, e.g. at angular positions 180 ° apart. Thus, when the device is in its stable position under the influence of the balancing weight, the window of the housing does not face the flat surface. Thus, the user of the device can still read the optical marks that are visible through the window.
According to an embodiment, the material of the balancing weight has a higher density than the material of most components of the dosing mechanism of the drug delivery device. The higher density of the balancing weight ensures that the balancing weight causes the centre of mass to move away from the longitudinal axis, which movement is large enough to ensure that the drug delivery device is in a stable position on a flat surface.
The balancing weight may be made of, for example, metal, such as stainless steel. Additionally or alternatively, the material of most components of the dosing mechanism of the drug delivery device may be a plastic material.
The dosing mechanism of the drug delivery device may comprise all elements that move relative to the housing of the device during setting of a dose of medicament to be delivered by the device and/or during delivery of the medicament.
According to an embodiment, the balancing weight is located at an inner surface of a shell of a housing (housing) of the drug delivery device. This provides a large effect of the balancing weight on the radial position of the centroid. The balance weight may be configured to contact an inner surface of the shell, e.g., the balance weight may rest against the inner surface of the shell. The shell of the housing may be an outer wall of the housing of the device, for example an outer wall of an outer housing.
According to an embodiment, the balancing weight is configured to be separate from a component of the dosing mechanism of the drug delivery device, wherein the balancing weight is for example located radially outside the dosing mechanism. Forming the balance weight separate from the dosing mechanism ensures that the balance weight does not move relative to the housing of the device. Thus, the device assumes a well-defined equilibrium position on a flat surface. Placing the balancing weights radially outward from the dosing mechanism also ensures that they have a relatively large effect on the radial position of the centroid.
The balancing weight may be located between the housing and the dosing mechanism.
The balancing weight may also be configured to be integral with at least one component of the dosing mechanism of the drug delivery device. For example, the member and the balance weight may form a single unitary member.
According to an embodiment, the housing comprises an outer housing and the drug delivery device comprises an inner housing. Thus, the inner housing is permanently rotated and/or axially fixed relative to the outer housing, and the balancing weight is located between the outer housing and the inner housing. This allows stable positioning of the balance weight in the radial direction between the inner housing and the outer housing. Furthermore, it provides a large distance between the longitudinal axis and the balancing weights.
The balancing weight may rest on an outer surface of the inner housing, for example. Additionally or alternatively, the balancing weight may rest against an inner surface of the outer housing. This allows the radial position of the balance weight to be easily fixed.
According to an embodiment, the balancing weight is axially and/or rotationally fixed relative to the housing. This ensures that the drug delivery device assumes a well-defined position under the influence of the balancing weight. Furthermore, it increases the safety of the device during use by avoiding distraction of the user due to movement of the balancing weight within the housing.
The balance weight may be secured to the housing by glue or a securing means such as screws or the like. The balancing weight can also be fixed to the housing by a form fit between the balancing weight and at least one counter element fixed relative to the housing, for example the housing itself or a component separate from the housing but axially and/or rotationally fixed relative to the housing. The balance weight may be secured to the housing solely by the form fit, thereby providing a connection to the housing without glue or other securing means.
According to an embodiment, the balancing weight is accommodated in a holder configured to fix the balancing weight axially and/or rotationally with respect to the housing. Such a stand provides for easy assembly of the drug delivery device.
The mount may provide a form fit that axially and/or rotationally secures the balance weight to the housing. The support may be provided directly by the housing and/or by an element (e.g. an inner housing) which is axially and/or rotationally fixed relative to the housing. This facilitates assembly of the drug delivery device.
The abutment may be provided at an outer surface of the inner housing of the drug delivery device. The outer surface may be formed complementary to the bottom surface of the balance weight. The outer surface may support the balance weight such that the balance weight is prevented from moving in a radial direction toward the longitudinal axis.
According to an embodiment, the abutment comprises a longitudinal stop element preventing the balancing weight from moving along the longitudinal axis. Additionally or alternatively, the mount may include a circumferential stop element that prevents the balance weight from moving about the longitudinal axis. Each of the stop elements may provide a form fit to limit movement of the balance weight.
The stop elements may each include at least one stop surface limiting movement of the balance weight relative to the housing, and the balance weight may rest on the stop surfaces. The stop surfaces of the longitudinal and/or circumferential stop elements may be oriented parallel to the radial direction of the drug delivery device. The stop surface of the longitudinal stop element may be oriented perpendicular to the longitudinal axis and/or the stop surface of the circumferential stop element may be oriented parallel to the longitudinal axis.
The stop element may be configured as a protrusion on a surface of the drug delivery device. For example, the stop element may be configured as a protrusion on an outer surface of the inner housing of the drug delivery device. The stop surface of such a stop element may then be provided by a side surface of the projection.
The drug delivery device may comprise several longitudinal stop elements and/or several circumferential stop elements. For example, a balancing weight may be placed between the two longitudinal stop elements. Additionally or alternatively, a balancing weight may be placed between the two circumferential stop elements.
According to an embodiment, a housing (such as an outer housing of the housing) is configured to cover the abutment in a radial direction perpendicular to the longitudinal axis to prevent radial movement of the balance weight. Thus, the outer housing may limit the radial movement of the balance weight by providing a form fit with the balance weight. The abutment may for example be covered by the inner surface of the outer casing.
According to an embodiment, the balancing weight has a bottom surface, e.g. a curved and/or concave bottom surface, wherein the bottom surface faces radially to the longitudinal axis. The bottom surface is formed complementary to a surface of one or more components of the drug delivery device located between the longitudinal axis and the counter weight and/or between the longitudinal axis and the outer housing. The bottom surface may for example be formed complementary to an outer surface of the inner housing of the drug delivery device.
According to an embodiment, the balancing weight has a top surface, e.g. a curved and/or convex top surface, wherein the top surface faces radially away from the longitudinal axis. The top surface is formed complementary to one or more inner surfaces of a housing of the drug delivery device. The bottom surface may for example be formed complementary to an inner surface of an outer housing of the drug delivery device.
The outer surface of the one or more members and the inner surface of the housing may be oriented parallel to each other. The outer surface and/or the inner surface may form part of a cylindrical surface.
According to an embodiment, the drug delivery device comprises a piston rod configured to move along a longitudinal axis to expel a drug from a drug compartment connected to the housing. The piston rod may be part of a dosing mechanism of the drug delivery device. The piston rod may be rotationally fixed with respect to the housing during dose setting and/or dose delivery. The drug compartment may be part of a cartridge, which may be attached to the housing, e.g. via a cartridge holder or directly via a connection means provided at the cartridge.
Drawings
Exemplary embodiments and functions of the present disclosure are described herein in connection with the following drawings, which schematically illustrate:
fig. 1 shows a perspective view of a drug delivery device according to the present disclosure with a cap attached;
fig. 2 shows a perspective view of the drug delivery device with the cap removed and the dispensing unit attached;
fig. 3 shows a perspective view of the drug delivery device, cap and dispensing unit;
fig. 4 shows a side view of a dispensing unit comprising a cartridge holder and a cartridge and a needle attachable to the dispensing unit;
Fig. 5 shows a longitudinal section through the first cross-sectional plane of the drug delivery device, the dispensing unit and the cap, wherein the drug delivery device is in a dose setting state;
fig. 6 shows a longitudinal section through the drug delivery device, the first dispensing unit and the cap through a second cross-sectional plane perpendicular to the first cross-sectional plane, wherein the drug delivery device is in a dose setting state;
fig. 7 shows an exploded partial view of the dosing mechanism of the drug delivery device;
fig. 8 shows a longitudinal section through a first cross-sectional plane of a dosing mechanism of a drug delivery device before setting a dose;
fig. 9 shows a longitudinal section through the first cross-sectional plane of the dosing mechanism after setting a dose, the dosing mechanism being in a dose setting state;
fig. 10 shows a longitudinal section through the first cross-sectional plane of the dosing mechanism after setting a dose, the dosing mechanism being in a dose delivery state;
fig. 11 shows a longitudinal section through the first cross-sectional plane of the dosing mechanism after delivery of a dose, the dosing mechanism being in a dose setting state;
fig. 12 shows the coupler mechanism of the dosing mechanism in a dose setting state;
Fig. 13 shows the coupler mechanism in a dose delivery state;
fig. 14 shows a radial section through a dose limiting mechanism of a drug delivery device;
fig. 15 shows a perspective view of the proximal side of the dose setting member of the drug delivery device;
fig. 16 shows a perspective view of the distal side of the coupling member of the drug delivery device;
fig. 17 shows a perspective view of the proximal side of the coupling member of the drug delivery device;
fig. 18 shows a longitudinal section through a dosing member and a dose selector member of a drug delivery device with a first friction reducing mechanism;
fig. 19 shows a perspective view of the connection between the nut and the driver of the drug delivery device with the second friction reducing mechanism;
fig. 20 shows a perspective view of a dosing member of the drug delivery device;
fig. 21 shows a longitudinal section through the inner housing of the drug delivery device;
FIG. 22 shows a perspective view of the inner housing with the dosing member in a zero dose position;
fig. 23 shows a perspective view of the inner housing with the dosing member in a maximum dose position;
fig. 24 shows a longitudinal section through an outer housing of the drug delivery device;
Fig. 25 shows a longitudinal section through an inner housing mounted within an outer housing of a drug delivery device;
fig. 26 shows a radial section through the outer housing and the inner housing of the drug delivery device;
fig. 27 shows an exploded partial view of a reset mechanism of the drug delivery device;
fig. 28 shows a longitudinal section through a reset mechanism of a drug delivery device with the reset element in a proximal position;
FIG. 29 shows a distal perspective view of a reset element of the reset mechanism;
FIG. 30 shows a proximal perspective view of the reset element;
FIG. 31 shows a proximal perspective view of a coupling portion of the reset mechanism;
fig. 32 shows a perspective view of the coupling portion and the inner housing;
fig. 33 shows a longitudinal section through the reset mechanism with the dispensing unit attached to the drug delivery device and the reset element in a distal position;
fig. 34 shows a longitudinal section through the proximal end of a cartridge holder attachable to a drug delivery device;
fig. 35 shows a perspective distal view in radial section through the proximal portion of the cartridge holder;
fig. 36 shows a longitudinal section through a first dispensing unit attachable to a first drug delivery device, a longitudinal section through a second dispensing unit attachable to a second drug delivery device, and a longitudinal section through a third dispensing unit attachable to a third drug delivery device;
Fig. 37 shows a longitudinal section through the first connecting means and a perspective view of the first connecting means of the first drug delivery device, a longitudinal section through the second connecting means and a perspective view of the second connecting means of the second drug delivery device and a longitudinal section through the third connecting means and a perspective view of the third connecting means of the third drug delivery device;
fig. 38 shows a perspective view of other drug delivery devices according to the present disclosure;
fig. 39 shows the other drug delivery device with the cap removed;
fig. 40 shows an exploded view of the other drug delivery device;
fig. 41 shows a coupling mechanism of the other drug delivery device;
fig. 42 shows a dose setting member of the other drug delivery device;
fig. 43 shows a dose selector member of the other drug delivery device;
fig. 44 shows an alternative embodiment of a reset element of the drug delivery device;
FIG. 45 shows a longitudinal section through an alternative embodiment of a reset element;
fig. 46 shows an alternative embodiment of a coupling portion of a drug delivery device;
fig. 47 shows an alternative embodiment of the reset element and an alternative embodiment of the coupling portion mounted to an alternative embodiment of the inner housing of the drug delivery device;
Fig. 48 shows a perspective view of an alternative connection between a further alternative embodiment of the inner housing and an alternative embodiment of the dose selector member;
fig. 49 shows a longitudinal section through a further alternative embodiment of the inner housing and an alternative embodiment of the dose selector member;
FIG. 50 shows an alternative embodiment of the inner housing, the dose selector member and the dosing member, wherein the dosing member is in a zero dose position;
FIG. 51 shows an alternative embodiment of the inner housing, the dose selector member and the dosing member, wherein the dosing member is in a maximum dose position;
FIG. 52 illustrates an alternative embodiment of a coupler member;
FIG. 53 shows a further alternative embodiment of a drug delivery device having an inner housing with a balancing weight located on an outer surface of the inner housing;
fig. 54 shows a radial section perpendicular to the longitudinal axis through a drug delivery device with a balancing weight;
FIG. 55 shows an alternative embodiment of the inner housing;
FIG. 56 illustrates a balance weight;
fig. 57 shows a radial section perpendicular to the longitudinal axis through an alternative embodiment of a drug delivery device with a balancing weight;
Fig. 58 shows a longitudinal section through the first, second and third dispensing units, which shows additional dimensions;
fig. 59 shows a longitudinal section through the first, second and third connection means of the first, second and third drug delivery device, showing additional dimensions and perspective views of the first, second and third connection means.
Detailed Description
In the present disclosure, the term "distal portion/end" refers to the following portions/ends of the device or parts or members thereof: depending on the use of the device, the portion/end is positioned furthest from the delivery/injection site of the patient. Accordingly, the term "proximal portion/end" refers to the following portion/end of the device or of a component or member thereof: depending on the use of the device, the portion/end is positioned closest to the delivery/injection site of the patient. The proximal direction points toward the delivery/injection site and the distal direction points away from the delivery/injection site.
The present disclosure of a balancing weight is applicable to a variety of medicament delivery devices, e.g., injection devices. One possible injection device is the pen-type design illustrated in fig. 1.
Fig. 1 shows a drug delivery device 200 according to the present disclosure, comprising connection means for attaching a dispensing unit. The drug delivery device 200 has a generally tubular housing 210, the generally tubular housing 210 being elongated along a longitudinal axis 207. A generally tubular cap 209 is attached to the proximal end 205 of the housing 210. At the distal end 206 of the housing 210 (the distal end 206 being positioned opposite the proximal end 205 along the longitudinal axis 207), the drug delivery device 200 comprises a dose setting member 290.
The dose setting member 290 is rotatable about the longitudinal axis 207 and is configured to be gripped and rotated by a user of the device 200 to set a dose to be delivered by the device 200. In this way, the dose setting member 290 may also be regarded as a knob or the like. In the embodiment shown in fig. 1, the dose setting member 290 is configured as a knob terminating the drug delivery device 200 at its distal end 206. For other embodiments, the dose setting member 290 may also be configured as a rotatable sleeve or ring surrounding the longitudinal axis 207, for example.
The dose setting member 290 is connected to the housing 210 via a dose selector member 310, the dose selector member 310 being rotationally locked and axially movable relative to the housing 210 during dose setting and during dose delivery. When the set dose is increased by rotating the dose setting member 290 relative to the housing 210 and the dose selector member 310, the dose selector member 310 moves distally out of the housing 210, thereby also moving the dose setting member 290 in the distal direction.
The housing 210 includes an outer housing 211 (which is made of metal in the present embodiment) and an inner housing 180. The inner housing 180 is located within the outer housing 211. In this embodiment, the inner housing 180 is made of a plastic material. The housing 210 includes a window (which is formed by window 211a in the outer housing 211) through which a user of the device 200 can see a portion of the inner housing 180 and the window 180a in the inner housing 180. The dose indicating member 330 is visible to a user through a window of the housing 210, the dose indicating member 330 being located inside the housing 210, i.e. inside the generally tubular inner housing 180.
The dose indicating member 330 is also configured as a generally tubular member and carries a dose scale on its outer cylindrical surface comprising a number of optical marks 331, the optical marks 331 corresponding to the respective set doses. When setting a dose, the dose indicating member 330 rotates within the inner housing 180, which changes the position of the scale and thus also the optical indicia 331 visible through the windows 211a and 180 a.
Fig. 2 shows the drug delivery device 200 with the cap 209 removed. A dispensing unit 410 comprising a medicament to be delivered by the device 200 is removably attached to the proximal end 205 of the housing 210. Fig. 3 shows cap 209 and dispensing unit 410 removed from drug delivery device 200. With the cap 209 and dispensing unit 410 attached to the housing 210 of the device 200, the dispensing unit 410 is fully received within the cap 209.
The dispensing unit 410 comprises a cartridge holder 412, the cartridge holder 412 being made of a plastic material in the present embodiment. The cartridge holder 412 may be formed, for example, by injection molding. The cartridge holder 412 is attached to the outer housing 211 of the drug delivery device 200 via a connection comprising a first connection means 510 at the proximal end of the housing 210 and a corresponding first connection means 414 at the distal end of the dispensing unit 410. The first connection means 510 of the housing 210 is formed as an integral part of the housing 210, i.e. as an integral part of the outer housing 211, and the first connection means 414 of the dispensing unit 410 is formed as an integral part of the cartridge holder 412.
At its proximal end, the cartridge holder 412 of the dispensing unit 410 comprises a needle connector 402, the needle connector 402 being configured to receive a hollow needle or cannula through which the drug delivery device 200 delivers a drug. In this embodiment, the needle connector 402 is configured as a threaded connector. For other embodiments, the needle connector 402 may also be configured as, for example, a snap fit, bayonet, or luer lock connection (Luer lock connection).
Fig. 4 shows a cartridge holder 412 of a dispensing unit 410 and a cartridge 8 that can be inserted into the cartridge holder 412 and a needle 4 that can be attached to a needle connector 402.
The cartridge 8 has a generally cylindrical body, which in this embodiment is made of glass, and which surrounds a drug compartment 81, the drug compartment 81 containing a liquid drug to be delivered by the drug delivery device 200. The drug compartment 81 is sealed at its distal end by a resilient plunger 9, the resilient plunger 9 being movable along a longitudinal axis within the body of the cartridge 8. At its proximal end, the cartridge 8 comprises an annular rim 82, the annular rim 82 being separated from the body by an annular pawl 85 located distally from the annular rim 82. At the proximal front surface of the cartridge 8, which is oriented perpendicular to the longitudinal axis 207, the cartridge 8 comprises a sealing means or septum 8a, which sealing means or septum 8a seals the drug compartment 81 in the proximal direction.
When fully inserted into the cartridge holder 412, the sealing means 8a is located at the proximal end of the cartridge holder 412 and is accessible through an opening at the proximal end of the cartridge holder 412. The cartridge 8 is non-releasably held in its inserted position by the connector 404. The connector 404 is configured as a flexible member. In this embodiment, it is configured as a snap hook. The connector 404 is formed by a cut-out portion of the cartridge holder 412. The connector 404 snaps over the annular rim 82 of the cartridge 8 when the cartridge 8 is inserted into the cartridge holder 412. The radially inwardly projecting fingers of the connector 404 are then located within the annular detent 85 of the cartridge 8 and prevent distal movement of the cartridge 8 by abutting against the distal surface 83 of the annular rim 82.
This non-releasable connection between the cartridge 8 and the cartridge holder 412 prevents removal of the cartridge 8 from the cartridge holder 412 during the intended use of the dispensing unit 410. For example, it prevents removal of the cartridge 8 unless the connector 404 is intentionally and/or forcibly out of engagement with the annular rim 82. Thus, the non-releasable connection is configured in the following manner: such disengagement is possible only with a tool or an excessive force that is larger than the force acting on the non-releasable connection during normal and/or intended use of the dispensing unit 410 (e.g. during mounting of the dispensing unit 410 to the housing 210, during attachment of the needle 4 to the cartridge holder 412 or during handling of the dispensing unit 410 with the cartridge 8 inserted into the cartridge holder 412). This manipulation may also include impact forces that may occur during transport and/or unintentional dropping of the dispensing unit and that do not apply forces that would damage the dispensing unit 410 and/or the cartridge holder 412 and/or the cartridge 8. This non-releasable connection between the cartridge 8 and the cartridge holder 412 allows the dispensing unit 410 with the inserted cartridge 8 to be provided and sold as a single pre-installed unit.
The needle 4 is configured as a pen needle. Which comprises a hub 5 carrying a double ended cannula 6. The cannula 6 is received longitudinally within the hub 5. Hub 5 includes a hub connector at its distal end that mates with needle connector 402 of cartridge holder 412. In this embodiment, the hub connector is configured to mate with the internal threads of the external threads of the needle connector 402. A cannula 6 protrudes from the proximal end of the hub 5. Which has sharp ends at both its proximal and distal ends. By means of its distal end, the cannula 6 penetrates the sealing means 8a of the cartridge 8 and thus a fluid connection is established between the drug compartment 81 and the proximal end of the cannula 6. The proximal end of the cannula 6 is configured to be inserted into a delivery site, such as the skin of a user of the device 200, thereby permitting injection of a drug into the delivery site.
Fig. 5 and 6 show longitudinal sections through the drug delivery device 200 along two different cross-sectional planes oriented perpendicular to each other. Fig. 7 shows a partial exploded view of the components of the drug delivery device 200 seen in fig. 5 and 6. The drug delivery device 200 comprises a dosing mechanism 230, the dosing mechanism 230 being configured to set a dose of drug to be delivered by the drug delivery device 200 and expel the set dose by moving the plunger 9 in a proximal direction.
The dosing mechanism 230 comprises a piston rod assembly having a piston rod 240 elongated along a longitudinal axis 207 and a plunger disc 242 mounted to a proximal end of the piston rod 240 (see fig. 5 and 6). The piston rod assembly is configured to directly contact the plunger 9 via the plunger disc 242 and to advance the plunger 9 within the cartridge 8 when the piston rod assembly is moved in the proximal direction. The piston rod 240 has a non-circular cross-section and an external thread 241 covering substantially its entire length. At its proximal end, the piston rod 240 includes a disk connector 244 for receiving the plunger disk 242. At its distal end, the piston rod 240 comprises a stop feature 243 terminating the external thread 241 and being exemplarily configured as a thickened portion of the piston rod 240 having a radial extent larger than the minor diameter of the thread 241.
The piston rod 240 is located within the housing 210, with the housing 210 being within the outer housing 211 and the inner housing 180. In use, the piston rod 240 may protrude from the proximal end of the housing 210 such that the plunger disc 242 may be moved completely out of the housing 210 and into the cartridge 8. The piston rod 240 always protrudes from the proximal end of the inner housing 180. For example, after resetting and/or before and/or immediately after attaching a new dispensing unit 410 to the device 200, the piston rod 240 may be fully retracted into the outer housing 211. During use of the device 200, the piston rod 240 is moved in a proximal direction so as to also protrude from the outer housing 211. For example, after completion of the reset operation and/or before and/or immediately after attaching a new dispensing unit 410 to the device 200, the plunger disc 242 is permanently located outside the inner housing 180 and may be fully retracted into the outer housing 211.
During both dose setting and dose delivery, the piston rod 240 is rotationally locked with respect to the housing 210. In the present embodiment, the piston rod 240 is connected to the housing 210 via the reset element 110 of the reset mechanism 100 of the drug delivery device 200, see fig. 5 and 6. During both dose delivery and dose setting, the reset element 110 is rotationally fixed relative to the housing 210. It includes a longitudinal opening 114 that receives the piston rod 240 such that the plunger disc 242 is located at a proximal side of the opening 114 and the stop feature 243 is located at a distal side of the opening 114. The opening 114 is configured as a through hole having a non-circular cross section matching the non-circular cross section of the piston rod 240, allowing axial movement but preventing rotational movement of the piston rod 240 relative to the reset element 110.
The piston rod 240 is surrounded by a hollow generally cylindrical nut 250. The nut 250 is threadedly engaged with the thread 241 of the piston rod 240. In this embodiment, the nut 250 includes a threaded section having internal threads 256, the internal threads 256 engaging the external threads 241 of the piston rod 240. The threaded section is located in a proximal portion 251 of the nut 250 at the proximal end of the nut 250. For other embodiments, the threaded section may also cover other portions of the nut 250 or be located at other portions of the nut 250. The nut 250 further permanently surrounds the stop feature 243 of the piston rod 240, irrespective of the set and/or delivered dose.
The nut 250 has a distal portion 252 surrounded by a proximal portion 274 of the coupler member 270 of the dosing mechanism 230. The nut 250 is rotationally fixed to the coupler member 270 and is axially movable relative to the coupler member 270.
In this embodiment, the nut 250 engages the coupler member 270 through a splined connection between the nut 250 and the coupler member 270. The spline connection illustratively includes longitudinal grooves 254 located on an outer surface of the distal portion 252 of the nut 250 and distributed around the circumference of the nut 250. The grooves 254 extend parallel to the longitudinal axis 207 and are engaged by corresponding longitudinal ridges 271 distributed on the inner surface of the coupler member 270, see fig. 6.
For other embodiments, the rotationally fixed and axially movable connection between the nut 250 and the coupler member 270 may also be achieved by different means, such as by a splined connection between longitudinal ridges on the outer surface of the nut 250 and corresponding longitudinal grooves on the inner surface of the coupler member 270. Additionally or alternatively, the connection may also be formed by one or more intermediate members.
The coupler member 270 is fixedly connected at its distal end to the dose setting member 290 by a connection 277, the connection 277 preventing relative axial and relative rotational movement between the coupler member 270 and the dose setting member 290. For other embodiments of the drug delivery device 200, the dose setting member 290 and the coupler member 270 may also be configured as a single component. Alternatively, the connection between the coupler member 270 and the dose setting member 290 may also be achieved by one or more intermediate members.
In its proximal portion 251, the nut 250 is surrounded by a driver 350. Driver 350 is configured as a hollow, generally cylindrical member. Further, during both dose setting and dose delivery, the driver 350 may be moved axially and rotationally with respect to the housing 210. Thus, the driver 350 is threadably engaged with the housing 210.
The inner housing 180 includes an inner sleeve 183 at its proximal end that receives the proximal portion 351 of the driver 350. Driver 350 includes threads 353 that engage drive threads 186 of inner sleeve 183. In an exemplary embodiment, threads 353 of driver 350 are configured as external threads and drive threads 186 are configured as internal threads. Threads 353 are located on proximal portion 351 of driver 350. For other embodiments, the threaded connection between the driver 350 and the housing 210 may also be accomplished in other ways, such as by external threads on the housing 210 and internal threads on the driver 350.
Further, the dosing mechanism 230 includes a dosing member 330. Dosing member 330 is configured as a hollow, generally cylindrical member. Which surrounds both the driver 350 and the coupler member 270. The dosing member 330 constitutes a dose setting sleeve of the drug delivery device 200.
The driver 350 is located within the proximal portion 331 of the dosing member 330 and the coupler member 270 is located with its proximal portion 274 in the distal portion 333 of the dosing member 330.
During both dose setting and dose delivery, the dosing member 330 is axially and rotationally movable with respect to the housing 210. Further, it is threadably engaged with the housing 210, forcing it to move in a helical path relative to the housing 210.
The dosing member 330 is located between the inner sleeve 183 and the outer wall of the inner housing 180. Which has threads 335 (see fig. 8) that engage the dose threads 185 of the housing 210. For the exemplary embodiment, the threads 335 of the dosing member 330 are configured as external threads and the dosing threads 185 are configured as internal threads on the inner surface of the outer wall of the inner housing 180. For other embodiments, the threaded connection between the dosing member 330 and the housing 210 may also be achieved in a different manner. For example, the threaded connection may be provided between the dosing member 330 and the inner sleeve 183 of the inner housing 180.
Dosing member 330 is configured as a dose indicating member and comprises optical indicia 331 on its outer surface. The optical mark 331 forms a helical scale having a pitch corresponding to the pitch of the thread 335 on the outer surface of the dosing member 330.
During both dose setting and dose delivery, the driver 350 may be axially movable and rotationally fixed relative to the dosing member 330. For the exemplary embodiment, this is accomplished by a splined connection between the driver 350 and the dosing member 330.
The driver 350 comprises radially extending longitudinal splines 360, which radially extending longitudinal splines 360 engage with corresponding longitudinal grooves 341 provided on the inner surface of the dosing member 330 (see fig. 6). Spline 360 is located in distal portion 359 of driver 350 and recess 341 is located in proximal portion 332 of dosing member 330. For other embodiments, the splined connection between the driver 350 and the dosing member 330 may also be implemented in a different manner. For example, the driver 350 may comprise grooves engaged by corresponding splines of the dosing member 330.
The dose selector member 310 is configured as a hollow, substantially cylindrical member. Which constitutes a dose selector sleeve of the drug delivery device 200.
The dose selector member 310 is axially fixed and rotationally movable with respect to the dosing member 330. Thus, the dose selector member 310 is forced to follow the movement of the dosing member 330 axially, while the dosing member 330 is free to rotate relative to the dose selector member 310, the dose selector member 310 itself being rotationally fixed relative to the housing 210.
The dosing member 330 is received within the dose selector member 310. For the current embodiment, the proximal portion 317 of the dose selector member 310 receives the distal portion 333 of the dosing member 330. The proximal portion 274 of the coupler member 270 is positioned within the dosing member 330 with the distal portion 275 extending axially from the dosing member 330. Thus, the distal portion 275 of the coupler member 270 extends through an opening 323 (see fig. 5) in a radially oriented inner wall 322 of the dose selector member 310, the inner wall 322 separating the proximal portion 317 of the dose selector member 310 from the distal portion 311.
Fig. 8 shows a longitudinal section through the first cross-sectional plane of the dosing mechanism 230 of the drug delivery device 200 before setting a dose to be delivered by the drug delivery device 200. To set a dose, the dose setting member 290 is gripped by a user and rotated relative to the housing 210. This causes the coupler member 270 to rotate with the dose setting member 290. Due to the rotationally fixed connection between the coupler member 270 and the nut 250, the nut 250 also rotates together with the dose setting member 290. Since the piston rod 240 is rotationally fixed relative to the housing 210 and the piston rod 240 is threadably engaged with the nut 250, rotation of the nut 250 causes the nut 250 to advance axially along the piston rod 240 in a distal direction. The nut 250 travels in the distal direction when the set dose is increased and the nut 250 travels in the proximal direction when the set dose is decreased.
During dose setting, the dose setting member 290 is rotationally fixed with respect to the dosing member 330. This is achieved by the coupler mechanism 234, the coupler mechanism 234 comprising a first portion 235 that acts between the dose setting member 290 and the dosing member 330.
The first portion 235 of the coupler mechanism 234 comprises a coupler element 336 (see fig. 7), the coupler element 336 being located on the dosing member 330 and engaging with a corresponding coupler element 273 located on the coupler member 270 during dose setting. Engagement between these coupler elements 336, 273 prevents relative rotational movement between the dose setting member 290 and the dosing member 330 while allowing axial movement to disengage from the first portion 235 of the coupler mechanism 234.
Since the first portion 235 of the coupler mechanism 234 is closed during dose setting, the dosing member 330 rotates with the dose setting member 270. The threaded engagement between the dosing member 330 and the housing 210 then causes the dosing member 330 to travel axially within the housing 210 during dose setting. Upon increasing the set dose, the dosing member 330 travels in the distal direction, and upon decreasing the set dose, the dosing member 330 travels in the proximal direction.
Since the dose selector member 310 is axially fixed relative to the dosing member 330, distal movement of the dosing member 330 causes the dose selector member 310 to axially move in and out of the housing 310 in a distal direction, thereby also moving the dose setting member 290 in a distal direction, while proximal movement of the dosing member 330 causes the dose selector member 310 to axially travel into the housing 210, thereby also moving the dose setting member 290 in a proximal direction.
Since the dosing member 330 is rotationally fixed relative to the driver 350, rotation of the dosing member 330 also causes the driver 350 to rotate with the dose setting member 290. The threaded connection between the driver 350 and the housing 210 then causes the driver 350 to move in the distal direction when increasing the set dose and in the proximal direction when decreasing the set dose.
The first pitch of the threaded connection between the piston rod 240 and the nut 250 and the second pitch of the threaded connection between the driver 350 and the housing 210 match each other such that the nut 250 and the driver 350 travel substantially the same axial distance upon rotational movement of the dose setting member 290. The first and second pitches are smaller than the third pitch of the threaded connection between the dosing member 330 and the housing 210. This causes the dosing member 330 to travel a greater axial distance than the nut 250 and the driver 350 when the dose setting member 290 is rotated.
For the apparatus 200, the nut 250 and the coupler member 270 are only rotationally locked, but are free to move axially relative to each other. This allows the coupling member 270 and the dose setting member 290 to travel a greater distance in the axial direction during dose setting than the nut 250. Likewise, the driver 350 and the dosing member 330 are only rotationally locked, but are free to move axially relative to each other. This allows the dosing member 330 to travel a greater distance in the axial direction during dose setting than the driver 350.
Fig. 9 shows the dose setting mechanism 232 after a dose has been set. During dose setting, the dosing member 330 has traveled a first distance x in the distal direction, while the driver 350 has traveled a second distance y, and the nut 250 has traveled a third distance z. The first distance x is greater than the second and third distances y, z.
Due to manufacturing tolerances, the first pitch of the threaded connection between the piston rod 240 and the nut 250 varies between different threaded connections between a minimum first pitch and a maximum first pitch, and the second pitch of the threaded connection between the driver 350 and the housing 210 varies between different threaded connections between a minimum second pitch and a maximum second pitch. For the drug delivery device 200, the maximum first pitch is less than or at most equal to the minimum second pitch. This ensures that the second distance y traveled by the driver 350 in the distal direction is always slightly greater than the third distance z traveled by the nut 250.
The dose setting member 290, which also acts as an actuation member to effect injection of a set dose, is axially movable relative to the dose selector member 310 and the dosing member 330 between a distal position and a proximal position. The biasing member 308 configured as a compression spring biases the dose setting member 290 into the distal position during dose setting.
To effect expelling of the set dose, a user of the device 200 pushes the actuation member formed by the dose setting member 290 from the distal position into the proximal position. This causes the dosing mechanism 230 to transition from the dose setting state to the dose delivery state. The dosing mechanism 230 of the drug delivery device 200 is configured to allow setting of a dose to be injected when the dose delivery device 200 and the dosing mechanism 230 are in a dose setting state, while it is configured to allow delivery of the set dose when the dose delivery device 200 and the dosing mechanism 230 are in a dose delivery state.
Fig. 10 shows the dosing mechanism 230 after a dose has been set and the dosing mechanism 230 has transitioned from a dose setting state to a dose delivery state. Moving the dose setting member 290 in the proximal direction also causes the coupler member 270 to move in the proximal direction. Thus, the first portion 235 of the coupler mechanism 234 is opened and the coupler element 273 of the coupler member 270 is disengaged from the coupler element 336 of the dosing member 330. Thus, the dosing member 330 and the driver 350 are free to rotate relative to the dose setting member 290, the coupler member 270 and the nut 250.
Proximal movement of the dose setting member 290 relative to the dose selector member 310 simultaneously causes the second portion 236 of the coupler mechanism 234 to close and rotationally lock the nut 250 relative to the piston rod 240 and the housing 210. The second portion 236 of the coupler mechanism 234 acts between the dose selector member 310 and the dose setting member 290 and is further described below in connection with fig. 12 and 13.
Further pushing of the dose setting member 290 in the proximal direction causes the dose selector member 310 to move linearly back into the housing 210. The dose selector member 310 thereby pushes against the dosing member 330, which causes the dosing member 330 to rotate due to its threaded engagement with the housing 210. Rotation of the dosing member 330 is transferred to the driver 350, whereby the driver 350 is also moved in the proximal direction due to its threaded engagement with the housing 210.
The difference in the pitch of the threaded connection between the dosing member 330 and the housing 210 and the threaded connection between the driver 350 and the housing 210 thus results in the following mechanical advantage: the first axial force applied by the user and acting on the dosing member 330 is converted into a second axial force applied by the driver 350. For the dose delivery device 200, the second axial force is greater than the first axial force.
When moved in the proximal direction during dose delivery, the driver 350 is pushed axially against the nut 250 and thereby pushes the nut 250 in the proximal direction. Since the nut 250 is prevented from rotating relative to the piston rod 240 during dose delivery due to its connection to the housing 210 via the coupler member 270, the dose setting member 290 and the dose selector member 310, the threaded connection between the nut 250 and the piston rod 240 axially secures the nut 250 and the piston rod 240 relative to each other during dose delivery. Thus, the axially moving nut 250 pushes the piston rod 240 to also move in the proximal direction and thereby the plunger 9 to expel drug from the drug compartment 81
The housing 250, the dosing member 330 threadedly engaged with the housing 250 and rotating relative to the driver 350, the driver 350 also threadedly engaged with the housing 250, and the nut 250 being pushed by the driver 350 in the proximal direction during dose delivery form a pushing mechanism of the drug delivery device 200. The advancement mechanism is configured to translate axial movement of the dosing member 330 into axial advancement of the piston rod 240 during dose delivery. Thus, the propulsion mechanism comprises a transmission mechanism provided by a threaded connection of different pitches between the housing 250 and the dosing member 330 (on the one hand) and between the housing 250 and the driver 350 (on the other hand). The transmission mechanism realizes the following mechanical advantages: the first axial force applied by the user and acting on the actuation member formed by the dose setting member 290 is converted into a second axial force applied by the piston rod 240 on the plunger 9. This second axial force corresponds to the second axial force exerted by the driver 350 on the nut 250. For this embodiment, the second axial force is different from the first axial force, i.e. higher than the first axial force. For other embodiments, the second axial force may also be less than the first axial force, or substantially equal to the first axial force.
Closure of the second portion 236 of the coupler mechanism 234 upon dose delivery also rotationally locks the dose setting member 290 to the housing 210 during dose delivery. This ensures that the dose setting member 290 does not rotate during dose delivery and thus avoids the user being disturbed by the rotation of the dose setting member 290 when the user presses the dose setting member 290 to effect dose delivery. The drug delivery device 200 does not comprise any components that the user would have access to from outside the device 200 and which rotate during dose delivery. This helps to ensure safe delivery of the drug during injection.
Fig. 11 shows the dosing mechanism 230 after a dose has been delivered. The nut 250, the driver 350 and the dosing member 330 have returned to their initial positions and the piston rod 240 has been advanced in the proximal direction a third distance z. Since the piston rod 240 is pressed against the plunger 9 via the plunger disc 242, the plunger 9 has also been moved a third distance z in the proximal direction.
Fig. 12 shows the coupler mechanism 234 of the dosing mechanism 230 in a dose setting state, and fig. 13 shows the coupler mechanism 234 in a dose delivery state.
In the dose setting state shown in fig. 12, the dose setting member 290 and the coupling member 270 are in their distal positions with respect to the dose selector member 310 and the dosing member 330. The first portion 235 of the coupler mechanism 234 is closed and rotationally secures the coupler member 270 to the dosing member 330.
The second portion 236 of the coupler mechanism 234 is configured to rotationally fix the dose setting member 290 to the dose selector member 310 during dose delivery. The second portion 236 comprises a coupler element 294 (see also fig. 15) provided at the dose setting member 290. As can be seen from fig. 13, moving the dose setting member 290 to the proximal position engages the coupler element 294 with the functional feature (functional component, functional feature) 312 of the dose selector member 311, thereby rotationally locking the dose setting member 290 to the dose selector member 311. The functional feature 312 is configured as a tooth. Functional features 312 are provided on the inner surface of the distal portion 311 of the dose selector member 310. Which constitutes a coupler element of the dose selector member 310. As can also be seen from fig. 13, pressing the dose setting member 290 into the proximal position disengages the coupler element 273 of the coupler member 270 from the coupler element 336 of the dosing member 330.
In general, the coupler mechanism 234 rotationally locks the nut 250 to the dosing member 330 and/or the driver 350 during dose setting and rotationally decouples the nut 250 from the dosing member 330 and/or the driver 350 during dose delivery. Further, in general, the dosing mechanism 230 is configured to prevent relative rotation between the nut 250 and the piston rod 240 and/or the housing 210 during dose delivery and to allow rotation of the nut 250 relative to the piston rod 240 and/or the housing 210 during dose setting. For the drug delivery device 200, this is achieved by the coupler mechanism 234.
Further, the coupler mechanism 234 rotationally locks the dose setting member 290 to the dosing member 330 during dose setting and allows relative rotation between the dose setting member 290 and the dosing member 330 during dose delivery. The coupler mechanism 234 also rotationally locks the dose setting member 290 to the housing 210 during dose delivery and allows relative rotation between the dose setting member 290 and the housing 210 during dose setting.
For other embodiments of the drug delivery device 200, the dose setting member 290 may also be permanently rotationally locked to the dosing member 330. For example, such a dose setting member 290 may be configured to dose the portion of the dosing member 330 that is accessible by a user of the device. Such an embodiment of the drug delivery device 200 may then comprise an actuation member which may be pushed by a user to achieve dose delivery and which is separate from the dose setting member 290. The actuation member may then be rotationally movable with respect to the dose setting member 290, at least during dose delivery. Pushing the actuation member in the proximal direction upon initial dose delivery may then rotationally decouple the nut 250 from the dosing member 330.
The dosing mechanism 230 of the drug delivery device 200 further comprises a dose limiting mechanism 232 acting between two members of the dosing mechanism 230, which members are rotationally movable relative to each other during dose setting. The dose limiting mechanism 232 defines different and/or discrete rotational positions of the dose setting member 290 and the dosing member 330 relative to the housing 210, which rotational positions correspond to individually settable doses of medicament to be expelled by the dosing mechanism 230. Furthermore, the dose limiting mechanism 232 provides audible and/or tactile feedback to a user of the drug delivery device 200 indicating the rotational position of the dose setting member 290 and the dosing member 330 corresponding to a settable dose.
For the exemplary embodiment of the drug delivery device 200, the dose setting member 290 is configured to perform more than one complete rotation during dose setting. Thus, one discrete rotational position of the dose setting member 290 may correspond to more than one settable dose. The dose setting member 219 then assumes a different axial position, e.g. a separate axial position, with respect to the housing 210 for each individually settable dose. For other embodiments of the drug delivery device 200, the dose setting member 290 may also be configured to perform less than one complete rotation during dose setting. The discrete rotational positions of the dose setting member 290 defined by the dose limiting mechanism 232 then correspond to different rotational positions. Generally, for different rotational positions, each individual rotational position corresponds to only a single dose value that can be set by the dose limiting mechanism 232.
For the drug delivery device 200, the dose limiting mechanism 232 acts between the dose selector member 310 and the dose setting member 290, as can be seen from fig. 12 and 13. Thus, the dose limiting mechanism 232 is realized by a direct engagement between the dose setting member 290 and the dose selector member 310. For other embodiments of a dose delivery device according to the present disclosure, the dose limiting mechanism 232 may also act between the dose selector member 310 and the dose setting member 290 via additional elements located between the dose selector member 310 and the dose setting member 290. Such additional elements may be, for example, the coupler member 270 and/or the dosing member 330.
As can also be seen from fig. 12, the dose limiting mechanism 232 comprises at least one element 292, which element 292 engages with at least one corresponding functional feature 312, illustratively one of the teeth, when the dose setting member 290 reaches a rotational position relative to the housing 210 corresponding to a respective dose as defined by the functional feature 312. Engagement between the element 292 and the functional feature 312 then provides audible and/or tactile feedback to a user of the drug delivery device 200. As can be seen from fig. 12, an element 292 is provided at the dose setting member 290. In particular, it is configured as a constituent element of the dose setting member 290.
At least one of the element 292 and the functional feature 312 is configured as a flexible element that deflects in a radial direction upon engagement between the element 292 and the functional feature 312. For drug delivery device 200, element 292 is configured as such a flexible element. Additionally or alternatively, for other embodiments of the dose limiting mechanism 232, the functional feature 312 may also be configured as a flexible element.
The functional feature 312 constitutes a dose stop of the drug delivery device 200. For the teeth, the drug delivery device 200 includes a number of functional features 312, the functional features 312 being distributed circumferentially about the longitudinal axis 207 to define a plurality of settable doses. The functional features 312 form rigid elements of the dose limiting mechanism 232 that interact with the flexible element formed by the element 292. During dose setting, the element 292 interacts with the functional feature 312 by riding over the functional feature 312. Thus, the flexible element, illustratively formed by element 292, is bent in a radial direction.
For each individual functional feature 312, the drug delivery device 200 includes at least one element that participates in performing both functions of the dosing mechanism 230. As part of the coupler mechanism 234, this element constitutes a coupler element for rotationally fixing the nut 250 and/or the dose setting member 290 to the piston rod 240 and/or the housing 210. As part of the dose limiting mechanism, it constitutes a dose stop defining the rotational position of the dosing member 330 and/or the dose setting member 290 relative to the housing 210. For other embodiments of the drug delivery device 200, the functional feature 312 may act only as a dose stop, not as a coupler element, or only as a coupler element, not as a dose stop. For the drug delivery device 200, the elements performing the two functions are configured as rigid teeth. Other embodiments may include elements configured in different ways, such as elastic elements or the like. In particular, the element acting as a dose stop may be configured as a resilient element.
Furthermore, the dose limiting mechanism 232 of the drug delivery device 200 comprises a plurality of elements 292, i.e. four elements 292, distributed around the longitudinal axis 207. The relative positions between the individual functional features 312 and the individual elements 292 are selected as follows: at each rotational position of the dose setting member 290 relative to the housing 210 (which corresponds to a settable dose), all of the elements 292 are engaged with a respective one of the functional features 312. Other embodiments of the drug delivery device 200 may also include other numbers of elements 292, such as a single element 292.
For the drug delivery device 200, the functional feature 312 is located on an inner surface of the dose selector member 310 and the element 292 is located on an outer surface of the dose setting member 290. In addition, the element 292 and three other elements 292 are configured as flexible arms. Which constitutes an integral part of the dose setting member 290 and is provided at the proximal end of the dose setting member 290.
For drug delivery device 200, functional feature 312 includes a flat side surface that engages a corresponding flat side surface of element 292. Further, the coupler element 294 also includes a flat side surface that engages with a flat side surface of the functional feature 312. As with the drug delivery device 200, the flat side surfaces of the functional features 312 and/or the coupler elements 294 and/or the elements 292 may be angled with respect to a radial plane including the longitudinal axis 207 and intersect the flat side surfaces of the respective functional features 312 and/or coupler elements 294 and/or the elements 292.
The functional feature 312 provided on the dose selector member 310 constitutes both the coupler element of the second portion 236 of the coupler mechanism 234 and the dose stop of the dose limiting mechanism 232.
The dose limiting mechanism 232 is configured to inhibit tactile and/or audible feedback provided to the user during dose setting when the drug delivery device 200 is in a dose delivery state. For the drug delivery device 200, this is illustratively achieved by preventing relative rotation between the two members providing the dose limiting mechanism 232 (i.e. the dose setting member 290 and the dose selector member 310).
Fig. 14 shows a radial section through the dose limiting mechanism 232 perpendicular to the longitudinal axis 207. Fig. 15 shows a perspective view of the proximal side of the dose setting member 290 of the drug delivery device 200 and fig. 16 shows a perspective view of the distal side of the coupler member 270.
As can be seen from fig. 14, the dose limiting mechanism 232 defines an uneven number of discrete rotational positions of the dose setting member 290 relative to the housing 210, which corresponds to a settable dose, i.e. 27 rotational positions/settable dose. To ensure proper rotational alignment between the first portion 235 and the second portion 236 of the coupler mechanism 234, the dose setting member 290 is connected to the coupler member 270 by a connection 277 having coding features that only allow a single relative rotational orientation between the coupler member 270 and the dose setting member 290.
The connection 277 includes a non-circular (i.e., rectangular) opening 296 in the dose setting member 290, the opening 296 receiving the non-circular (i.e., rectangular) distal portion 275 of the coupler member 270. The coding feature then includes a first longitudinal ridge 279 and a second longitudinal ridge 280, whereby the longitudinal ridges 279, 280 extend radially from opposite sides of the distal portion 275 of the coupler member 270. The first ridge 279 is received in a corresponding first longitudinal groove 297 located in an opening 296 of the dose setting member 290 and the second ridge 280 is received in a corresponding second longitudinal groove 298 of the dose setting member 290. The first ridges 279 and the first grooves 297 have different dimensions, particularly different widths, than the respective dimensions, particularly widths, of the second ridges 280 and the second grooves 298. For other embodiments of the drug delivery device 200, the coding feature of the connection 277 may also be implemented in a different way, for example by providing a ridge on the dose setting member 290 and a corresponding groove at the coupling member 270.
To permanently and non-releasably couple the dose setting member 290 to the coupler member 270 during assembly of the drug delivery device 200, the coupler member 270 is locked to the dose setting member 290 by a snap fit connection 277. As can be seen, for example, in fig. 15 and 16, this snap-fit connection 277 includes two flexible snap hooks 278 located at opposite sides of the distal portion 275 of the coupler member 270. Upon insertion of the distal portion 275 into the opening 296 of the dose setting member 290, the snap hooks 278 engage with corresponding recesses 295 provided in a side surface of the opening 296. For other embodiments, the non-releasable connection 277 may also be provided in a different manner, for example by at least one snap hook at the dose setting member 290 and at least one corresponding recess on the coupler member 270.
As will be described further below, the axial position of the dosing member 330 corresponding to the minimum and maximum settable doses is defined by the interaction between the dosing member 330 and the inner housing 180. Thus, the connection between the dose selector member 310 and the inner housing 180 is configured in the following way: these axial positions correspond to the settable dose defined by the dose limiting mechanism 232.
For the drug delivery device 200, this connection shown in fig. 14 is achieved by limiting the relative rotational orientation between the dose selector member 310 and the inner housing 180 to a single orientation. The connection is established by a first longitudinal ridge 315, the first longitudinal ridge 315 being provided on the outer surface of the dose selector member 310 and being received in a corresponding first longitudinal groove 187 provided on the inner surface of the inner housing 180. The first longitudinal ridge 315 has a dimension, in particular a width, which is different from the corresponding dimension, in particular width, of at least one, in particular three, other longitudinal ridges 316 distributed over the remaining outer surface of the dose selector member 310. The other longitudinal ridges 316 engage with corresponding other longitudinal grooves 188 distributed on the remaining inner surface of the inner housing 180 and have a corresponding width different from the width of the first longitudinal groove 187.
Generally, the first longitudinal ridges 315 and the first longitudinal grooves 187 form a first longitudinal spline connection, and the other longitudinal ridges 316 and the other longitudinal grooves 188 form at least a second longitudinal spline connection, the first longitudinal spline connection being of a different dimension, in particular of a different transverse width, than the second longitudinal spline connection. For other embodiments, the connection between the dose selector member 310 and the inner housing 180 may also be achieved in a different way, for example by a spline connection with grooves on the dose selector member 310 and ridges on the inner housing 180.
Fig. 17 shows a perspective view of the proximal side of the coupler member 270 of the drug delivery device 200. On an inner surface of its proximal portion 274, the coupler member 270 has a longitudinal ridge 271, the longitudinal ridge 271 engaging with the longitudinal groove 254 of the nut 250 to rotationally lock the coupler member 270 relative to the nut 250 while allowing relative axial movement. Generally, the longitudinal ridges 271 and corresponding longitudinal grooves 254 form a spline connection between the coupler member 270 and the nut 250. For other embodiments, the rotationally fixed and axially movable connection between the coupler member 270 and the nut 250 may also be achieved by other means, for example, by longitudinal ridges provided on the nut 250 and corresponding grooves provided on the coupler member 270.
Fig. 18 shows a longitudinal section through the dosing member 330 and the dose selector member 310 of the drug delivery device 200. The drug delivery device 200 comprises a friction reducing mechanism acting between the dosing member 330 and the dose selector member 310. The friction reducing mechanism is configured to reduce friction upon relative rotational movement between the dosing member 330 and the dose selector member 310.
The friction reducing mechanism comprises a ball bearing 370 provided between the distal surface 346 of the dosing member 330 and the contact surface 314 of the dose selector member 310. Thus, the contact surface 314 is provided by a proximal front surface of the radially inner wall 322 of the dose selector member 310. Distal surface 346 is generally the distally facing surface of dosing member 330. For the drug delivery device 200, the distal surface 346 is the distal end surface of the dosing member 330. For other embodiments, distal surface 346 may also be located at a different location of dosing member 330.
When a dose is increased during dose setting, a distally directed axial force is transferred from the dosing member 330 to the dose selector member 310 via the ball bearing 370. When the dose selector member 310 is pushed in the proximal direction during injection, a proximally directed axial force is transferred from the dose selector member 310 to the dosing member 330 via the ball bearing 370.
The ball bearing 370 comprises a number of balls 375 sandwiched between a distal disc 371 touching the contact surface 314 of the dose selector member 310 and a proximal disc 372 contacting the distal surface 346 of the dosing member 330. In addition, the ball bearing 370 includes a retainer 372 sandwiched between the distal disc 371 and the proximal disc 372. Retainer 372 encircles ball 375 in a radial direction and holds it in place.
The dose selector member 310 has a connection to the dosing member 330 configured to axially limit movement between the dose selector member 310 and the dosing member 330 and to allow relative rotation between the dose selector member 310 and the dosing member 330. Distal movement of the dose selector member 310 relative to the dosing member 330 is prevented by the snap fit connection. The snap-fit connection comprises a circumferential annular ridge 344 on the outer surface of the dosing member 330 and at least one (i.e. four) flexible members 319 formed on the dose selector member 310. When the dose selector member 310 is moved in a proximal direction over the dosing member 330 during assembly, the flexible member 319 snaps over the annular ridge 344 and engages with the proximal front surface of the annular ridge 344. For other embodiments, the distal movement of the dose selector member 310 may also be achieved by a different connection, e.g. by a flexible member of the dosing member 330 engaging an annular ridge of the dose selector member 310. Proximal movement of the dose selector member 310 relative to the dosing member 330 is prevented by the contact surface 314 of the dose selector member 310, the contact surface 314 resting on the distal end surface 346 of the dosing member 330 via the ball bearing 370.
For other embodiments of the drug delivery device 200, the bearing element 370 may also be configured in other ways. For example, the bearing element 370 may also be configured as a disk bearing, such as a single annular disk made of a low friction material such as PTFE.
Fig. 19 shows a perspective view of the connection 354 between the nut 250 and the driver 350 of the drug delivery device 200. The connection 354 is configured to axially constrain the driver 350 relative to the nut 250 and allow relative rotational movement between the nut 250 and the driver 350.
The connection 354 includes two flexible arms 356, the flexible arms 356 being formed at the distal end of the driver 350 and projecting radially inward to engage an annular detent 255 between the proximal and distal portions 251, 252 of the nut 250. When the driver 350 is moved distally relative to the nut 250, the flexible arms 356 abut the distal side surface of the annular pawl 255. A gap is provided between the distal side surface and the flexible arm 356 to allow the nut 250 and driver 350 to travel different distances in the distal direction during dose setting.
The drug delivery device 200 comprises other friction reducing mechanisms configured to reduce friction between the nut 250 and the driver 350 when the nut 250 and the driver 350 are relatively rotationally moved with respect to each other during dose delivery. The other friction reducing mechanism includes a bearing element 380 positioned between the driver 350 and the nut 250.
Bearing element 380 is located between proximal front surface 358 of driver 350 and a projection 253 at the proximal end of nut 250. The proximal projection 253 defines a rim extending radially from the nut 250. When rotated into the inner sleeve 183 of the inner housing 180 during dose delivery, the proximal front surface 358 of the driver 350 is urged against the ledge 253 via the other bearing element 380 and thereby also urges the nut 250 in the proximal direction.
The bearing element 380 is configured as a bearing disk made of a low friction material such as PTFE. For other embodiments, the bearing element 380 may also be configured as a different type of bearing, such as a ball bearing.
For drug delivery device 200, driver 350 is generally configured to axially advance nut 250 during dose delivery by indirectly transmitting an axial force to nut 250 (i.e., by transmitting an axial force to nut 250 via one or more intermediate members (i.e., bearing elements 380)).
The piston rod 240 is rotationally fixed relative to the housing 210 at least during dose delivery, and the nut 350 and the piston rod 240 are rotationally fixed relative to each other during dose delivery such that the threaded connection 241, 256 between the nut 250 and the piston rod 240 axially locks the nut 250 relative to the piston rod 240 during dose delivery. Thus, the nut 250 and the piston rod 240 are configured to move axially simultaneously during dose delivery as if they were a single member.
During dose setting, the nut 250 is configured to rotate relative to the piston rod 240. Thus, the piston rod 240 is also rotationally locked to the housing 210 during dose setting, and the nut 250 is configured to rotate relative to the housing 210 during dose setting. Due to the threaded connection 241, 256 between the nut 250 and the piston rod 240, rotation of the nut 250 then axially advances the nut 250 relative to the piston rod 240 during dose setting. Axial advancement of the nut 250 relative to the piston rod 240 and/or relative to the housing 210 also defines axial advancement of the piston rod 240 relative to the housing 210 during dose delivery.
Fig. 20 shows a perspective view of the dosing member 330 of the drug delivery device 200. Dosing member 330 includes a maximum dose stop 337 configured to engage inner housing 180 when a maximum dose is set. Engagement of the maximum dose stop 337 with the inner housing 180 thereby limits further axial movement of the dosing member 330 in the distal direction and defines an axial and rotational position of the dosing member 330 corresponding to a maximum dose that can be set by the dosing mechanism 230.
As can be seen from fig. 21, which shows the inner housing 180 in a longitudinal section through the longitudinal axis 207, the inner housing 180 comprises at least one maximum stop feature 190, i.e. four maximum stop features 190. The maximum stop feature 190 is formed as an integral part of the inner housing 180. Each of which includes a flexible hook 191, the flexible hooks 191 projecting radially inwardly into a housing cavity 189 of the inner housing 180 that receives the dosing member 330. The flexible hooks 191 each include a limiting surface 192, the limiting surfaces 192 oriented perpendicular to the longitudinal axis 207 and facing in a proximal direction.
Upon insertion of the dosing member 330 into the housing cavity 189, the flexible hooks 191 snap over the maximum dose stop 337 to subsequently limit axial movement of the dosing member 330 in the distal direction. When the maximum dose is set, the distal stop surface 338 of the maximum dose stop 337 abuts the limiting surface 192 of the maximum stop feature 190. The distal stop surface 338 is configured as a side surface of the maximum dose stop 337 and is oriented perpendicular to the longitudinal axis 207.
As can be seen from fig. 20, the dosing member 330 further comprises a zero dose stop 340, the zero dose stop 340 defining the rotational and axial position of the dosing member 330 corresponding to zero or no set dose. A zero dose stop 340 is located at the proximal end of the dosing member 330. Which is configured as a limiting surface oriented parallel to the longitudinal axis 207. The limiting surface forms a side surface of the cutout at the proximal end of the dosing member 330.
When the zero dose position is reached, the zero dose stop 340 engages with the zero stop feature (zero stop structure, zero stop feature) 196 of the inner housing 180 shown in fig. 21. Zero stop feature 196 is located at the proximal end of housing cavity 189. Like zero dose stop 340, zero stop feature 196 is also configured as a limiting surface 197 oriented parallel to longitudinal axis 207. Further, the limiting surface 197 of the zero stop feature 196 is oriented parallel to the limiting surface of the zero dose stop 340.
The zero dose stop 340 engages the zero stop feature 196 in a contact plane that is angled relative to a radial plane oriented perpendicular to the longitudinal axis 207. For this embodiment, the contact plane is oriented perpendicular to the radial plane and parallel to the limiting surface 197 provided by the zero dose stop 340 and the zero stop feature 196. Limiting surface 197 of zero stop feature 196 provided at the housing of device 200 thereby coincides with the contact plane.
Fig. 22 shows a perspective view of the inner housing 180 with the dosing member 330 in the zero dose position and fig. 23 shows a perspective view of the inner housing 180 with the dosing member 330 in the maximum dose position.
Dosing member 330 is configured to perform two complete rotations about longitudinal axis 207 when moving from a zero dose position to a maximum dose position. In the zero dose position, a minimum dose marker is visible in window 188a of inner housing 180, indicating a set dose of 0.0; and in the maximum dose position, a maximum dose marker is visible in window 188a indicating a set dose of 5.4.
For other embodiments of the drug delivery device 200, the dosing member 330 may be configured to perform less than or more than two complete rotations about the longitudinal axis 207 when moving from the zero dose position to the maximum dose position. In particular, the drug delivery device 200 may be configured to implement a non-integer rotation that deviates from a complete rotation or an integer multiple of a complete rotation. Likewise, the maximum dose indicator may indicate any other dose that deviates from the set dose of 5.4, for example a set dose of 1.8 or 3.6.
The inwardly protruding maximum stop feature 190 of the inner housing 180 is located inside the longitudinal detent 320 of the dose selector member 310. This allows the limiting surface 192 to engage with the stop surface 338 of the dosing member 330, although the dose selector member 310 surrounds the dosing member 330 in its distal portion 333.
The inner housing 180 is axially and rotationally locked relative to the outer housing 211. As can be seen from fig. 22 and 23, the inner housing 180 includes protrusions 194 distributed circumferentially around the outer surface of the distal portion 182 of the inner housing 180. In addition, the inner housing 180 includes a radial projection 195 on an outer surface of the proximal portion 181 of the inner housing 180. For the embodiment shown in fig. 22 and 23, two radial projections 195 are positioned adjacent to each other parallel to the longitudinal axis 207. Both projections 195 are placed at the same circumferential position on the outer surface of the inner housing 180.
As can be seen from fig. 24, which shows a longitudinal section through the outer housing 211 of the drug delivery device 200, the outer housing 211 comprises a circumferential groove 218 on its inner surface, the circumferential groove 218 being located in a distal portion of the outer housing 211. Further, the outer housing 211 includes a detent 216 in a proximal portion of its inner surface.
Fig. 25 shows a longitudinal section of the inner housing 180 mounted within the outer housing 211 of the drug delivery device 200. The projection 194 in the distal portion 182 of the inner housing 180 is configured to prevent axial movement of the inner housing 180 relative to the outer housing 211 in the distal direction. When the inner housing 180 is mounted inside the outer housing 211 by inserting the inner housing 180 into the outer housing 211 from the distal end of the outer housing 211, the projection 194 snaps into the circumferential groove 218. When inner housing 180 is pushed in the distal direction after full insertion, projection 194 engages the distal end surface of circumferential groove 218 and thereby prevents axial movement. In the proximal direction, the inner housing 180 abuts a step in the inner surface of the outer housing 211 that limits proximal movement of the inner housing.
For other embodiments of the drug delivery device 200, axial movement of the inner housing 180 relative to the other housing 211 may also be prevented by other means. For example, the outer housing 211 may include a flexible element that engages a groove positioned on the outer surface of the inner housing 180.
The radial projection 195 in the proximal portion of the inner housing 180 is configured to prevent rotational movement of the inner housing 180 relative to the outer housing 211. Which engages a detent 216 in a proximal portion of the inner surface of the outer housing 211. This is further illustrated in fig. 26, which shows a radial cross-section through the outer and inner housings 211, 180 of the drug delivery device 200 through the line A-A shown in fig. 25. For other embodiments of the drug delivery device 200, rotational movement of the inner housing 180 relative to the other housing 211 may also be prevented by other means. For example, the outer housing 211 may include protrusions that engage detents positioned on the outer surface of the inner housing 180.
In assembling the drug delivery device 200, the dose selector member 310 and the dosing member 330 are first assembled to each other and inserted into the inner housing 180. The inner housing 180 is then inserted into the outer housing 211. After being inserted into the outer housing 211, the flexible hooks 191 rest on the inner surface of the outer housing 211, thus preventing outward bending of the flexible hooks 191. This prevents the hook 191 from disengaging from the maximum dose stop 337 when the maximum dose is set.
For all drug delivery devices according to the present disclosure, the design of the respective maximum and zero dose stops 337, 340 is typically independent of the design of the remaining devices, in particular of the details of the rotational coupling between the respective dose setting member and the respective dose sleeve, the design of the respective coupler mechanism, the dose limiting mechanism, the reset mechanism or the like.
The drug delivery device 200 is configured to deliver a plurality of individual doses from a cartridge 8 attached to the device 200 via a cartridge holder 412. Furthermore, the drug delivery device 200 is configured as a reusable drug delivery device, which allows a user to replace an empty cartridge 8 with a new cartridge 8 after the last dose has been delivered from a given cartridge 8.
The reset mechanism 100, shown in an exploded partial view in fig. 27, thereby allows the piston rod 240 to be moved back into the housing 210 after the last dose is delivered and the cartridge holder 412 is disengaged from the housing 210.
The reset element 110 of the reset mechanism 100, which guides the piston rod 240 in the non-circular opening 114, is mounted to the housing 210, i.e. the outer housing 211. The connection between the reset element 110 and the housing 210 is achieved by the coupling portion 130, the coupling portion 130 being rotationally and axially fixed relative to the housing 210. The coupling portion 130 is configured to be received as an insert within the housing 210 (i.e., within the outer housing 211).
According to the present disclosure, the housing 210 comprises all components that are permanently rotationally and axially fixed relative to the outer housing 211 during intended use of the drug delivery device 200. As such, the coupling portion 130 may also be considered as part of the housing 210. For other embodiments of the drug delivery device 200, the coupling portion 130 may be configured as an integral part of the housing 210.
A biasing element 150 configured as a compression spring is mounted between the coupling portion 130 and the reset element 110, and thus also between the housing 210 and the reset element 110. The biasing element 150 biases the reset element 110 in a proximal direction into a proximal position relative to the housing 210 and the coupling portion 130.
Fig. 28 shows a longitudinal section through the reset mechanism 100 of the drug delivery device 200 with the reset element 110 in a proximal position. In this configuration, the reset element 110 is rotationally movable relative to the housing 210. The reset element 110 includes a gripping zone 111 at its proximal end, the gripping zone 111 being gripable by a user of the device 200 to rotate the reset element 110. Within the gripping zone 111, the reset element 110 acts as a roughened outer surface, such as a contoured outer surface.
Due to the rotationally fixed connection between the reset element 110 and the piston rod 240, the piston rod 240 is forced to rotate together with the reset element 110 when the user rotates the reset element 110. Upon rotating the reset element 110 in the reset direction, the engagement between the threads 241 of the piston rod 240 and the threads 256 of the nut 250 forces the piston rod 240 to travel in a distal direction back into the housing 210. In this way, the reset element 110 is configured to move the piston rod 240 back into the housing 210 when rotated by a user.
In general, the piston rod 240 is threadedly engaged with a component of the dose setting mechanism 230 (i.e. with the nut 250) and the reset element 110 rotates relative to this component during resetting of the piston rod 240. As in the exemplary case of the drug delivery device 200, the components may be rotationally and/or axially fixed relative to the housing 210 of the device 200, and the reset element 110 may be configured to rotate relative to the housing 210 upon resetting the piston rod 240.
Furthermore, the piston rod 250 is generally rotationally fixed relative to the reset element 110 and is axially movable relative to the reset element 110 at least during a reset operation. For the drug delivery device 200, the piston rod 250 is permanently rotationally fixed with respect to the reset element 110. Furthermore, it can be permanently axially movable relative to reset element 110.
After the cartridge holder 412 is disengaged from the housing 210, the piston rod 240 is accessible to a user of the device 200. The connection 354 of the driver 350 is axially limited relative to the nut 250 for preventing unwanted movement of the piston rod 240, which could be caused by a user directly pushing or pulling the piston rod 240 without simultaneously rotating the reset element 110.
For example, if the user sets a dose when the cartridge holder 412 is detached from the housing 210, the nut 250 and the driver 350 move together in a distal direction. Without the connection 354, if the user then pulls the piston rod 240, the nut 250 will not be prevented from moving proximally again and the user will be able to pull the piston rod 240 out of the housing 210. This may lead to the impression of damage to the device 200.
With the connection 354, the user is prevented from pulling the piston rod 240 out of the housing 210 without simultaneously rotating the piston rod 240. That is, axial movement of the piston rod 240 without rotation would require the nut 250 to move axially. Due to the connection 354 between the nut 250 and the driver 350, and due to the threaded connection 352 between the driver 350 and the inner housing 180, the driver 350 will also have to move and rotate axially relative to the housing 210. However, due to the gearing or mechanical advantage caused by the different pitches of the threaded connection 352 between the driver 350 and the inner housing 180 and the threaded connection 334 between the dosing member 330 and the inner housing 180, the force that a user can typically apply by pulling or pushing the piston rod 240 is insufficient to overcome the resistance required to cause rotation of the dosing member 330, the coupling member 270 and the dose setting member 290 by directly forcing the driver 350 to rotate. Thus, when the dose setting member 290 is not actuated, the driver 350 as well as the nut 250 via the connection 354 are substantially rotationally and axially locked.
Fig. 29 shows a distal perspective view of reset element 110, fig. 30 shows a proximal perspective view of reset element 110, and fig. 31 shows a proximal perspective view of coupling portion 130 of reset mechanism 110.
As can be seen from fig. 28, the distal portion of the reset element 110 is received within the coupling portion 130. In the proximal position shown in fig. 28, further proximal movement of the reset element 110 by the biasing member 150 within the coupling portion 130 is prevented by the reset element 110 engaging the coupling portion 130. Thus, the radial stop 119 at the distal end of the reset element 110 engages with a corresponding stop feature 140 on the inner surface of the coupling portion 130. For other embodiments, further proximal movement of reset element 110 may be prevented in other ways as well.
As can also be seen from fig. 28, the coupling portion 130 is axially locked relative to the housing 210 by an annular notch 136 on the outer surface of the coupling portion 130, whereby the annular notch 136 is received in a corresponding collar 213 on the inner surface of the outer housing 211. The notch 136 is distally bounded by a locking structure 137 that protrudes radially from the outer surface of the coupling portion 130. Upon insertion of coupling portion 130 into outer housing 211 in the distal direction, locking structure 137 flexes radially inward and snaps over annular collar 213 of outer housing 211. In this way, the coupling portion 130 is axially fixed relative to the housing 210 by a snap-fit connection. For other embodiments, axial movement between the coupling portion 130 and the housing 210 may also be prevented by other means, such as by a notch on the housing 210 and a collar or protrusion at the coupling portion 130.
To rotationally lock the coupling portion 130 relative to the housing 210, the coupling portion 130 includes a protrusion 138 located within the notch 136. The tab 138 engages a corresponding detent 214 in the annular collar 213. These pawls 214 are shown in particular in fig. 24. For other embodiments, rotation between the coupling portion 130 and the housing 210 may also be prevented by other means, for example by protrusions provided at the housing 210 and corresponding detents provided at the coupling portion 130.
The locking structure 137 of the coupling portion 130 comprises two parts separated by a longitudinal slot 139. This allows these portions of the locking structure 137 to flex radially inward when the coupling portion 130 is mounted to the outer housing 211. After the coupling portion 130 is installed, and after the inner housing 180 is installed to the outer housing 211, these portions of the locking structure 137 are prevented from being inwardly bent by engagement with the inner housing 180. In assembling the apparatus 200, the coupling portion 130 and the reset element 110 are first snapped to the outer housing 211 and then the inner housing 180 is inserted into the outer housing 211.
Fig. 32 shows a perspective view of the coupling portion 130 and the inner housing 180. The inner housing 180 comprises at its front surface two longitudinally protruding lifters (tappets) 184, the lifters 184 also being visible for example in fig. 23. The tappet 184 is received within the longitudinal slot 139 and thereby prevents these portions of the locking structure 137 from bending radially inward.
Fig. 33 shows a longitudinal section through the reset mechanism 100, wherein the dispensing unit 410 is attached to the drug delivery device 200. Upon attaching the dispensing unit 410, the internal threads of the connection means 414 of the dispensing unit 410 are screwed onto the external threads of the connection means 510 of the outer housing 211 until the distal end of the cartridge holder 412 rests on a step formed on the outer surface of the outer housing 211.
During installation of the dispensing unit 410, the reset element 110 is moved in a distal direction to its distal position to rotationally lock the reset element 110 relative to the housing 210. When in its distal position, the engagement feature 120 of the reset element 110 engages with the corresponding engagement feature 135 of the coupling portion 130 and thereby rotationally locks the reset element 110 relative to the coupling portion 130 and the housing 210.
The engagement features 120 of the reset element 110 are configured as distally facing teeth. The engagement feature 135 of the coupling portion 130 is located at a coupling site formed by the front surface of the coupling portion 130. The engagement feature 135 is configured as a proximally facing tooth that mates between distally facing teeth of the engagement feature 120 of the reset element 110.
In the embodiment shown in fig. 27-33, the engagement features 120, 135 are configured as symmetrical teeth having circumferential side surfaces with the same slope. For other embodiments, the teeth of the engagement features 120, 135 may also be configured as asymmetric teeth. For example, the asymmetric teeth may have circumferential side surfaces with different slopes. Thus, one side surface of an individual tooth may be oriented, for example, parallel to the longitudinal axis 207, and the respective other side surface may be inclined relative to the longitudinal axis 207. Such asymmetric teeth may, for example, provide a saw tooth profile.
For the asymmetric engagement features 120, 135, the side surfaces of the individual engagement features 120, 135 having steeper slopes than the respective other side surfaces may be configured to press against each other when the reset element 110 is rotated in a circumferential direction (which screws the piston rod 240 back into the housing 210). This effectively prevents a reverse rotation of the piston rod 240 relative to the nut 250 when the dose setting member 290 and the nut 250 are inverted, either during dose delivery or during dose setting, when a dose is increased, after the thread 256 of the nut 250 has engaged the stop feature 243 of the piston rod 240.
As can be seen from fig. 33, upon mounting the dispensing unit 410 to the housing 210, the cartridge holder 412 of the dispensing unit 410 directly engages the reset element 110 to urge the reset element 110 in a distal direction. Thus, the proximally facing contact structure 117 of the reset element 110 rests on the distally facing contact feature 450 of the cartridge holder 412. The proximally facing contact structure 117 is illustratively configured as a proximal circumferential edge of the reset member 110. The distally facing contact feature 450 is illustratively provided as a distally facing annular surface at an inwardly projecting step of the cartridge holder 412.
The proximal position of the reset element 110 is the reset position of the reset element 110 and the distal position of the reset element 110 is the locked position of the reset element 110. The locking distance between the reset position and the locking position may be, for example, less than 2mm, 1.5mm, 1.25mm, 1.1mm or 1mm and/or greater than 0.5mm, 0.7mm or 0.8mm. It may for example reach 0.8mm, 0.9mm, 1.0mm or 1.1mm.
With the cartridge holder 412 mounted to the housing 210, the cartridge 8 does not contact the reset element 110. Thus, the reset element 110 is moved in the distal direction only by its contact with the cartridge holder 412. The distal end of the cartridge 8 is received within a cartridge cavity 115 of the reset element 110, the cartridge cavity 115 being accessible from the proximal side of the reset element 110.
The direct engagement between the cartridge holder 412 and the reset element 110 allows the engagement features 120, 135 to be configured with tighter axial tolerances and smaller axial heights than the engagement between the cartridge 8 and the reset element 110. Typically, the individual cartridges 8 are made of glass and have a larger variation in their longitudinal extent than the individual cartridge holders 412, which are typically made of plastic material. Thus, the engagement features 120, 135 will have to have a relatively large axial height to provide a secure rotational lock between the reset element 110 and the coupling portion 130 despite possible variations in the length of the individual cartridges 8 due to manufacturing tolerances.
When fully retracted into the housing 210, the plunger disc 242 of the piston rod 240 is located within the receiving area 112 of the reset element 110. The receiving area 112 is configured as a further cavity accessible from the proximal side of the reset element 110. Further, the receiving area 112 is located at the distal end of the cartridge cavity 115 and is accessible from the distal end of the cartridge cavity 115. In its fully retracted position, the plunger disc 242 of the piston rod 240 rests on the inner surface 113 of the receiving area 112. This inner surface 113 forms the distal end surface of the receiving area 112 and surrounds the opening 114 of the reset element 110 guiding the piston rod 240.
Fig. 34 shows a longitudinal section through the proximal end of a cartridge holder 412 attachable to the drug delivery device 200, wherein a cartridge 8 is inserted into the cartridge holder 412. Fig. 35 shows a perspective distal view of a radial section through the proximal portion of the cartridge holder 412 along line B-B in fig. 34. Inside the cartridge holder 412, the cartridge 8 is pushed against the stop 408 by the biasing element 406. The biasing element 406 engages the distal surface 83 of the annular rim 82 of the cartridge 8. Thereby engaging the radially outer end of the distal surface 83. The biasing element 406 is configured as a flexible member that snaps over the annular rim 82 when the cartridge 8 is inserted into the cartridge holder 412. The biasing element 406 is configured as an integral part of the cartridge holder 412. The biasing element 406 is formed in a cutout provided in the outer wall of the cartridge holder 412.
The outer wall of the cartridge holder 412 surrounds a cartridge cavity 413 configured to receive the cartridge 8. Both the biasing element 406 and the connector 404 protrude radially into the cartridge cavity 413. The longitudinal extent of the cartridge cavity 413 is larger than the longitudinal extent of the cartridge 8. This prevents the user of the dispensing unit 410 from being able to touch or grasp the cartridge 8 and remove it from the cartridge holder 412.
As can be seen from fig. 34, the cartridge holder 412 comprises both a biasing element 406 and a connector 404, the biasing element 406 and the connector 404 being configured as separate elements of the cartridge holder 412. The biasing element 406 and the connector 404 are located at opposite sides of the cartridge holder 412 relative to the longitudinal axis 207. Furthermore, both the biasing element 406 and the connector 404 are located at the same longitudinal position.
Thereby, the biasing element 406 is configured to bias, in particular permanently bias, the cartridge 8 in a proximal direction towards the stop 408. Thereby, the cartridge 8 is clamped between the stopper 408 and the biasing element 406 such that both the stopper 408 and the biasing element 406 rest on the cartridge 8 at the same time. The biasing element 406 prevents movement of the cartridge 8 within the cartridge holder 412. For example, when the needle 4 is mounted to the cartridge holder 412, the biasing element 406 biases the cartridge 8 in a proximal direction against the hollow cannula 6.
The connector 404 typically constitutes a locking element that prevents the cartridge 8 from being removed after insertion into the cartridge holder 412. Thereby, removal is prevented by the contact surface 405 of the connector 404. The contact surface 405 is configured to engage with the cartridge 8 to prevent removal of the cartridge 8 from the cartridge holder 412. Thus, the contact surface 405 acts as a blocking surface preventing removal of the cartridge 8 from the cartridge holder 412. For the embodiment shown in fig. 34, the contact surface 405 is provided by the proximal surface of the connector 404. The contact surface 405 points in a proximal direction. Further, it is angled with respect to the longitudinal axis 207. It may be oriented substantially perpendicular to the longitudinal axis 207, in particular it may be oriented perpendicular to the longitudinal axis 207.
The contact surface 405 engages with a corresponding counter surface of the cartridge 8. The mating surface of the cartridge 8 is a distally facing surface that is angled with respect to the longitudinal axis 207. It may also be oriented substantially perpendicular to the longitudinal axis 207, in particular it may be oriented perpendicular to the longitudinal axis 207. This mating surface is illustratively provided by the distal surface 83 of the annular rim 82 of the cartridge 8.
Connector 404 is configured to deflect toward longitudinal axis 207 when cartridge 8 is engaged with connector 404 when cartridge 8 is attempted to be removed from cartridge holder 412. This further prevents removal of the cartridge 8 from the cartridge holder 412 by locking the cartridge 8 inside the cartridge holder 412.
For cartridge holder 412, contact surface 405 is at a greater angle to longitudinal axis 207 than mating surface 83. When contacting the mating surface 83 of the cartridge 8 when moving distally of the cartridge 8, the connector 404 is bent such that its contact surface 405 is oriented parallel to the mating surface 83. When attempting to remove the cartridge 8 from the cartridge holder 412, this deflects the connector 404 radially toward the longitudinal axis 207 and toward the cartridge 8.
When fully inserted into the cartridge holder 412, the cartridge 8 is positioned away from the contact surface 405. The cartridge 8 then does not contact the contact surface 405. The action of the biasing element 406 biases the cartridge 8 into its fully inserted position.
The gripping end of the connector 404 is connected to the body of the cartridge holder 412 and the free end of the connector 404 is configured to be separated from the body of the cartridge holder 412. For the connector 404, the free end is located at the proximal end of the connector 404 and the clamping end is located at the distal end of the connector 404. The connector 404 is configured as a flexible member. Thus, the free end of the connector 404 may deflect radially. Upon insertion of the cartridge 8 into the cartridge holder 412, the cartridge 8 first deflects the connector 404 radially away from the longitudinal axis 207. Upon further moving the cartridge 8 in the proximal direction, the connector 404 then snaps over the cartridge 8, i.e. over the annular rim 82 of the cartridge 8.
Likewise, the gripping end of the biasing element 406 is connected to the body of the cartridge holder 412, and the free end of the biasing element 406 is configured to be separated from the body of the cartridge holder 412. For the biasing element 406, the free end is located at the proximal end of the biasing element 406 and the clamping end is located at the distal end of the biasing element 406. The biasing element 406 is configured as a flexible member. Thus, the free end of the biasing element 406 may deflect radially. Upon insertion of the cartridge 8 into the cartridge holder 412, the cartridge 8 first deflects the biasing element 406 radially away from the longitudinal axis 207. Upon further moving the cartridge 8 in the proximal direction, the biasing element 406 then snaps over the cartridge 8, i.e. over the annular rim 82 of the cartridge 8.
For cartridge holder 412, contact surface 407 of biasing element 406 is configured to rest on cartridge 8 to apply a biasing force in a proximal direction. The angle of this contact surface 407 with the longitudinal axis 207 is smaller than the angle of the contact surface 405 of the connector 404 with the longitudinal axis 207.
The biasing element 406 is configured to bend radially away from the longitudinal axis 207 and the cartridge 8 when attempting to remove the cartridge 8 from the cartridge holder 412. For the cartridge holder 412, the contact surface 407 of the biasing element 406 has a larger angle to the longitudinal axis 207 than the mating surface 83 of the cartridge 8.
The cartridge holder 412 has two functions. First, it prevents the user from removing the cartridge 8 from the cartridge holder 412 without using a tool. Second, it prevents the cartridge 8 from moving axially when the user attaches the needle 4 to the needle connector 402.
The first function is fulfilled by the connector 404, the connector 404 being securely snapped in after insertion of the cartridge 8. This is illustratively accomplished by a connector 404 having some space with the distal surface 83 of the cartridge 8 after insertion of the cartridge. The distance between the stop 408 and the connector 404 is adapted to accommodate different thicknesses of the annular rim 82 of the cartridge 8. Thus, it is suitable for different distances of the surface 83 from the stop 408. Generally, the connector 404 is spaced from the surface 83 at least for cartridges 8 having an annular rim 8 that is axially shorter than the maximum thickness of a cartridge 8 that can be inserted into the cartridge holder 412. This allows the connector 404 to snap radially in even when inserting a cartridge 8 having an axially long annular rim 82.
For the cartridge holder 412, the body of the cartridge 8 is not held at its distal end (see fig. 8). Without the biasing element 406, the cartridge 8 would be pushed in the proximal direction only by the plunger disc 242 touching the piston 9 of the cartridge 8. When a user attaches a new needle 4, the cannula 6 pushes the cartridge 8 in the distal direction, which results in the plunger disc 242 and the piston rod 240 pushing the piston 9 in the proximal direction relative to the body of the cartridge 8. Once the cannula 6 penetrates the septum, the pressure on the piston 9 may cause a loss of medication. To avoid this loss of medication, axial movement of the cartridge 8 is prevented by the biasing element 406 when the needle 4 is mounted to the cartridge holder 412 and/or when the cannula 6 penetrates the septum of the cartridge 8.
The biasing element 406 is adapted to compensate for tolerances of the dimensions of the annular rim 82 of the cartridge 8, such as tolerances of its axial length and/or diameter. This is illustratively achieved by a biasing element 406 configured to rest on the cartridge 8 after full cartridge insertion and/or by a biasing element 406 configured to flex radially outwardly when the cartridge 8 is moved in a distal direction after cartridge insertion.
The connector 404 does not bias the cartridge 8 in the proximal direction after insertion of the cartridge, but allows a point to move axially. The biasing element 406 is configured to exert a force on the cartridge 8 that prevents the cartridge 8 from moving during attachment of the needle 4. After insertion of the cartridge holder 412 and/or attachment of the cartridge holder 412 to the drug delivery device 200, this force may also act in addition to the friction forces acting on the cartridge 8. Thus, the biasing element 406 does not completely inhibit distal axial movement of the cartridge 8 after insertion. For example, the user may still be able to move the cartridge 8 against the force of the biasing element 406.
For other embodiments, the drug delivery device 200 may be configured as a disposable device having a cartridge holder 412 permanently and inseparably connected to the housing 210. Thus, the cartridge holder 412 may not be disconnected from the housing 210 during the intended use of the device 200 and/or without damaging the device 200. For example, these embodiments may then have cartridge holder 412 featuring only biasing element 406, rather than connector 404.
The drug delivery device 200 is a reusable device that allows for the removal of a used cartridge holder 412 and the reattachment of a new cartridge holder 412. Furthermore, as described in more detail below, the drug delivery device 200 is provided in different versions adapted to deliver at least different concentrations of a drug. Different drugs are provided in the cartridge 8, and the cartridge 8 is inserted into a dedicated cartridge holder 412. Furthermore, the separate version of the connection means 510 of the drug delivery device 200 and the separate version of the connection means 412 of the cartridge holder 412 are configured as keyed connectors. Thus, each individual version of the connection means 510 of the drug delivery device 200 is only connected to a specific version of the connection means 414 of the cartridge holder 412 holding a drug to be delivered by the respective drug delivery device 200 and is not connected to other versions of the connection means 414 of the cartridge holder 412.
The connector 404 preventing removal of the cartridge 8 from its cartridge holder 412 then increases the safety during use of the device 200 and cartridge holder 412. For example, if a user accidentally obtains cartridge holders 412 for a different version of the drug delivery device 200 than the version used by the user, those cartridge holders 412 will contain the wrong drug and will not be able to fit to the user's drug delivery device 200 due to the keyed features of the connection means 414, 510. The connector 404 then prevents the user from removing the cartridge 8 holding the wrong drug from the version of the cartridge holder 412, inserting it into the version of the cartridge holder 412 of the drug delivery device 200 suitable for use by the user, and thus using the cartridge 8 with the wrong version of the drug delivery device 200 and/or using the cartridge 8 holding the wrong drug.
Other embodiments of cartridge holder 412 may include only biasing element 406 without connector 404, or only connector 404 without biasing element 406.
Further, the proximal portion of the cartridge holder 412 comprises an annular ridge 409 extending radially from the outer surface of the cartridge holder 412. The annular ridge 409 is configured to be engaged by a flexible locking arm of the cap 209, which is provided on an inner surface of the cap 209. The engagement between the locking arms and the annular ridge 409 releasably locks the cap 209 to the drug delivery device 200 after attachment.
According to the present disclosure, the drug delivery device 200 may be part of a kit of several drug delivery devices and the dispensing unit 410 may be part of a kit of several dispensing units, whereby each drug delivery device comprises connecting means allowing only a dedicated dispensing unit to be attached and preventing all other dispensing units of the kit from being attached, and vice versa. The connection means is thereby configured as a keyed connection means providing a one-to-one assignment between individual dispensing units and individual drug delivery devices.
The kit of drug delivery devices may comprise further variants of the drug delivery device 200 having at least one common member that is identical between the drug delivery device 200 and these further variants. The kit may also include different types of drug delivery devices that do not share such common components with the drug delivery device 200.
Fig. 36 and 37 show a set of three drug delivery devices and a set of three corresponding dispensing units according to the present disclosure. Each drug delivery device is connected to its corresponding dispensing unit by a keyed connection which prevents the respective drug delivery device from being connected to the other dispensing unit and, conversely, which prevents the corresponding dispensing unit from being connected to the other drug delivery device.
Thus, fig. 36 shows a longitudinal section through a first dispensing unit 420 attachable to a first housing 221 of a first drug delivery device 220 via a first connection means 424 of a first cartridge holder 422, a longitudinal section through a second dispensing unit 430 attachable to a second housing 223 of a second drug delivery device 222 via a second connection means 434 of a second cartridge holder 432 of a second dispensing unit 430, and a longitudinal section through a third dispensing unit 440 attachable to a third housing 226 of a third drug delivery device 225 via a third connection means 444 of a third cartridge holder 442 of a third dispensing unit 440. Fig. 37 shows a side view and a perspective view of the first connection means 511 of the first housing 221 of the first drug delivery device 220, the second connection means 520 of the second housing 223 of the second drug delivery device 222 and the third connection means 530 of the third housing 226 of the third drug delivery device 225.
The connection means 424, 434, 444 of the cartridge holder 422, 432, 442 and the corresponding connection means 511, 520, 530 of the drug delivery device 220, 222, 225 form a keyed connector according to the present disclosure. Thus, the connection means 424, 434, 444 are of the same type and the connection means 511, 520, 530 are also of the same type.
The individual connection means 424, 434, 444 of the cartridge holder 422, 432, 442 each form the female part of these connections and the individual connection means 511, 520, 530 of the drug delivery device 220, 222, 225 form the corresponding male part. All connection means 424, 434, 444, 511, 520, 530 are configured as threads, whereby the connection means 424, 434, 444 of the cartridge holder 422, 432, 442 form an internal thread and the connection means 511, 520, 530 of the drug delivery device 220, 222, 225 form an external thread.
The geometry of the threads 424, 434, 444, 511, 520, 530 is defined by a number of thread dimensions. These thread dimensions include a core diameter or minor diameter that specifies the minimum internal diameter of the female portions of these connections, an outer diameter or major diameter that specifies the maximum internal diameter of the female portions of these connections, a pitch that specifies the distance between adjacent ridges 501 or valleys 502 of the threads, a width of the ridges 501 provided on the male portion of the threads (which corresponds to the width of the valleys 502 provided on the female portion of the threads), an opening angle between the sidewalls of adjacent ridges 501 of the male portion, and a height of the ridges 501 of the male portion and a corresponding height of the valleys 502 of the female portion (which is given by the difference between the outer diameter and the core diameter).
The term "ridge" as used in this disclosure, unless otherwise indicated, always refers to the ridge 501 of a male thread of a given threaded connection, regardless of whether the described part actually includes a male thread or a female thread. These ridges may also be referred to as thread peaks (crest) of the threaded connection. The corresponding valleys on the female thread may also be referred to as roots (root) of the threaded connection.
Keying is achieved by at least one of these thread dimensions, such as at least one of a core diameter, an outer diameter, a pitch, a width of the ridge 501 and an opening angle that are different from each other between a separate pair of corresponding connection means 424, 434, 444, 511, 520, 530 of the cartridge holder 422, 432, 442 and the drug delivery device 220, 222, 225.
For the embodiment shown in fig. 36 and 37, the only thread dimensions that differ between the individual dispensing units 420, 430, 440, and thus also between the individual drug delivery devices 220, 222, 225, are the width and height of the individual ridges 501 of the male part and the corresponding width and height of the valleys 502 of the female part. Thus, the ridge 501 of the first connection means 511 has a first width w 1 The ridge 501 of the second connecting means 520 has a second width w 2 And the ridge 501 of the third connecting means 530 has a third width w 3 . First width w 1 Less than the second width w 2 And a second width w 2 Less than the third width w 3 . Illustratively a second width w 2 Is a first width w 1 And a third width w of twice 3 Is a first width w 1 Three times (1).
Furthermore, the ridge 501 of the first connection means 511 has a first height h 1 The ridge 501 of the second connection means 520 has a second height h 2 And the ridge 501 of the third connecting means 530 has a third height h 3 . First height h 1 Greater than the second height h 2 And a second height h 2 Greater than a third height h 3 . Thereby a second height h 2 Is a third height h 3 And a first height h of twice 1 Is a third height h 3 Three times (1).
Height h 1 、h 2 、h 3 The above-mentioned difference of (a) combines with the width w 1 、w 2 、w 3 The above-mentioned differences of the individual dispensing units 420, 430, 440 are reliably prevented from being mounted to drug delivery devices other than their corresponding drug delivery devices 220, 222, 225 having mating connection means 511, 520, 530.
At different heights h 1 、h 2 、h 3 Caused by different outer diameters, wherein the first outer diameter D of the first connection means 424, 511 1 Greater than the second outer diameter D of the second connection means 434, 520 2 And a second outer diameter D of the second connecting means 434, 520 2 Greater than the third outer diameter D of the third connection means 444, 530 3 . The first connecting means 424, 511 have a first core diameter CD 1 The second connecting means 434, 520 has a second core diameter CD 2 And the third connection means 444, 530 has a third core diameter CD 3 And all core diameters CD 1 、CD 2 、CD 3 Are equal.
For other embodiments, different heights h 1 、h 2 、h 3 It is also possible to use different core diameters CD 1 、CD 2 、CD 3 And optionally also by different outer diameters D 1 、D 2 、D 3 Resulting in the following. For example, different heights h 1 、h 2 、h 3 May be caused by the following reasons: core diameter CD 1 、CD 2 、CD 3 And outer diameter D 1 、D 2 、D 3 One of which differs between the connection means 424, 434, 444, 511, 520, 530 and the core diameter CD 1 、CD 2 、CD 3 And outer diameter D 1 、D 2 、D 3 Is the same between the connection means 424, 434, 444, 511, 520, 530. According to a further embodiment, the core diameter CD for all connections 1 、CD 2 、CD 3 Can be selected to be identical to each other and have an outer diameter D 1 、D 2 、D 3 It may also be chosen to be identical to each other such that all devices 220, 222, 225 comprise threads 511, 520, 530 having ridges 501 of the same height.
For the embodiment shown in fig. 36 and 37, the firstFirst pitch P of a connection 424, 511 1 Second pitch P of second coupling means 434, 520 2 And a third pitch P of the third coupling means 444, 530 3 The same applies. Furthermore, a first angle A of the first connection means 424, 511 1 Second angle a of second connection means 434, 520 2 And a third angle a of the third connection means 444, 530 3 The same applies.
For the exemplary embodiment shown in fig. 36 and 37, the individual thread dimensions may be as follows: CD (compact disc) 1 ＝CD 2 ＝CD 3 ＝12.60mm、D 1 ＝14.70mm、D 2 ＝14.00mm、D 3 ＝13.30mm、h 1 ＝2.10mm、h 2 ＝1.40mm、h 3 ＝0.70mm、w 1 ＝0.65mm、w 2 ＝1.30mm、w 3 ＝1.95mm、A 1 ＝A 2 ＝A 3 =60°. The pitch of the individual threads can thus all reach P 1 ＝P 2 ＝P 3 ＝3.80mm。
The thread dimensions may also be as follows: CD (compact disc) 1 ＝CD 2 ＝CD 3 ＝12.60mm、D 1 ＝14.70mm、D 2 ＝14.00mm、D 3 ＝13.30mm、h 1 ＝1.05mm、h 2 ＝0.70mm、h 3 ＝0.35mm、w 1 ＝0.65mm、w 2 ＝1.30mm、w 3 ＝1.95mm、A 1 ＝A 2 ＝A 3 =60°. The pitch of the individual threads can all reach P 1 ＝P 2 ＝P 3 ＝3.80mm。
Alternatively, the above-described dimensions of the width w of the ridge of the male thread may be applied to the width g of the valley of the male thread instead of the width w of the ridge of the male thread. The width g of the valleys of the individual male threads may thus be defined as the bottom section of the grooves of the male threads located at the core diameter and extending between the angled side surfaces of the ridges bounding the male threads, as depicted in fig. 58 and 59.
These thread dimensions may then be as follows: CD (compact disc) 1 ＝CD 2 ＝CD 3 ＝12.60mm、D 1 ＝14.70mm、D 2 ＝14.00mm、D 3 ＝13.30mm、h 1 ＝1.05mm、h 2 ＝0.70mm、h 3 ＝0.35mm、g 1 ＝1.95mm、g 2 ＝1.30mm、g 3 ＝0.65mm、A 1 ＝A 2 ＝A 3 =60° and P 1 ＝P 2 ＝P 3 =3.80 mm. For this embodiment, the width w of the ridge of the male thread may reach: w (w) 1 ＝1.84mm、w 2 ＝2.50mm、w 3 =3.15 mm. The width w of the ridge is thus defined to include the width of the top surface defining the outer diameter D and the two angled side surfaces connecting the separate top surface to the adjacent valleys. Thus, the width w reaches w=p-g. These dimensions are shown in fig. 58 and 59, fig. 58 showing the dispensing units 420, 430, 440, and fig. 59 showing the corresponding connection means 511, 520, 530 of the dispensing units 220, 222, 225.
In general, among a set of N drug delivery devices 200, the nth device may have a thread with a ridge of a width N times the width of the ridge of the thread of the first device and the first device may have a thread with a ridge of a height N times the height of the ridge of the nth device. The mth device (where 1.ltoreq.m.ltoreq.N) may then have a thread with such a ridge having a width m times the width of the ridge of the thread of the first device and a height (N-m+1) times the height of the ridge of the thread of the Nth device.
Alternatively, the above relationship may similarly apply to the width g of the valleys of the male threads, rather than the width w of the ridges of the male threads. Thus, the first device may have a thread with such a valley, the width g of the valley being N times the width g of the valley of the thread of the nth device, and the first device may have a thread with such a ridge, the height of the ridge being N times the height of the ridge of the nth device. The mth device (where 1.ltoreq.m.ltoreq.N) may then have a thread with a valley of width g (N-m+1) times the width g of the valley of the thread of the Nth device and of height (N-m+1) times the height of the ridge of the thread of the Nth device.
In one embodiment, the first, second and third drug delivery devices 220, 222, 225 are each variants of the drug delivery device 200 disclosed in connection with fig. 1-35. The first, second and third drug delivery devices 220, 222, 225 are configured as disclosed in connection with the drug delivery device 200, and vice versa, as long as the differences are not described or apparent from the figures. Furthermore, the first, second and third dispensing units 420, 430, 440 are each a modification of the dispensing unit 410 disclosed in connection with fig. 1 to 35. The first, second and third dispensing units 420, 430, 440 are configured as disclosed in connection with the dispensing unit 410, and vice versa, as long as the differences are not described or apparent from the figures.
The second drug delivery device 222 and the first drug delivery device 220 share at least one common component that is the same between the first and second drug delivery devices 220, 222, and the third drug delivery device 225 and the first drug delivery device 220 share at least one other common component that is the same between the first and third drug delivery devices 220, 225. Thus, the common member is identical to the other common members. For other embodiments, the common member and the other common member may also be different. The common components are thus mechanically identical, i.e. identical in shape, and identical in their appearance (such as in their color and printing).
The second drug delivery device 222 and the first drug delivery device 220 each comprise at least one distinguishing member that differs between the first and second drug delivery devices 220, 222, and the third drug delivery device 225 and the first drug delivery device 220 each comprise at least one other distinguishing member that differs between the first and third drug delivery devices 220, 225. Thereby, the differentiating member and the other differentiating member are the same functional member and thus perform the same function during use of the dosing mechanism. For other embodiments, the common component and the other common component may also be different functional components.
The differentiating member differs at least in its appearance, such as color and printing. In addition, they may also be mechanically different, i.e. they may differ in shape. The separate differentiating member performs the same function during dose setting and dose delivery, despite being different in appearance and optionally shape, and thus constitutes the same functional member between the separate drug delivery devices 220, 222, 225. Thus, in all drug delivery devices 200, 220, 222, 225, the same terminology is used to denote separate distinguishing elements.
The functional components constitute separate parts of the assembled drug delivery device 220, 225. While the individual parts may differ in their exact shape and appearance, for example to provide different dose increments among the individual drug delivery devices 220, 225, they perform the same function and are located at the same location within the dosing mechanism 230 of the individual drug delivery devices 220, 225. Furthermore, it interacts and interfaces with the same other functional components of the dosing mechanism 230 among all drug delivery devices 220, 225 in the kit. The functional component may consist of several sub-parts which are rigidly connected to each other to form a single mechanical part. For one embodiment of the present disclosure, the dosing member may for example constitute a functional member consisting of two sub-parts, i.e. the dose sleeve and the snap element.
The first and second drug delivery devices 220, 222 form a first set of drug delivery devices that differs mechanically only on their outer housings 221, 223 carrying the keyed connection means 510, 520. All other functional components of the drug delivery devices 220, 222 in the first set are mechanically identical. Thus, the dosing mechanism 240, the coupler mechanism 234 and the dose limiting mechanism 232 of the two drug delivery devices 220, 222 are also identical. Thus, the two drug delivery devices 220, 222 are configured to define the same rotational dose position of the dose setting member 290 and each settable dose increment expels the same amount of liquid.
One of the first packages of drug delivery devices 220, 222 is configured for use with its corresponding dispensing unit 420, 430 containing a drug having an active pharmaceutical ingredient at a first concentration, and the other of the first packages of drug delivery devices 220, 222 is configured for use with its corresponding dispensing unit 420, 430 containing a drug having an active pharmaceutical ingredient at a second concentration different from the first concentration.
Among the drug delivery devices 220, 222 in the first set, the piston rod 240, the plunger disc 242, the driver 350, the nut 250, the dose setting member 290, the first and second bearing elements 370, 380, the biasing member 308, the inner housing 180 and all elements of the reset mechanism 110, i.e. the reset element 110, the coupling portion 130 and the biasing member 150, each form a common member between the two drug delivery devices 220, 222 that is identical in appearance and shape to each other.
The dosing member 330 of the two drug delivery devices 220, 222 in the first set forms a distinguishing member that differs in appearance but not in shape between the two drug delivery devices 220, 222. Thus, the appearance differences comprise different numbers of visual indicators 331, whereby individual indicators 331 are located at the same position on the dosing member 330 of the respective two drug delivery devices 220, 222.
The outer housings 211 of the two drug delivery devices 220, 222 in the first set form differentiating elements that differ in shape due to the differences in their connecting means 511, 520. Further, the outer housing 211 is different in appearance (such as in color and/or label) to allow a user to clearly distinguish between the two devices 220, 222.
The dose selector member 310 and the cap 209 of the two drug delivery devices 220, 222 in the first set also form a distinguishing member that differs in appearance but not in shape between the two drug delivery devices 220, 222. Thus, the appearance differences include different labels on the dose selector member 310 and the cap 209. Furthermore, the caps 209 are different in color to match the color of the respective bodies of their drug delivery devices 220, 222. For other embodiments, the dose selector member 310 and/or the cap 209 may also be configured as a common member. Furthermore, the caps 209 may also differ only in color, but not in labels, or vice versa.
Each of the first and second drug delivery devices 220, 222 together with the third drug delivery device 225 forms a second set of drug delivery devices 200, 220, 225 which is mechanically different not only on its outer housing 211, but also on the functional components of its dosing mechanism 230, in particular its dose limiting mechanism 232.
The dosing mechanism 230 of the third drug delivery device 225 is configured to provide a dial resolution that is different from the dial resolution of the first and second drug delivery devices 220, 222. While the dosing mechanism 230 of the first and second drug delivery devices 220, 222 comprises the dose selector member 310 and the dose setting member 290 described in connection with fig. 1-35, which are configured to define 27 settable dose positions, the third drug delivery device 225 comprises an embodiment of the dose selector member 310 and the dose setting member 290 configured to define 18 settable dose positions.
The dose selector member 310 of the third drug delivery device 225 comprises 18 functional features 312 distributed around its inner surface. The position of the resilient element 292 of the dose setting member 290 is thereby adapted to a larger distance between the individual functional features 312 to allow a reliable engagement between the resilient element 292 and the functional features 312.
Since the dose limiting mechanism 332 of the third drug delivery device 225 defines an even number of settable doses, the connection 277 between the coupler member 270 and the dose setting member 290 is configured to connect the coupler member 270 and the dose setting member 290 in two different relative rotational orientations differing from each other by 180 °. To achieve this, the first and second longitudinal grooves 297 and 298 of the dose setting member 290 and the corresponding first and second ridges 279, 280 of the coupler member 270 each have the same width.
The coupling member 270 of the third drug delivery device 225 comprises 18 coupling elements 273, the circumferential position of which is adapted to the circumferential position of the functional feature 312 of the dose selector member 310. Thus, the number and circumferential position of the coupler elements 273 of the coupler member 270 of the third drug delivery device 225 is different from the number and circumferential position of the coupler elements 273 of the coupler members 270 of the first and second drug delivery devices 220, 222.
The coupling members 270 of the first and second drug delivery devices 220, 222 (on the one hand) and the third drug delivery device 225 (on the other hand) form a distinguishing member that differs in shape among the second set of drug delivery devices 220, 222, 225. Likewise, the dose setting members 290 of the first and second drug delivery devices 220, 222 (on the one hand) and the third drug delivery device 225 (on the other hand) also form a distinguishing member that differs in shape among the second set of drug delivery devices 220, 222, 225.
The dosing member 330 of the third drug delivery device 225 comprises 18 coupling elements 336, the circumferential position of which is adapted to the circumferential position of the coupling elements 273 of the coupling member 270. Thus, the dosing member 330 of the third drug delivery device 225 and each of the dosing members 330 of the first and second drug delivery devices 220, 222 form a distinguishing member that differs in shape among the second set of drug delivery devices 220, 222, 225.
In general, the coupler mechanism 234 of the first drug delivery device 220 and the coupler mechanism 234 of the second drug delivery device 222 are configured to rotationally couple the nut 250 to the dosing member 330 and/or the housing 210 in the same relative rotational position. The coupler mechanism 234 of the first and second drug delivery devices 220, 222 (on the one hand) and the coupler mechanism 234 of the third drug delivery device 225 (on the other hand) are configured to rotationally couple the nut 250 to the dosing member 330 and/or the housing 210 in different relative rotational positions.
Likewise, the coupler mechanism 234 of the first drug delivery device 220 and the coupler mechanism 234 of the second drug delivery device 222 are configured to rotationally couple the dose setting member 290 to the dosing member 330 and/or the housing 210 in the same relative rotational position. The coupler mechanism 234 of the first and second drug delivery devices 220, 222 on the one hand and the coupler mechanism 234 of the third drug delivery device 225 on the other hand are configured to rotationally couple the dose setting member 290 to the dosing member 330 and/or the housing 210 in different relative rotational positions.
For all drug delivery devices 200, 220, 222, 225, the coupler element 273 of the coupler member 270, the coupler element 336 of the dosing member 330, the coupler element 312 of the dose selector member 310 and the coupler element 294 of the dose setting member 290 are rotationally aligned with respect to each other as follows: in each rotational position of the dose setting member 290, wherein the coupler element 273 of the coupler member 270 and the coupler member 336 of the dosing member 360 are aligned relative to each other to allow mutual engagement, the coupler element 294 of the dose setting member 290 and the coupler element 312 of the dose selector member 310 are also aligned relative to each other to allow mutual engagement.
Furthermore, the dosing member 330 of the third drug delivery device 225 differs in appearance from the dosing member 330 of the first and second drug delivery devices 220, 222 in that the position of the optical marker 331 on the dosing member 330 of the third drug delivery device 225 differs from the position of the optical marker 331 on the dosing member 330 of the first and second drug delivery devices 220, 222 to reflect the different number of doses settable per revolution of the dose setting member 290.
The number of individual optical marks 331 on the dosing member 330 of the first drug delivery device 220 is different from the number of individual optical marks 331 on the dosing member 330 of the third drug delivery device 225. This allows the first drug delivery device 220 to be used with a drug having a first concentration of active drug ingredient and the third drug delivery device 225 to be used with a drug having a third concentration of active drug ingredient, whereby the product of the first concentration and the amount of liquid expelled by the first drug delivery device 220 per dose increment is different from the product of the third concentration and the amount of liquid expelled by the third drug delivery device 225 per dose increment.
The number of individual optical marks 331 on the dosing member 330 of the second drug delivery device 222 is equal to the number of individual optical marks 331 on the dosing member 330 of the third drug delivery device 225. This allows the second drug delivery device 220 to be used with a drug having a second concentration of active drug ingredient and the third drug delivery device 225 to be used with a drug having a third concentration of active drug ingredient, whereby the product of the second concentration and the amount of liquid expelled by the second drug delivery device 222 per dose increment is equal to the product of the third concentration and the amount of liquid expelled by the third drug delivery device 225 per dose increment.
Due to the shape and appearance differences, the dosing member 330 constitutes a distinguishing member among the second set of drug delivery devices 220, 222, 225.
In general, the common components of the second suit of drug delivery devices 220, 222, 225 are the piston rod 240, the plunger disc 242, the nut 250, the driver 350, the bearing elements 370, 380, the biasing member 308, the inner housing 180 and all elements of the reset mechanism 110 (i.e. the reset element 110, the coupling portion 130 and the biasing member 150).
The differentiating member, which differs only in appearance but not in shape, among the second set of drug delivery devices 220, 222, 225 is a cap 209, each of which has a different color. The differentiating members that differ in both appearance and shape among the second set of drug delivery devices 220, 222, 225 are an outer housing 211 (each of which has a different color and differently shaped connecting means 511, 520, 530), a dosing member 330 (each of which has a different position and/or number and/or label of its optical marker 331 and a differently shaped coupler element 336), a dose selector member 310 (each of which has a different label and a different number of functional features 312), a coupler member 270 (which differs in shape and/or number of its coupler elements 273, and thus also in appearance), and a dose setting member 290 (which differs in the position of its elastic element 292 and its coupler element 294, and thus also in appearance).
The first drug delivery device 220 is configured for use with a drug containing an active pharmaceutical ingredient at a concentration of 5mg/1.5ml, the second drug delivery device 222 is configured for use with a drug containing an active pharmaceutical ingredient at a concentration of 10mg/1.5ml, and the third drug delivery device 225 is configured for use with a drug containing an active pharmaceutical ingredient at a concentration of 15mg/1.5 ml. Both the first and second drug delivery devices 220, 222 have a dial resolution of 0.015ml per dose increment and the third drug delivery device 225 has a dial resolution of 0.010ml per dose increment.
The optical mark 331 on the dosing member 330 of the first drug delivery device 220 then shows a dose increment of 0.05mg, and the optical marks 331 on the dosing member 330 of the second and third drug delivery devices 222, 225 each show a dose increment of 0.10 mg. All drug delivery devices 220, 222, 225 allow two complete rotations of the dose setting member 290 during dose setting. For 27 dose increments per revolution of the dose setting member 290, the first drug delivery device 220 is configured to expel a maximum dose of 1.80mg of active pharmaceutical ingredient and the second drug delivery device 222 is configured to expel a maximum dose of 3.60mg of active pharmaceutical ingredient. Since the third drug delivery device 225 provides 18 dose increments per revolution of the dose setting member 290, it is configured to deliver a maximum dose of 5.40mg of active pharmaceutical ingredient.
Balance weights according to the present disclosure are also applicable to other drug delivery devices, such as injection devices. A further possible injection device is the pen-type other drug delivery device 10 illustrated in fig. 38 to 40. Other drug delivery devices 10 are configured as disclosed in connection with drug delivery device 200, and vice versa, as long as the differences are not described or apparent from the figures. Other drug delivery devices 10 are also described in more detail in international applications WO2020/015980A1 and WO 2019/01394 A1, the disclosure of each of which is incorporated by reference into the present disclosure in its respective entirety.
Other drug delivery devices 10 have an outer housing 3 connected to a dispensing unit 410, the dispensing unit 410 having a cartridge holder 2 holding a cartridge 8. The cartridge holder 2 has a needle connector 402. The injection device 10 has a dosing mechanism 30 and is illustrated in a zero dose state, as indicated by an optical marker 40 showing zero through the window 3a of the outer housing 3. The outer housing 3 terminates at its proximal end in a keyed connection 510, the keyed connection 510 having a threaded form.
Fig. 40 schematically shows a simplified exploded view of the device 10 with the cap 1 removed to expose the cartridge holder 2 and the proximal needle connector 402. The needle 4 is attached to the needle connector 402, typically by a snap fit, threads, luer lock or other secure attachment with the hub 5, so that the double ended needle cannula 6 may enable fluid communication with the medicament contained in the cartridge 8 positioned within the cartridge holder 2.
The specific design of the device 10 allows one or more of the predetermined fixed doses to be set by the interaction of the snap element 33 with the dose selector member 35. Rotation of the dose setting member 31 and the catch element 33 occurs during dose setting and relative to the outer housing 3. During initiation of a dose delivery procedure, the dose setting member 31 is pressed in a proximal direction, causing it and the dose selector member 35 to move axially relative to the catch element 33. As with the drug delivery device 200, the dose selector member 35 is axially movable and rotationally fixed with respect to the outer housing 3 of the other drug delivery device 10.
Part of the dosing mechanism of most pen-type injectors, including the device 10, is a piston rod 42, as illustrated in fig. 40. The piston rod 42 has a non-circular cross-section and two flat surfaces designed to prevent the piston rod 42 from rotating relative to the outer housing 3 but allow it to move linearly in the proximal direction. The nut 36 and the coupler member 32 are permanently splined to each other by a spline connection 37 during assembly of the dosing mechanism 30. The spline connection 37 ensures that the coupler member 32 and the nut 36 are always rotationally fixed relative to each other during dose setting and dose delivery. This spline connection 37 also allows the coupler member 32 and the nut 36 to move axially relative to each other during dose setting and dose delivery.
The proximal end of the nut 36 has an internal thread that mates with a corresponding external thread 60 of the piston rod 42. The distal end of the coupler member 32 is configured as a dose button 61 and is permanently attached to the distal end of the dose setting member 31 by engagement of a connector, which may be configured as a snap lock, adhesive and/or sonic welding. This connection ensures that the coupling member 32 is rotationally and axially fixed to the dose setting member 31 during dose setting and dose delivery. Alternatively, the coupler member 32 and the dose setting member 31 may also be configured as a single member.
At the distal proximal end of the piston rod 42 is a connector configured as a snap fit that connects with the plunger disc or foot 42 a. At the distal end of the piston rod 42, a stop feature 63 of the dosing mechanism 30, the stop feature 63 is illustrated as an enlarged section. This enlarged section 63 is designed to prevent rotation of the nut 36 around the thread 60 when the amount of medicament remaining in the cartridge 8 is less than the next highest predetermined dose setting. In other words, if the user tries to set one of the predetermined fixed dose settings that exceeds the amount of drug remaining in the cartridge 8, the enlarged section 63 will act as a hard stop preventing further rotation of the nut 36 along the thread 60 when the user tries to reach the desired predetermined fixed dose setting. For the drug delivery device 200, the stop feature 243 interacts with the nut 250 in the same way and thus also prevents setting of a dose that is larger than the remaining dose within the cartridge 8.
During dose setting and dose delivery, the piston rod 42 is maintained in a non-rotated state with respect to the outer housing 3 by the piston rod guide 43. The piston rod guide 43 is rotationally and axially fixed to the outer housing 3. Thus, it forms part of the housing of the device 10. As illustrated, this fixation may be achieved when the piston rod guide 43 is a separate component from the outer housing 3, or the piston rod guide 43 may be integrally made with the outer housing 3, similar to the inner sleeve 183 of the inner housing 180 of the drug delivery device 200. Although not shown in the figures, the piston rod guide 43 may be configured as a resetting mechanism that prevents rotation of the piston rod 42 relative to the housing 3 when the dispensing unit 410 is attached to the housing 3 of the drug delivery device 10, like the resetting mechanism 100 of the drug delivery device 200; and said resetting mechanism allows a rotational movement of the piston rod 42 relative to the housing 3 when the dispensing unit 410 is disengaged from the housing 3.
The reset mechanism of the other drug delivery device 10 may be configured as disclosed in connection with the reset mechanism 100 of the drug delivery device 200. In particular, the reset mechanism of other drug delivery devices 10 may include a reset element 110, a coupling portion 130, and a biasing element 150.
The piston rod guide 43 also engages the proximal end of a rotary biasing member 90 (shown as a torsion spring), the function of which will be explained below. This connection of the rotary biasing member 90 to the piston rod guide 43 anchors one end of the rotary biasing member 90 in a rotationally fixed position relative to the outer housing 3.
The distal end of the rotary biasing member 90 is connected to the driver 41. The driver 41 is connected to and rotationally fixed relative to the inner surface of the dosing member 330 by a spline connection on the distal outer surface of the driver 41. This spline connection includes at least one (such as two) longitudinal ridges on the outer diameter of the driver 41 that engage corresponding grooves on the inner surface of the dosing member 330. Threads 67 are on the outer surface of the proximal end of driver 41 that engage mating threads on the inner distal surface of piston rod guide 43.
The dosing member 330 comprises two parts which are rotationally and axially fixed to each other, e.g. by a snap fit connection. One part forms the dose sleeve 38 which is connected to the driver 41 by a splined connection and the other part forms the snap element 33. As such, dosing member 330 forms a single functional member.
The dosing member 330, i.e. the dosing sleeve 38, is threadedly engaged with the body 3 by means of a helical groove 39 on the outer surface of the dosing member 330, the helical groove 39 being engaged with a corresponding helical ridge on the inner surface of the body 3. The thread between the driver 41 and the piston guide 43 has a significantly different pitch than the thread between the dosing member 330 and the outer housing 3. The axially sliding connection between the nut 36 and the coupler member 32 allows compensating for differences in the pitch of the thread between the inner surface of the nut 36 and the outer surface of the piston rod 42 and the pitch of the thread between the dosing member 330 and the body 3. The thread between the driver 41 and the piston guide 43 has substantially the same pitch as the thread between the piston rod 42 and the nut 36.
The nut 36 and the driver 41 rotate together during dose setting and dose cancelling and as such they perform substantially the same axial movement. However, these movements are mutually independent, i.e. the nut 36 is turned by the coupler member 32 and performs an axial movement due to the thread of the piston rod 42, whereas the driver 41 is turned by the dosing member 330 and performs an axial movement due to the thread of the piston guide 43. The driver 41 also rotates during injection and thus it actively moves in the proximal direction during injection. However, the nut 36 does not rotate during injection and as such does not perform active axial movement. The nut 36 is only moved in the proximal direction during injection, as it is pushed axially by the driver 41, the driver 41 encircling the nut 36 and abutting against the projection 64 at the proximal end of the nut 36. The driver 41 pushing the rotation of the non-rotating nut 36 causes an injection as the piston rod 42 is pushed forward due to the threaded engagement with the nut 36.
Since the torsion spring 90 is attached to the driver 41 and the driver 41 is rotationally fixed to the dosing member 330, rotation of the dosing member 330 in a first direction during dose setting will wind the torsion spring 90 such that it exerts a counter-rotational force on the dosing member 330 in an opposite second direction. This counter-rotational force biases the dosing member 330 to rotate in the dose cancelling direction.
In general, other drug delivery devices 10 include a biasing member, which is illustratively configured as a torsion spring 90, which is strained when the set dose is increased. Furthermore, the biasing member is released during dose delivery. Thus, the biasing member assists in the delivery of the set dose by providing a force pushing the piston rod 60 in a proximal direction at least. Such a biasing member may also be provided in the drug delivery device 200. For example, it may also be configured as a torsion spring provided between the inner housing 180 and the driver 350 of the device 200 and acting between the inner housing 180 and the driver 350 in the same way as the torsion spring 90 acts between the piston guide 43 and the driver 41 of the other drug delivery device 10.
The function of the complete other drug delivery device 10 and dosing mechanism 30 will now be described. Other drug delivery devices 10 are provided to the user as reusable or semi-reusable devices. Semi-reusable means that only the dosing mechanism 30 housed in the outer housing 3 is reused whenever a new dispensing unit 410 with a cartridge holder 2 of a new cartridge 8 containing a medicament is connected to the outer housing 3. The reusable device will allow reattachment of an old or previously used cartridge holder 2, wherein the user has inserted a new full cartridge 8 of medicament. In one configuration according to the present disclosure, the device 10 has a semi-reusable design, wherein a user will be required to disconnect the cartridge holder 2 containing an empty cartridge 8, the cartridge 8 not being removable from the cartridge holder 2, each time the medicament in the cartridge 8 is ejected or emptied. As such, the user will dispose of both the cartridge holder 2 and the empty cartridge 8 together. If the keyed connection 510 on the outer housing 3 matches the keyed connection 414 provided on the distal end of the cartridge holder 2, a new cartridge holder 2 and cartridge 8 assembly will be connected to the outer housing 3.
For other drug delivery devices 10, the dose sleeve 38 and the snap element 33 are fixed axially and rotationally to each other via a snap fit connection. Thus, the dose sleeve 38 and the catch element 33 constitute a single functional element, namely the dosing member 330. For other embodiments of other drug delivery devices 10, the dosing member 330 may also be configured as a single component or member.
The housing of the other drug delivery device 10 comprises an outer housing 3 and a piston guide 43, which are rotationally and axially fixed relative to each other.
Like the drug delivery device 200, other drug delivery devices 10 include a coupler mechanism 237. During dose setting, the coupler mechanism 237 rotationally fixes the nut 36 relative to the driver 41 and the dosing member 330 and allows rotation of the nut 36 relative to the housing 3, 43. During dose delivery, the coupler mechanism 237 rotationally fixes the nut 36 relative to the dose selector member 35 and the housing 3, 43 and allows relative rotation between the nut 36 (on the one hand) and the driver 41 and dosing member 330 (on the other hand).
As can be seen from fig. 41 and 42, the first portion 238 of the coupler mechanism 237 comprises a coupler element 33a, the coupler element 33a being configured as radially extending teeth and being provided on an outer surface at the distal end of the catch element 33 of the dosing member 330. The second portion 239 of the coupler mechanism 237 includes a coupler element 34a, the coupler element 34a being configured as radially extending teeth and being provided on an outer surface at the distal end of the coupler 34.
The connector 34 is located within an annular recess of the dosing member 330 and is thereby rotationally movable and axially fixed relative to the dosing member 330. The connector 34 is axially movable and rotationally fixed with respect to the dose selector member 35. This is illustratively achieved by radially protruding ridges 34b of the connector 34, the ridges 34b being received in corresponding longitudinal grooves on the inner surface of the dose selector member 35. The rotationally fixed connection to the dose selector member 35 also rotationally fixes the connector 34 to the housing 3, 34 of the other drug delivery device 10.
The dosing member 330 surrounds the coupling member 32 and the coupling member 32 together with the dose setting member 31 and the dose selector member 35 is axially movable with respect to the dosing member 330. Thereby, the dose setting member 31 and the coupling member 32 are biased in distal direction by a compression spring 91 (shown in fig. 40) acting between the dosing member 330 and the coupling member 32. Axial movement of the coupling member 32 and the dose setting member 31 in the proximal direction is allowed until the dose setting member 31 pushes the dosing member 330 via the coupling member 32. Thereby, the pushing member 32a, which is exemplarily configured as a ridge protruding from the outer surface of the cylindrical portion of the coupling member 32, pushes the dosing member 330, i.e. the distal end of the snap element 33.
During dose setting, the coupler member 32 and the dose setting member 31 are in their distal positions with respect to the dosing member 330. In this position, the dose setting member 31 is rotationally coupled to the dosing member 330 via the first portion 238 of the coupler mechanism 237, the coupler mechanism 237 comprising a coupler element 33a at the distal end of the catch element 33 of the dosing member 330 and a corresponding coupler element 31a on the inner surface of the dose setting member 31, which is shown in fig. 42. When the dose setting member 31 is rotated during dose setting, the dosing member 330 is also rotated via the closed first part 238 of the coupling mechanism 237 between the dose setting member 31 and the dosing member 330 and is unscrewed from the outer housing 3. This forces the dose selector member 35 and the dose setting member 31 to also move in the distal direction. The rotation of the dosing member 330 also forces a corresponding rotation of the driver 41, and thus the driver 41 is also unscrewed from the piston guide 43.
Since the nut 36 is rotationally fixed relative to the coupler member 32, rotation of the dose setting member 31 also causes rotation of the nut 36 during dose setting. Thereby, the nut 36 is screwed along the piston rod 42 and also moves in the distal direction. The pitch of the threads of the piston rod 42 and the driver 41 are adapted such that the nut 36 and the driver 41 move substantially the same axial distance when rotated. Thus, the nominal pitch of the connection between the driver 41 and the piston guide 43 is slightly higher than the nominal pitch of the threads between the piston rod 42 and the nut 36, to prevent mutual blocking of the nut 36 and the driver 41, irrespective of manufacturing tolerances.
To expel the set dose, the dose setting member 31, the coupling member 32 and the dose selector member 35 are moved into their proximal position with respect to the dosing member 330. This releases the first portion 238 of the coupler mechanism 237 between the catch element 33 of the dosing member 330 and the dose setting member 31 and engages the second portion 239 of the coupler mechanism 237, which is achieved between the dose setting member 31 and the connector 34 surrounding the dosing member 330. Upon engagement of the second portion 239 of the coupler mechanism 237, the coupler element 31a of the dose setting member 31 is engaged with the coupler element 34a of the connector 34.
Engagement of the second portion 239 of the coupler mechanism 237 rotationally locks the dose setting member 31 and the coupler member 32 to the connector 34 and rotationally locks the dose selector member 35 and the housing 3, 43 via the ridge 34b of the connector 34. Thus, during dose delivery, the nut 36 is rotationally locked with respect to the housing 3, 43 and the piston rod 42. This locking is achieved via the nut 36, the coupling member 32, the dose setting member 31, the connector 34 and the dose selector member 35.
Disengagement of the first portion 238 of the coupler mechanism 237 allows rotational movement between the nut 36 and the driver 41 and dosing member 330 during dose delivery.
When the dose setting member 31 is pushed further in the proximal direction, the coupler member 32 abuts the dosing member 330 and forces the dosing member 330 to move in the proximal direction. Due to the threaded connection between the dosing member 330 and the outer housing 3, the dosing member 330 rotates when moving in the proximal direction. This rotation is transmitted to the driver 41, which driver 41 is screwed into the piston guide 43 in the proximal direction and thus also moves axially in the proximal direction. The driver 41 thereby abuts and advances the nut 36, the nut 36 now being rotationally fixed to the outer housing 3 and the piston rod 42 via the coupler member 32, the dose setting member 31, the connector 34 and the dose selector member 35. Thus, both the piston rod 42 and the nut 36 are rotationally fixed relative to each other, and axial advancement of the nut 36 causes a corresponding axial advancement of the piston rod 42, thus expelling the set dose.
Like the drug delivery device 200, other drug delivery devices 10 may also include one or more friction reducing mechanisms that reduce friction within the dosing mechanism 30 during delivery of a set dose. These friction reducing mechanisms may be configured in the same manner as disclosed in connection with the drug delivery device 200.
For example, a first friction reducing mechanism may be provided between the actuation member formed by the coupling member 32 and the dosing member 330 of the other drug delivery device 10. The coupler member 32 acts as an actuation member which, when the user pushes the distal portion of the coupler member 32, provides a force in the proximal direction which force effects the delivery of the set dose.
Thus, the coupler member 32 and dosing member 330 may directly contact the first friction reducing mechanism. For example, the friction reducing mechanism may be provided before the distal end of the dosing member 330 and the protruding ridge 32a of the coupling member 32.
For other embodiments of other drug delivery devices 10, the first friction reducing mechanism provided between the actuation member and the dosing member 330 may also be contacted via one or more intermediate members. For example, a first friction reducing mechanism may be provided between the dose selector member 35 and the dosing member 330. When the coupler member 32, and thus the dose setting member 31, is pushed in the proximal direction, the dose selector member 35 (e.g. the proximal end of the dose selector member 35) may abut against the dose sleeve 38, e.g. against the distal end of the dose sleeve 38. A first friction reducing mechanism, such as a ball bearing 370, may then be provided between the dose selector member 35 and the dose sleeve 38, for example between the proximal end of the dose selector member 35 and the distal end of the dose sleeve 38.
Additionally or alternatively, a second friction reducing mechanism may be provided between the driver 41 and the nut 36 in the same manner as disclosed in connection with the second friction reducing mechanism of the drug delivery device 200, such as the disc bearing 380.
Other drug delivery devices 10 comprise a dose limiting mechanism 232 acting between a dosing member 330 and a dose selector member 35. During dose setting, the dosing member 330 rotates relative to the dose selector member 35. As can be seen from fig. 41, the dosing member 330 (i.e. the snap element 33) has on its outer surface flexible arms 33c with radial protrusions 33d forming resilient elements and engaging with the dose stop 35a on the inner surface of the dose selector 35. The dose stop 35a shown in fig. 43 forms a functional feature 312 of the dose limiting mechanism 232.
The circumferential position of the individual dose stop 35a thereby defines an individual relative rotational position between the dosing member 330 and the housing 3, 43, which corresponds to a settable dose. To prevent intermediate doses from being dialled between the individual dose stops 35a, a torsion spring 90 is provided between the piston guide 43 and the driver 41. This torsion spring 90 loads upon increasing the set dose and causes the dosing member 330 to rotate back to the last set dose in the case where the dose setting member 31 is released and the protrusion 33d on the dosing member 330 is positioned between the two dose stops 35 a.
For other drug delivery devices 10, the dosing member 330 is restricted to perform less than one complete rotation at dose setting. Other drug delivery devices 10 include a stop mechanism that defines the maximum and minimum rotational positions of the dosing member 330 during dose setting.
The stop mechanism acts between the catch element 33 of the dosing member 330 and the dose selector member 35. It comprises further protrusions 33f, which further protrusions 33f are located on the outer surface of the dosing member 330 and protrude radially towards the dose selector member 35. The dose selector member 35 comprises a maximum stop feature 35b, the maximum stop feature 35b being located on an inner surface of the dose selector member 33 and being configured as a side surface of a step located on the inner surface. Furthermore, the dose selector member 35 comprises a zero stop feature 35c, the zero stop feature 35c also being located on the inner surface of the dose selector member 33. The zero stop feature 35c is illustratively configured as a side surface of the step opposite the side surface forming the maximum stop feature 35 b. For other embodiments of the dose selector member 33, the zero stop feature 35c and the maximum stop feature 35b may also be provided at separate protrusions or steps on the inner surface of the dose selector member 33.
The other projections 33f of the dosing member 330 are configured to abut the maximum stop feature 35b when the dosing member 330 is rotated into a rotational position corresponding to or exceeding the maximum settable dose and thereby prevent further rotation of the dosing member 330. Likewise, the other protrusions 33f of the dosing member 330 are configured to abut the zero stop feature 35c when the dosing member 330 is rotated into a rotational position corresponding to a zero dose setting and thereby prevent further rotation of the dosing member 330.
Other drug delivery devices 10 may also include alternative embodiments of a stop mechanism defining a maximum dose position and/or a zero dose position of the dosing member 330 relative to the housing 3, 43. This alternative embodiment may be configured like a stop mechanism of the drug delivery device 200. Thus, a maximum dose stop may be provided at the dosing member 330 (such as at the dose sleeve 38 or the catch element 33), and a corresponding maximum stop feature may be provided at the housing 3, 43. The maximum dose stop and/or the maximum stop feature may be configured as described in connection with the maximum dose stop 337 and the maximum stop feature 190 of the drug delivery device 200.
Likewise, alternative embodiments of the stop mechanism of other drug delivery devices 10 may comprise a zero dose stop provided at the dosing member 330, such as at the dose sleeve 38 or the catch element 33, and a corresponding zero stop feature provided at the housing 3, 43, e.g. at the piston guide 43. The zero dose stop and/or zero stop feature may be configured as described in connection with the maximum dose stop 337 and the maximum stop feature 190 of the drug delivery device 200.
Like the drug delivery device 200, other dose delivery devices 10 may be provided in several variants, which are distinguished by their connection means 510 being configured to connect only to dedicated variants of the dispensing unit 410. The connection means 510 may thus be configured as disclosed in connection with fig. 36 and 37.
In one embodiment, several variations of the other drug delivery device 10 include the outer housing 3, the cap 1, the dose sleeve 38 and the dose selector member 35 as differentiating members. The outer housing 3 is different in shape due to the difference of the connection means 510 and also different in appearance due to different colors and/or labels. The dose selector member 35 is different in shape due to different numbers and/or different positions of the dose stops 35a, which allows different dial resolutions or settable doses to be achieved. Alternatively or additionally, the dose selector member 35 may also differ in the position of the maximum stop feature 35 c. The dose sleeve 38 is mechanically identical between the individual variants, but differs in appearance due to the different positions and/or numbers of its optical markings. The caps 1 are identical in shape but differ in their appearance (e.g. colour and/or label). For other embodiments, cap 1 may also be configured as a common member.
The common component of the variants of the other drug delivery device 10 may then be all other elements of the dosing mechanism 30.
For both types of drug delivery devices 10, 200, the mechanical advantage of the dosing mechanism 230 during dose dispensing may differ between the devices in a separate kit. For example, the kit may include one of the following devices: this device has a higher mechanical advantage than another device in the corresponding kit. Among these devices, the driver 41, 350 and the portion of the housing 210 that is threadably connected to the driver 41, 350 (such as the inner housing 180 and the piston guide 43) may be mechanically distinct components from each other due to the different pitches of their threads 67, 186, 353. Additionally or alternatively, the portions of the dosing member 330, in particular the dosing sleeve 38 and the housing 210, which are threadedly connected to the dosing member 330 (like the inner housing 180 and the housing 3) may be mechanically distinct members from each other due to the different pitches of their threads 39, 185, 335. All of the kits of drug delivery devices 10, 200 described in the present disclosure may include drug delivery devices 10, 200 that differ in terms of the mechanical advantage of their dosing mechanism 230 during dose dispensing.
Fig. 44 and 45 show an alternative embodiment of the reset element 110 of the drug delivery device 200. The reset element 110 according to alternative embodiments is configured as described above in connection with the reset element 110 of the drug delivery device 200, and vice versa, as long as the differences are not described or apparent from the figures.
The reset element 110 includes a guide structure 116 located within the cartridge cavity 115. The guide structure 116 has an elongated shape and extends parallel to the longitudinal axis 207. They are placed on the circumferential side wall of the cartridge cavity 115. The guide structures 116 are thus equally spaced from each other. For the embodiment shown in fig. 44 and 45, reset element 110 illustratively includes eight guide structures 116. For other embodiments, the reset element 110 may include more or fewer guide structures 116.
The guiding structure 116 is configured to center the distal end of the cartridge 8 with respect to the longitudinal axis 207 when the dispensing unit 410 is attached to the drug delivery device 200. The guide structure 116 radially touches the cartridge 8 inserted into the cartridge holder 412. As such, it only defines the lateral position of the cartridge 8 relative to the longitudinal axis 207, but does not define the axial position of the distal end of the cartridge 8. Furthermore, the axial position of the distal end of the cartridge 8 does not define the axial position of the reset element 110 either.
The guiding structure 116 is configured not to be pushed by the cartridge 8 during attachment of the dispensing unit 410 to the drug delivery device 200. The guide structure 116 includes an inclined front surface 116a facing in a proximal direction. The sloped front surface 116a centers the cartridge 8 but prevents the reset element 110 from receiving an axial force via the cartridge 8 that would axially displace the reset element 110. The guide structure 116 further includes an angled rear surface 116b facing in a distal direction.
Both the front surface 116a and the rear surface 116b may have an angle of at most 45 ° (e.g., at most 30 °, 20 °, or 10 °) with the longitudinal axis 207. For example, the front surface 116a may have an angle with the longitudinal axis 207 of greater than 5 °, greater than 10 °, or greater than 15 °, and/or less than 45 °, less than 30 °, or less than 25 °. The angle may for example be equal to 20 °. The rear surface 116b may, for example, have an angle with the longitudinal axis 207 of greater than 0 ° or greater than 0.5 ° and/or less than 10 °, less than 5 °, or less than 2.5 °. The angle may for example be equal to 1 °.
Fig. 46 shows an alternative embodiment of the coupling portion 130 of the drug delivery device 200. As long as the differences are not described or apparent from the figures, the coupling portion 130 according to an alternative embodiment is configured as described above in connection with the coupling portion 130 of the drug delivery device 200 and vice versa.
An alternative embodiment of the coupling portion 130 includes four lugs 138. The lugs 138 are circumferentially distributed about the longitudinal axis 207 and are equally spaced from one another in the circumferential direction.
Furthermore, alternative embodiments of the coupling portion 130 include recesses 139a in addition to slots 139. In fig. 46, the coupling portion 130 is exemplarily shown with two recesses 139a. Recess 139a is located at the distal end of coupling portion 130. Each recess 139a is centered with respect to one of the first locking structures 137 and divides the respective first locking structure 137 into two portions. As further seen in fig. 46, the slots 139 and recesses 139a are alternately distributed in the circumferential direction and equally spaced from each other.
Fig. 47 shows an alternative embodiment of the reset element 110 and an alternative embodiment of the coupling portion 130 mounted to an alternative embodiment of the inner housing 180. Alternate embodiments of the housing 180 are configured as described above in connection with the inner housing 180 of the drug delivery device 200, and vice versa, as long as the differences are not described or apparent from the figures.
An alternative embodiment of the inner housing 180 includes one tappet 184 for each of the slot 139 and recess 139a. Thus, in general, the inner housing 180 includes four lifters 184. A tappet 184 is provided at the proximal end of the inner housing 180. Furthermore, they are equally spaced from each other in the circumferential direction about the longitudinal axis 207.
Fig. 48-49 show alternative connections between alternative embodiments of the inner housing 180 and alternative embodiments of the dose selector member 310. Alternate embodiments of the inner housing 180 and/or alternate embodiments of the dose selector member 310 are configured as described in connection with other embodiments of the inner housing 180 and the dose selector member 310 according to the present disclosure, as long as the differences are not described or apparent from the figures.
The dose selector member 310 shown in fig. 48 and 49 comprises longitudinal protrusions 319a on two flexible members 319, wherein the longitudinal protrusions 319a protrude radially outwards into the longitudinal slots 198 in the inner housing 180. As can be seen from fig. 48, the longitudinal slot 198 receiving the projection 319a has a recess 193 at its distal end. The recess 193 of each slot 198 is configured to receive a protrusion 319a located within the respective slot 198 when the dose selector member 310 is fully extended in a distal direction from the inner housing 180 (e.g., when a maximum settable dose is set). This is further illustrated in fig. 50 and 51, fig. 50 showing the inner housing 180, the dose selector member 310 and the dosing member 330 in the absence of dose setting, and fig. 51 showing the inner housing 180, the dose selector member 310 and the dosing member 330 in the maximum dose setting.
When the maximum dose is set, the stop surface 338 of the maximum dose stop 337 abuts the limiting surface 192 of the maximum stop feature 190. Further, a radial projection 198a is received within the recess 193. For the embodiment of the drug delivery device 200 shown in fig. 48-51, the inner housing 180 includes two maximum stop features 190 that are positioned opposite each other relative to the longitudinal axis 207. Instead of two other maximum stop features 190, the inner housing 180 includes two longitudinal slots 198, the longitudinal slots 198 having recesses 193 at the distal ends. Longitudinal slots 198 having recesses 193 are positioned opposite one another relative to longitudinal axis 207. In the circumferential direction, the inner housing 180 alternately includes a longitudinal slot 198 featuring a limiting surface 192 and a longitudinal slot 188 featuring a recess 193.
The radial protrusions 319a and recesses 193 may act as other maximum dose stop mechanisms provided between the dose selector member 310 and the inner housing 180 and limiting axial movement of the dosing member 330 and the dose selector member 310 when a maximum settable dose has been set. Alternatively or additionally, they may provide locking means that prevent the dose selector member 310 from being detached from the housing 210 after assembly of the drug delivery device 200. For example, the radial protrusion 319a and the recess 193 may be configured as follows: which do not touch each other when the stop surface 338 is engaged with the limiting surface 192, but only when the dose selector member 310 is further forcefully moved in the distal direction. Alternatively, radial projection 319a and recess 193 may be configured to touch limiting surface 192 substantially simultaneously with the touching of stop surface 338.
As can be seen from fig. 49 and 50, the inner housing 180 configured to receive an alternative embodiment of the dose selector member 310 having radial projections 319a may also have four lifters 183 and be configured for use in a drug delivery device 200 featuring an alternative embodiment of the coupling portion 130 shown in fig. 46 and 47. Alternatively, such an inner housing 118 may also feature only two lifters 184 and be configured for use with the coupling portion 130 described in connection with fig. 27-33.
As can further be seen from fig. 51, the dose limiting mechanism 232 of the drug delivery device 200 with an alternative embodiment of the dose selector member 310 and the inner housing 180 is exemplarily configured as described in connection with fig. 36 and 37 for the first drug delivery device 220, the first drug delivery device 220 being configured to expel a maximum dose of 1.8mg of active drug ingredient.
As already described in connection with the first, second and third drug delivery devices 220, 222, 225, the coupler mechanism 234 of the individual drug delivery devices 220, 222, 225 in the individual kit may define a different number of rotational coupling positions, wherein the first portion 235 of the coupler mechanism 234 may be closed to rotationally couple the nut 250 and/or the coupler member 270 to the dosing member 330. These rotational coupling positions are defined by the circumferential positions of the coupler elements 273, 336.
The angular spacing between these rotational coupling positions corresponds to the angular spacing between dose positions settable by rotating the dose setting member 290. For drug delivery devices 200 of the type described in connection with fig. 1 to 37 and 44 to 51, the angular spacing between the rotationally coupled positions is equal to the angular spacing between the dose positions. In general, these positions may correspond in the following manner: the angular spacing between the dose locations is an integer multiple of the angular spacing between the coupling locations. For example, depending on the circumferential position of the dose stop 35a on the inner surface of the dose selector member 35 of the other drug delivery device 10, the angular spacing between the dose positions defined by the dose stop 35a may be an integer multiple of the rotational coupling position defined by the coupler element 34a on the connector 34 and the coupler element 33a on the catch element 33.
The embodiment of the coupling member 270 of the drug delivery device 200 shown in fig. 16 and 17 comprises one coupling element 273 for each rotational coupling position. Thus, in principle, a single coupler element 336 on the dosing member 330 will be sufficient to define the rotational coupling position. For alternative embodiments of the coupler member 270, the number of coupler elements 273 may also be different from the number of rotational coupling positions. For example, the number of coupling elements 273 may be less than the number of rotational coupling positions per revolution of the dose setting member 290. Thus, the number of coupler elements 273 may be at least one, at least two (such as one or two), or more coupler elements 273 less.
The embodiment of dosing member 330 shown in fig. 20 comprises one coupler element 336 for each rotational coupling position. Thus, in principle, a single coupler element 273 on coupler member 270 would be sufficient to define a rotationally coupled position. For alternative embodiments of the dosing member 330, the number of coupler elements 336 may also be different from the number of rotational coupling positions. For example, the number of coupler elements 336 may be less than the number of rotational coupling positions per revolution of the dose setting member 290. Thus, the number of coupler elements 336 may be at least one, at least two (such as one or two), or more coupler elements 336.
Fig. 52 shows an alternative embodiment of a coupling member 270 of the drug delivery device 200. Alternate embodiments of the coupler member 270 are configured as disclosed in connection with the coupler member 270 described above, so long as the differences are not described or apparent from the figures.
The number of coupler elements 273 of the alternative embodiment of coupler member 270 is two less than the number of rotational coupling positions. The coupler elements 273 are positioned adjacent to each other in two groups, wherein each group comprises the same number of coupler elements 273, i.e. illustratively eight coupler elements 273, and wherein the coupler elements 273 in the individual groups are equally spaced from each other. In the gap between the two groups, the ninth coupling element 273 is absent. The two groups of coupler elements 273 are circumferentially spaced apart from each other by a distance that is twice the distance between coupler elements 273 in the individual groups.
The drug delivery device 10, 200, 220, 222, 225 according to the present disclosure may comprise a balancing weight. The balancing weight may be located at a position offset from the longitudinal axis 207 of the device 10, 200, 220, 222, 225 such that the position of the centroid of the device 10, 200, 220, 222, 225 is displaced away from the longitudinal axis 207 toward the outer circumferential shell of the device 10, 200, 220, 222, 225. This prevents the device 10, 200, 220, 222, 225 from rolling when it is placed on a flat surface.
Fig. 53 shows a perspective view 200 of a drug delivery device without an outer housing 211 equipped with such a balancing weight 160, and fig. 54 shows a radial section through the device 200 perpendicular to the longitudinal axis 207 and balancing weight 160. The balance weight 160 is located within the housing 210 of the device 200, i.e., the outer housing 211. Thus, it is placed between the inner housing 180 and the outer housing 211, and between the dosing mechanism 230 and the outer housing 211.
The balance weight 160 is placed on the outer surface 199 of the inner housing 180. Having a curved bottom surface 161 facing toward longitudinal axis 207 and a curved top surface 162 facing away from longitudinal axis 207. The bottom surface 161 forms a segment of a cylindrical shell whose axis of rotation coincides with the longitudinal axis 207. Likewise, top surface 162 forms a segment of a cylindrical shell, the axis of rotation of which coincides with longitudinal axis 207. The bottom and top surfaces 161, 162 are oriented parallel to each other.
The balance weight 160 is placed in a support 170, the support 170 being formed on an outer surface 199 of the inner housing 180, and is particularly depicted in fig. 55. The stand 170 includes a support surface 175, the support surface 175 carries the balance weight 160, and the bottom surface 161 of the balance weight 160 rests on the support surface 175. The support surface 175 is formed by an outer surface 199 of the inner housing 180. Furthermore, the abutment 170 comprises at least one (i.e. two) first longitudinal stop element 171 and a second longitudinal stop element 173, the first longitudinal stop element 171 delimiting the abutment 170 towards the proximal end 205, the second longitudinal stop element 173 delimiting the abutment 170 towards the distal end 20. To prevent rotation of the balance weight 160 in the circumferential direction, the mount 170 includes two circumferential stop elements 172 that limit the mount 170 in the circumferential direction.
The first longitudinal stop element 171 is configured as a protrusion on the outer surface 199 of the inner housing 180. The first longitudinal stop elements 171 are spaced apart from each other in the circumferential direction and are located at the same axial position along the longitudinal axis 207. The first longitudinal stop element 171 has an elongated shape oriented perpendicular to the longitudinal axis 207.
The second longitudinal stop element 173 is configured as a protrusion forming a step in the outer surface 199 of the inner housing 180. The second longitudinal stop element 173 extends perpendicular to the longitudinal axis 207 and forms a radial surface oriented perpendicular to the longitudinal axis 207.
The circumferential stop element 172 is configured as a separate protrusion on the outer surface 199 of the inner housing 180. Which is placed at the distal end of the abutment 170. Furthermore, it is configured as a projection extending in the proximal direction from the second longitudinal stop element 173. The longitudinal stop element 172 has an elongated shape oriented parallel to the longitudinal axis 207.
As can be seen from fig. 54, the stand-offs are covered by an outer housing 211. The balance weight 160 is configured with its top surface 162 against the inner surface of the outer housing 211. The balance weight 160 is sandwiched between the inner housing 180 and the outer housing 211. The covered support 170 forms a cavity into which the balance weight 160 is inserted. Thus, the balance weight 160 is held in place only by the stop elements 171, 172, 173, the support surface 175, and the inner surface of the outer housing 211.
As can be further seen from fig. 54, the balancing weight 160 causes the centroid 208 of the drug delivery device 200 to be positioned away from the longitudinal axis 207 of the device 200 towards the balancing weight 160. The centroid 208 is located between the longitudinal axis 207 and the balance weight 160. Further, the distance between the balance weight 160 and the centroid 208 is less than the distance between the centroid 208 and the longitudinal axis 207.
The balance weight 160 and the window in the housing 210 (which illustratively is formed by window 211a in the outer housing 211 and window 180a in the inner housing 180) are located at different angular positions relative to the longitudinal axis 207. In the exemplary embodiment of fig. 54, the counterweight 160 and the window in the housing 210 are located at angular positions 180 ° apart and thus correspond to opposite sides of the longitudinal axis 207.
With the cap 209 removed, the contact surface of the drug delivery device 200 comprises all surface elements of the drug delivery device 200 that touch the planar surface when the drug delivery device 200 without the cap 209 is rolled over the planar surface. For the drug delivery device 200, the contact surface has a cylindrical outer surface lacking protrusions that will inhibit rolling of the housing 210 when the housing 210 is placed on a flat surface. Due to the balancing weight 160, the drug delivery device 200 will rotate on the flat surface until it assumes a stable position and the centroid 280 is located between the surface and the longitudinal axis 207.
In the stable position, the viewing window in the housing 210 is located on an upper side of the drug delivery device 200 facing away from the surface on which the drug delivery device 200 is placed. For other embodiments of the device 200 and other placements of the balancing weight 160, the viewing window may also be located on the other side of the drug delivery device 200, e.g. on a lateral side.
Fig. 56 shows a perspective view of the balance weight 160. Which is configured as a metal part and has a higher density than the plastic parts of the dosing mechanism 230 and the inner housing 180.
The balance weight 160 is curved about a longitudinal axis 207 of the drug delivery device 200. Which is symmetrical about its central plane oriented perpendicular to the longitudinal axis 207.
The balance weight 160 has a first projection 163 at one longitudinal end surface and a second projection 165 at the opposite longitudinal end surface. When inserted into the abutment 170, one of the projections 163, 165 (e.g., the first projection 163 as shown in fig. 56) is placed between the first longitudinal stop elements 171 as a proximal projection. Two front faces 164 of the balancing weight 160 extending radially from the proximal projection and retracting along the longitudinal axis 207 with respect to the proximal projection are configured to abut against the first longitudinal stop element 171. The other of the projections 163, 165 (e.g., the second projection 165 shown in fig. 56) is then configured to abut the second longitudinal stop element 173 as a distal projection. The width of the balance weight 160 perpendicular to the longitudinal axis 207 is adapted to allow the balance weight 162 to be placed between the circumferential stop elements 172.
For other embodiments, the distance between the balancing weight 160 and the centroid 208 may also be less than the distance between the centroid 208 and the longitudinal axis 207, as can be seen from fig. 57, fig. 57 shows a radial cross section perpendicular to the longitudinal axis 207 through an alternative embodiment of the drug delivery device 200 with the balancing weight 160. Positioning the centroid 208 a smaller distance from the longitudinal axis 207 than the balance weight 160 allows for the use of a relatively small balance weight 160 while still displacing the centroid away from the longitudinal axis 207.
The cross-sectional views of fig. 54 and 57 only schematically depict the radial position of centroid 208. For the drug delivery device 200, the longitudinal position of the centroid 208 may not lie in the cross-sectional planes depicted in fig. 54 and 57, but in other cross-sectional planes. The longitudinal location of centroid 208 may be located distally from the longitudinal center of window 211a within outer housing 211, for example, along longitudinal axis 207, or it may be located proximally from the longitudinal center of window 211a within outer housing 211, along longitudinal axis 207.
The present disclosure also relates generally to a dose limiting mechanism 232 of the drug delivery device 10, 200, 220, 222, 225. The construction and details of these dose limiting mechanisms 232 are independent of other construction details of the drug delivery device 10, 200, 220, 222, 225, such as the friction reducing mechanism 370, 380, the maximum and/or minimum dose stop 35a, 35b, 35c, the connecting means 414, 424, 434, 444, 510, 511, 520, 530, the reset mechanism 100 or the balancing weight 160. For example, the present disclosure relates to the following embodiments:
1. a drug delivery device (10, 200, 220, 222, 225) for expelling a user settable dose, having:
a housing (3, 43, 210, 221, 223, 226),
A dose selector member (35, 310), the dose selector member (35, 310) being rotationally fixed to the housing (3, 43, 210, 221, 223, 226) and being axially movable relative to the housing (3, 43, 210, 221, 223, 226) at least during dose setting,
dosing member (330)
A dose limiting mechanism (232),
wherein the dosing member (330) is configured to rotate relative to the dose selector member (35, 310) to change the set dose,
wherein the dose limiting mechanism (232) is configured to limit discrete relative rotational positions of the dosing member (330) and the dose selector member (35, 310), which discrete relative rotational positions correspond to settable doses of the device.
2. The drug delivery device (10, 200, 220, 222, 225) according to embodiment 1,
wherein the dosing member (330) is rotationally and axially movable relative to the housing (3, 43, 210, 221, 223, 226) at least during dose setting.
3. The drug delivery device (10, 200, 220, 222, 225) according to at least one of the preceding embodiments,
wherein the axial distance (x) traveled by the dosing member (330) from its zero dose position during dose setting is proportional to the set dose.
4. The drug delivery device (10, 200, 220, 222, 225) according to at least one of the preceding embodiments,
wherein the dosing member (330) is configured to perform at least one complete rotation during dose setting.
5. The drug delivery device (10, 200, 220, 222, 225) according to at least one of the preceding embodiments,
wherein the dosing member (330) is configured to move axially with the dose selector member (35, 310) relative to the housing (3, 43, 210, 221, 223, 226) during dose setting.
6. The drug delivery device (10, 200, 220, 222, 225) according to at least one of the preceding embodiments,
wherein the dosing member (330) is threadably coupled to the housing (3, 43, 210, 221, 223, 226).
7. The drug delivery device (10, 200, 220, 222, 225) according to at least one of the preceding embodiments,
wherein the dose limiting mechanism (232) is realized by an interaction between two members of the drug delivery device (10, 200, 220, 222, 225) that rotate relative to each other during a change of a set dose.
8. The drug delivery device (10, 200, 220, 222, 225) of embodiment 7,
Wherein the two members interact by a resilient element (33 c, 33d, 292) of one of the two members, which resilient element (33 c, 33d, 292) rides over at least one rigid element (35 a, 312) of the other of the two members, such as a dose stop (35 a).
9. The drug delivery device (10, 200, 220, 222, 225) according to one of embodiments 7 and 8,
wherein the interaction is inhibited during dose delivery.
10. The drug delivery device (10, 200, 220, 222, 225) according to embodiment 9,
wherein the interaction is inhibited by preventing relative rotation of the two members during dose delivery.
11. The drug delivery device (10, 200, 220, 222, 225) according to at least one of the preceding embodiments,
comprising a dose setting member (31, 290) actuatable by a user to set a dose,
wherein the dose limiting mechanism (232) acts between the dose setting member (31, 290) and the dose selector member (35, 310).
12. The drug delivery device (10, 200, 220, 222, 225) of embodiment 11,
wherein the dose setting member (31, 290) is configured to move axially with the dose selector member (35, 310) during dose setting.
13. The drug delivery device (10, 200, 220, 222, 225) according to at least one of embodiments 11 and 12,
wherein the dose setting member (31, 290) is rotationally locked with respect to the dose selector member (35, 310) during dose delivery.
14. The drug delivery device (10, 200, 220, 222, 225) according to at least one of embodiments 11 to 13,
wherein the dose setting member (31, 290) is axially movable with respect to the dose selector member (35, 310).
15. The drug delivery device (10, 200, 220, 222, 225) according to at least one of embodiments 11 to 14,
wherein the dose limiting mechanism (232) is realized by direct engagement of the dose setting member (31, 290) or a part permanently fixed to the dose setting member (31, 290) with the dose selector member (35, 310) or a part permanently fixed to the dose selector member (35, 310).
16. The drug delivery device (10, 200, 220, 222, 225) according to at least one of the preceding embodiments,
wherein the dose limiting mechanism (232) comprises at least one resilient element (33 c, 33d, 292) which engages with a functional feature (35 a, 312) such as a dose stop,
Wherein a circumferential position of the functional feature (35 a, 312) around the longitudinal axis (207) of the drug delivery device (10, 200, 220, 222, 225) defines a rotational position of the dosing member (330), which corresponds to the settable dose.
17. The drug delivery device (10, 200, 220, 222, 225) according to embodiment 16, wherein the functional features (35 a, 312) are located directly adjacent to each other.
18. The drug delivery device (10, 200, 220, 222, 225) according to at least one of the preceding embodiments,
wherein the drug delivery device (10, 200, 220, 222, 225) comprises a coupler mechanism rotationally coupling the dose selector member (35, 310) and/or a nut of the drug delivery device (10, 200, 220, 222, 225) to the housing (3, 43, 210, 221, 223, 226) during dose delivery.
19. The drug delivery device (10, 200, 220, 222, 225) according to embodiment 18 and at least one of embodiments 16 and 17,
wherein the coupler mechanism includes a functional feature (35 a, 312).
20. The drug delivery device (10, 200, 220, 222, 225) of embodiment 19,
wherein the coupler mechanism comprises at least one coupler element (294), the coupler element (294) being configured to engage with a functional feature (35 a, 312) to rotationally couple the dose selector member (35, 310) and/or the nut to the housing (3, 43, 210, 221, 223, 226) during dose delivery,
Wherein the coupler element (294) is arranged separately from the elastic element (33 c, 33d, 292).
21. The drug delivery device (10, 200, 220, 222, 225) of embodiment 20,
wherein the coupler element (294) is positioned co-linear with the resilient element (33 c, 33d, 292) in a longitudinal direction parallel to the longitudinal axis (207) of the drug delivery device (10, 200, 220, 222, 225).
22. The drug delivery device (10, 200, 220, 222, 225) according to at least one of the embodiments 16 to 21,
wherein the coupler element (294) and/or the functional feature (35 a, 312) and/or the resilient element (33 c, 33d, 292) have angled flat side surfaces for interengagement.
23. The drug delivery device (10, 200, 220, 222, 225) according to at least one of the preceding embodiments,
wherein the dose limiting mechanism (232) defines equidistant rotational dose positions.
24. The drug delivery device (10, 200, 220, 222, 225) according to at least one of the preceding embodiments,
wherein the dose selector member (35, 310) surrounds the dosing member (330).
25. The drug delivery device (10, 200, 220, 222, 225) according to at least one of the preceding embodiments,
Wherein the rotating part of the drug delivery device (10, 200, 220, 222, 225) is not accessible to a user of the drug delivery device (10, 200, 220, 222, 225) during dose delivery.
The present disclosure also relates generally to the connection means 414, 424, 434, 444, 510, 511, 520, 530 of the drug delivery device 10, 200, 220, 222, 225 and/or the dispensing unit 410, 420, 430, 440. The construction and details of these connection means 414, 424, 434, 444, 510, 511, 520, 530 are independent of other construction details of the drug delivery device 10, 200, 220, 222, 225, such as the friction reducing mechanism 370, 380, the maximum and/or minimum dose stop 35a, 35b, 35c, the reset mechanism 100 or the balancing weight 160. For example, the present disclosure relates to the following embodiments:
1. a kit of two or more drug delivery devices (10, 200, 220, 222, 225), comprising:
a first drug delivery device (10, 200, 220, 222, 225), the first drug delivery device (10, 200, 220, 222, 225) having a proximal end comprising a first keyed connection means (510, 511, 520, 530);
a second drug delivery device (10, 200, 220, 222, 225), the second drug delivery device (10, 200, 220, 222, 225) having a proximal end comprising a second keyed connection means (510, 511, 520, 530);
Wherein a first keyed connection means (510, 511, 520, 530) of the first drug delivery device (10, 200, 220, 222, 225) is configured to engage and form a connection with a first keyed connection means (414, 424, 434, 444) of the first dispensing unit (410, 420, 430, 440), and a second keyed connection means (510, 511, 520, 530) of the second drug delivery device (10, 200, 220, 222, 225) is configured to engage and form a connection with a second keyed connection means (414, 424, 434, 444) of a second dispensing unit (410, 420, 430, 440) different from the first dispensing unit (410, 420, 430, 440), and
wherein the first keyed connection means (510, 511, 520, 530) of the first drug delivery device (10, 200, 220, 222, 225) is configured to not form a connection with the second keyed connection means (414, 424, 434, 444) of the second dispensing unit (410, 420, 430, 440), and the second keyed connection means (510, 511, 520, 530) of the second drug delivery device (10, 200, 220, 222, 225) is configured to not form a connection with the first keyed connection means (414, 424, 434, 444) of the first dispensing unit (410, 420, 430, 440).
2. According to the kit of embodiment 1,
Wherein the keyed connection means (510, 511, 520, 530) of the drug delivery device (10, 200, 220, 222, 225) each comprise, e.g. consist of, a thread form.
3. According to the kit of embodiment 2,
wherein the keyed connection means (510, 511, 520, 530) of the drug delivery device (10, 200, 220, 222, 225) each comprise a male thread form.
4. The kit according to one of embodiments 2 and 3,
wherein the thread forms of the keyed connection means (510, 511, 520, 530) of the drug delivery device (10, 200, 220, 222, 225) each have the same Core Diameter (CD) 1 、CD 2 、CD 3 )。
5. The kit according to one of embodiments 2 to 4,
wherein the threaded forms of the keyed connection means (510, 511, 520, 530) of the drug delivery device (10, 200, 220, 222, 225) each have a different outer diameter (D) 1 、D 2 、D 3 )。
6. The kit according to one of embodiments 2 to 5,
wherein the threaded forms of the keyed connection means (510, 511, 520, 530) of the drug delivery device (10, 200, 220, 222, 225) have the same handedness (of).
7. The kit according to one of embodiments 2 to 6,
wherein the thread form of the keyed connection means (510, 511, 520, 530) of the drug delivery device (10, 200, 220, 222, 225) differs in at least one thread dimension, such as an outer diameter (D 1 、D 2 、D 3 ) And/or thread width (w 1 、w 2 、w 3 ) And/or thread height (h 1 、h 2 、h 3 ) And/or pitch (P) 1 、P 2 、P 3 ) And/or Core Diameter (CD) 1 、CD 2 、CD 3 ) And/or opening angle (A) 1 、A 2 、A 3 )。
8. The kit according to one of embodiments 2 to 7,
wherein the thread forms of the keyed connection means (510, 511, 520, 530) of the drug delivery device (10, 200, 220, 222, 225) each have the same pitch (P) 1 、P 2 、P 3 )。
9. The kit according to one of embodiments 2 to 8,
wherein the thread forms of the keyed connection means (510, 511, 520, 530) of the drug delivery device (10, 200, 220, 222, 225) each have a different thread width (w) 1 、w 2 、w 3 )。
10. According to the kit of embodiment 9,
wherein the thread width (w) of the keyed connection means (520, 530) of the second drug delivery device (222, 225) 2 、w 3 ) Thread width (w) of keyed connection means (511) of a first drug delivery device (220) 1 ) Large, for example the thread width (w) of the keyed connection means (511) of the first drug delivery device (220) 1 ) Two or three times as many as possible.
11. The kit according to one of embodiments 2 to 10,
wherein the thread forms of the keyed connection means (510, 511, 520, 530) of the drug delivery device (10, 200, 220, 222, 225) each have a different thread height (h) 1 、h 2 、h 3 )。
12. According to the kit of embodiment 11,
wherein the thread height (h) of the keyed connection means (511) of the first drug delivery device (220) 1 ) Thread height (h) of keyed connection means (520, 530) of a second drug delivery device (222, 225) 2 、h 3 ) Large, for example the thread height (h) of the keyed connection means (520, 530) of the second drug delivery device (222, 225) 2 、h 3 ) Two or three times as many as possible.
13. The kit according to one of embodiments 2 to 12,
wherein the thread forms of the keyed connection means (510, 511, 520, 530) of the drug delivery device (10, 200, 220, 222, 225) each have the same opening angle (a) of an amount of e.g. 60 ° 1 、A 2 、A 3 )。
14. According to the kit of one of embodiments 1 to 13,
wherein the toggle resolutions of the drug delivery devices (10, 200, 220, 222, 225) are different or identical to each other.
15. A kit of two or more dispensing units (410, 420, 430, 440), comprising:
a first dispensing unit (410, 420, 430, 440), the first dispensing unit (410, 420, 430, 440) having a distal end comprising a first keyed connection means (414, 424, 434, 444);
a second dispensing unit (410, 420, 430, 440), the second dispensing unit (410, 420, 430, 440) having a distal end comprising a second keyed connection means (414, 424, 434, 444);
Wherein a first keyed connection means (414, 424, 434, 444) of the first dispensing unit (410, 420, 430, 440) is configured to engage and form a connection with a first keyed connection means (510, 511, 520, 530) of the first drug delivery device (10, 200, 220, 222, 225), and a second keyed connection means (414, 424, 434, 444) of the second dispensing unit (410, 420, 430, 440) is configured to engage and form a connection with a second keyed connection means (510, 511, 520, 530) of a second drug delivery device (10, 200, 220, 222, 225) different from the first drug delivery device (10, 200, 220, 222, 225), and
wherein the first keyed connection means (414, 424, 434, 444) of the first dispensing unit (410, 420, 430, 440) is configured to not form a connection with the second keyed connection means (510, 511, 520, 530) of the second drug delivery device (10, 200, 220, 222, 225), and the second keyed connection means (414, 424, 434, 444) of the second dispensing unit (410, 420, 430, 440) is configured to not form a connection with the first keyed connection means (510, 511, 520, 530) of the first drug delivery device (10, 200, 220, 222, 225).
16. The kit according to embodiment 15,
Wherein each of the dispensing units (410, 420, 430, 440) has a drug compartment (81) containing a fluid containing a drug, such as insulin or HGH.
17. The kit according to embodiment 16,
wherein the fluids in the drug compartments (81) of the dispensing units (410, 420, 430, 440) differ from each other at least in the concentration of the drug.
18. The kit according to one of embodiments 15 to 17,
wherein each of the dispensing units (410, 420, 430, 440) has an open distal end configured to allow axial movement of a piston rod (42, 240) contained within the corresponding drug delivery device (10, 200, 220, 222, 225) such that when attached to the corresponding drug delivery device (10, 200, 220, 222, 225), the piston rod (42, 240) may move beyond the distal end into the dispensing unit (410, 420, 430, 440).
19. The kit according to one of embodiments 15 to 18,
wherein the keyed connection means (414, 424, 434, 444) of the dispensing units (410, 420, 430, 440) each comprise, e.g. consist of, a thread form.
20. The kit according to embodiment 19,
wherein the keyed connection means (414, 424, 434, 444) of the dispensing units (410, 420, 430, 440) each comprise a female thread form.
21. According to one of embodiments 19 and 20,
wherein the threaded forms of the keyed connection means (414, 424, 434, 444) of the dispensing units (410, 420, 430, 440) each have the same Core Diameter (CD) 1 、CD 2 、CD 3 )。
22. According to one of embodiments 19 to 21,
wherein the threaded forms of the keyed connection means (414, 424, 434, 444) of the dispensing units (410, 420, 430, 440) each have a different outer diameter (D) 1 、D 2 、D 3 )。
23. The kit according to one of embodiments 19 to 22,
wherein the thread forms of the keyed connection means (414, 424, 434, 444) of the dispensing units (410, 420, 430, 440) have the same handedness.
24. The kit according to one of embodiments 19 to 23,
wherein the thread forms of the keyed connection means (414, 424, 434, 444) of the dispensing units (410, 420, 430, 440) each have the same pitch (P) 1 、P 2 、P 3 )。
25. According to one of embodiments 19 to 24,
wherein the thread forms of the keyed connection means (414, 424, 434, 444) of the dispensing units (410, 420, 430, 440) each have a different thread width (w) 1 、w 2 、w 3 )。
26. The kit according to embodiment 25,
wherein the thread width (w) of the keyed connection means (434, 444) of the second dispensing unit (430, 440) 2 、w 3 ) Thread width (w) of keyed connection means (424) of the first dispensing unit (420) 1 ) Large, for example, the thread width (w) of the keyed connection (424) of the first dispensing unit (420) 1 ) Two or three times as many as possible.
27. According to one of embodiments 19 to 26,
wherein the thread forms of the keyed connection means (414, 424, 434, 444) of the dispensing units (410, 420, 430, 440) each have a different thread height (h) 1 、h 2 、h 3 )。
28. The kit according to embodiment 27,
wherein the thread height (h) of the keyed connection (424) of the first dispensing unit (420) 1 ) Thread height (h) of the keyed connection means (434, 444) of the second dispensing unit (430, 440) 2 、h 3 ) Large, for example the thread height (h) of the keyed connection means (434, 444) of the second dispensing unit (430, 440) 2 、h 3 ) Two or three times as many as possible.
29. The kit according to one of embodiments 19 to 28,
wherein the thread forms of the keyed connection means (414, 424, 434, 444) of the dispensing units (410, 420, 430, 440) each have an opening angle (A1, A2, A3) of an amount of, for example, 60 °.
30. The kit according to one of embodiments 15 to 29,
wherein at least the keyed connection means (414, 424, 434, 444) of the dispensing unit (410, 420, 430, 440) is formed by injection molding.
31. A kit of at least one drug delivery device (10, 200, 220, 222, 225) from the kit according to one of the embodiments 1 to 14 and at least one dispensing unit (410, 420, 430, 440) from the kit according to one of the embodiments 15 to 30,
wherein the keyed connection means (510, 511, 520, 530) of the at least one drug delivery device (10, 200, 220, 222, 225) is configured to engage and form a connection with the connection means (414, 424, 434, 444) of the at least one dispensing unit (410, 420, 430, 440).
32. The kit according to embodiment 31,
wherein the kit comprises at least two drug delivery devices (10, 200, 220, 222, 225) from the kit according to one of the embodiments 1 to 14 and at least two dispensing units (410, 420, 430, 440) from the kit according to one of the embodiments 15 to 30,
wherein the keyed connection means (510, 511, 520, 530) of each of the drug delivery devices (10, 200, 220, 222, 225) is configured to form a connection only with the connection means (414, 424, 434, 444) of a different one of the dispensing units (410, 420, 430, 440) and not with the connection means (414, 424, 434, 444) of the other dispensing units (410, 420, 430, 440).
The present disclosure also relates generally to a cartridge holder 2, 412, 422, 432 for a dispensing unit 410, 420, 430, 440 of a drug delivery device 10, 200, 220, 222, 225. The construction and details of these cartridge holders 2, 412, 422, 432 are independent of other construction details of the drug delivery device 10, 200, 220, 222, 225, such as the friction reducing mechanism 370, 380, the maximum and/or minimum dose stop 35a, 35b, 35c, the connecting means 414, 424, 434, 444, 510, 511, 520, 530, the reset mechanism 100 or the balancing weight 160. For example, the present disclosure relates to the following embodiments:
1. a cartridge holder (2, 412, 422, 432) for a dispensing unit (410, 420, 430, 440) of a drug delivery device (10, 200, 220, 222, 225),
wherein the cartridge holder (2, 412, 422, 432) is configured for receiving a cartridge (8), the cartridge (8) comprising a drug compartment (81) filled with a drug,
wherein the cartridge holder (2, 412, 422, 432) comprises a locking element (404), which locking element (404) is configured to non-releasably, e.g. permanently, connect the cartridge to the cartridge holder (2, 412, 422, 432) during use of the dispensing unit (410, 420, 430, 440).
2. The cartridge holder (2, 412, 422, 432) according to embodiment 1,
wherein the cartridge holder (2, 412, 422, 432) comprises a biasing element (406), the biasing element (406) being configured to bias and/or push the cartridge (8) into the cartridge holder (2, 412, 422, 432) after insertion of the cartridge (8).
3. The cartridge holder (2, 412, 422, 432) of embodiment 2, wherein the biasing element (406) is configured separately from the locking element (404).
4. The cartridge holder (2, 412, 422, 432) according to embodiment 3,
wherein the biasing element (406) and the locking element (404) are located at opposite sides of the cartridge holder (2, 412, 422, 432).
5. The cartridge holder (2, 412, 422, 432) according to at least one of embodiments 3 and 4,
wherein the biasing element (406) and the locking element (404) are located at the same longitudinal position of the cartridge holder (2, 412, 422, 432).
6. The cartridge holder (2, 412, 422, 432) according to at least one of embodiments 3 to 5,
wherein both the locking element (404) and the biasing element (406) are configured to act on the same surface (83) of the cartridge (8).
7. The cartridge holder (2, 412, 422, 432) according to at least one of embodiments 2 to 6,
wherein the biasing element (406) is located in a proximal portion of the cartridge holder (2, 412, 422, 432), such as a proximal half, a proximal third or a proximal quarter of the cartridge holder (2, 412, 422, 432).
8. The cartridge holder (2, 412, 422, 432) according to at least one of embodiments 2 to 7,
wherein the biasing element (406) protrudes radially into the cartridge cavity (413) of the cartridge holder (2, 412, 422, 432).
9. The cartridge holder (2, 412, 422, 432) according to at least one of embodiments 2 to 8,
wherein the biasing element (406) is configured to bend radially away from the longitudinal axis (207) of the cartridge holder (2, 412, 422, 432) and away from the cartridge (8) when attempting to remove the cartridge (8) from the cartridge holder (412).
10. The cartridge holder (2, 412, 422, 432) according to at least one of embodiments 2 to 9,
wherein the biasing element (406) is configured to engage with a distal surface (83) of the cartridge (8) facing away from the needle end of the cartridge holder (2, 412, 422, 432) after insertion of the cartridge (8).
11. The cartridge holder (2, 412, 422, 432) according to at least one of embodiments 2 to 10,
wherein the biasing element (406) is configured to engage with the annular rim (82) of the cartridge (8).
12. The cartridge holder (2, 412, 422, 432) according to at least one of embodiments 2 to 11,
wherein the biasing element (406) is configured to permanently contact the cartridge (8) after insertion of the cartridge (8) into the cartridge holder (2, 412, 422, 432).
13. The cartridge holder (2, 412, 422, 432) according to at least one of embodiments 2 to 12,
wherein the biasing element (406) is configured to bias the cartridge (8) against a stop (408), the stop (408) being configured to prevent proximal movement of the cartridge (8).
14. The cartridge holder (2, 412, 422, 432) according to at least one of embodiments 2 to 13,
wherein the biasing element (406) is configured to clamp the cartridge (8) between the stopper (408) and the biasing element (406) such that both the stopper (408) and the biasing element (406) rest on the cartridge (8) at the same time.
15. The cartridge holder (2, 412, 422, 432) according to at least one of embodiments 13 and 14,
Wherein the stopper (408) is located at the needle end of the cartridge holder (2, 412, 422, 432).
16. The cartridge holder (2, 412, 422, 432) according to at least one of embodiments 2 to 15,
wherein the biasing element (406) is configured to bias the cartridge (8) away from the contact surface (405) of the locking element (404).
17. The cartridge holder (2, 412, 422, 432) according to at least one of embodiments 2 to 16,
wherein the biasing element (406) is configured as an integral part of the cartridge holder (2, 412, 422, 432).
18. The cartridge holder (2, 412, 422, 432) of embodiment 17,
wherein the biasing element (406) is configured as a cut-out portion of the cartridge holder (2, 412, 422, 432).
19. The cartridge holder (2, 412, 422, 432) according to at least one of the preceding embodiments,
wherein the locking element (404) is configured to deflect towards the longitudinal axis (207) of the cartridge holder (2, 412, 422, 432) when the cartridge (8) is engaged with the locking element (404) when attempting to remove the cartridge (8) from the cartridge holder (412).
20. The cartridge holder (2, 412, 422, 432) according to at least one of the preceding embodiments,
Wherein the locking element (404) comprises a contact surface (405), the contact surface (405) being configured to engage with the cartridge (8) to prevent removal of the cartridge (8) from the cartridge holder (2, 412, 422, 432).
21. The cartridge holder (2, 412, 422, 432) of embodiment 20,
wherein the contact surface (405) is angled with respect to a longitudinal axis (207) of the cartridge holder (2, 412, 422, 432) and faces towards a proximal end of the cartridge holder (2, 412, 422, 432).
22. The cartridge holder (2, 412, 422, 432) according to at least one of embodiments 19 and 21,
wherein the contact surface (405) is oriented perpendicular to the longitudinal axis (207) of the cartridge holder (2, 412, 422, 432).
23. The cartridge holder (2, 412, 422, 432) according to at least one of embodiments 19 to 22,
wherein the contact surface (405) is located away from the cartridge (8) after full insertion of the cartridge (8) into the cartridge holder (2, 412, 422, 432).
24. The cartridge holder (2, 412, 422, 432) according to at least one of the preceding embodiments,
wherein the locking element (404) is configured to engage with a distal surface (83) of the cartridge (8) facing away from the needle end of the cartridge holder (2, 412, 422, 432) after insertion.
25. The cartridge holder (2, 412, 422, 432) according to at least one of the preceding embodiments,
wherein the locking element (404) is configured to engage with the annular rim (82) of the cartridge (8).
26. The cartridge holder (2, 412, 422, 432) according to at least one of the preceding embodiments,
wherein the locking element (404) is designed as a snap-fit connection, for example as a snap-hook.
27. The cartridge holder (2, 412, 422, 432) according to at least one of the preceding embodiments,
wherein the locking element (404) is configured as an integral part of the cartridge holder (2, 412, 422, 432).
28. The cartridge holder (2, 412, 422, 432) of embodiment 27,
wherein the locking element (404) is configured as a cut-out portion of the cartridge holder (2, 412, 422, 432).
29. The cartridge holder (2, 412, 422, 432) according to at least one of the preceding embodiments,
wherein the locking element (404) is located in a proximal portion of the cartridge holder (2, 412, 422, 432), such as a proximal half, a proximal third or a proximal quarter of the cartridge holder (2, 412, 422, 432).
30. The cartridge holder (2, 412, 422, 432) according to at least one of the preceding embodiments,
wherein the locking element (404) protrudes radially into the cartridge cavity (413) of the cartridge holder (2, 412, 422, 432).
31. The cartridge holder (2, 412, 422, 432) according to at least one of the preceding embodiments,
wherein the cartridge holder (2, 412, 422, 432) comprises connection means (414, 424, 434, 444), which connection means (414, 424, 434, 444) are configured to be connected to corresponding connection means (510, 511, 520, 530) of the drug delivery device (10, 200, 220, 222, 225) for detachably connecting the cartridge holder (2, 412, 422, 432) with the drug delivery device (10, 200, 220, 222, 225).
32. A kit of at least a first cartridge holder (2, 412, 422, 432) according to embodiment 31 and at least a second cartridge holder (2, 412, 422, 432) according to embodiment 31,
wherein the connection means (414, 424, 434, 444) of the first and second cartridge holder (2, 412, 422, 432) are configured as keyed connection means,
wherein the connection means (414, 424, 434, 444) of the first cartridge holder (2, 412, 422, 432) is configured to engage and form a connection with the connection means (510, 511, 520, 530) of the first drug delivery device (10, 200, 220, 222, 225), and the connection means (414, 424, 434, 444) of the second cartridge holder (2, 412, 422, 432) is configured to engage and form a connection with the connection means (510, 511, 520, 530) of a second drug delivery device (10, 200, 220, 222, 225) different from the first drug delivery device (10, 200, 220, 222, 225), and
Wherein the connection means (414, 424, 434, 444) of the first cartridge holder (2, 412, 422, 432) is configured to not form a connection with the connection means (510, 511, 520, 530) of the second drug delivery device (10, 200, 220, 222, 225), and the connection means (414, 424, 434, 444) of the second cartridge holder (2, 412, 422, 432) is configured to not form a connection with the connection means (510, 511, 520, 530) of the first drug delivery device (10, 200, 220, 222, 225).
33. A kit of a cartridge holder (2, 412, 422, 432) according to at least one of the preceding embodiments with a cartridge (8) containing a medicament,
wherein a cartridge (8) is inserted into a cartridge holder (2, 412, 422, 432) and is non-releasably held within the cartridge holder.
The present disclosure also relates to the following embodiments of the drug delivery device:
1. a drug delivery device (10, 200, 220, 222, 225), such as an injection device, e.g. a pen-type injector, has an elongated, e.g. substantially cylindrical, housing (3, 43, 210, 221, 223, 226) extending along a longitudinal axis (207) between a distal end (206) and a proximal end (205),
wherein the drug delivery device (10, 200, 220, 222, 225) comprises a balancing weight (160) within the housing (3, 43, 210, 221, 223, 226),
Wherein a centroid (208) of the drug delivery device (10, 200, 220, 222, 225) is positioned radially offset from the longitudinal axis (207) towards the balance weight (160) in a radial direction.
2. The drug delivery device (10, 200, 220, 222, 225) according to embodiment 1,
wherein the drug delivery device (10, 200, 220, 222, 225) comprises a piston rod (42, 240), the piston rod (42, 240) being configured to move longitudinally along the longitudinal axis (207) to expel a drug to be delivered from a drug compartment (81) connected to the housing (3, 43, 210, 221, 223, 226).
3. The drug delivery device (10, 200, 220, 222, 225) according to one of the preceding embodiments,
wherein the centroid (208) is located between the balance weight (160) and the longitudinal axis (207).
4. The drug delivery device (10, 200, 220, 222, 225) according to one of the preceding embodiments,
wherein a distance between a radial position of the balance weight (160) and a radial position of the centroid (208) is greater than a distance between a radial position of the centroid (208) and the longitudinal axis (207).
5. The drug delivery device (10, 200, 220, 222, 225) according to one of the preceding embodiments,
Wherein the balance weight (160) and the housing (3, 43, 210, 221, 223, 226) are located at different angular positions, e.g. at angular positions 180 ° apart, relative to the longitudinal axis (207) for showing windows (3 a, 180a, 211 a) indicative of the optical indicia (40, 331) of the set dose.
6. The drug delivery device (10, 200, 220, 222, 225) according to one of the preceding embodiments,
wherein the balancing weight (160) is configured as a separate component of the drug delivery device (10, 200, 220, 222, 225).
7. The drug delivery device (10, 200, 220, 222, 225) according to one of the preceding embodiments,
wherein the balance weight (160) is made of metal.
8. The drug delivery device (10, 200, 220, 222, 225) according to one of the preceding embodiments,
wherein the material of the balancing weight (160) has a higher density than the material of most components of the dosing mechanism (230) of the drug delivery device (10, 200, 220, 222, 225).
9. The drug delivery device (10, 200, 220, 222, 225) according to one of the preceding embodiments,
wherein the balancing weight (160) is located at an inner surface of a shell of the housing (3, 43, 210, 221, 223, 226) of the drug delivery device (10, 200, 220, 222, 225).
10. The drug delivery device (10, 200, 220, 222, 225) according to one of the preceding embodiments,
wherein the balancing weight (160) is configured to be separated from a component of a dosing mechanism (30, 230) of the drug delivery device (10, 200, 220, 222, 225).
11. The drug delivery device (10, 200, 220, 222, 225) of embodiment 10,
wherein the balancing weight (160) is located between the housing (3, 43, 210, 221, 223, 226) and the dosing mechanism (30, 230).
12. The drug delivery device (10, 200, 220, 222, 225) according to one of the preceding embodiments,
wherein the housing (3, 43, 210, 221, 223, 226) comprises an outer housing (3, 211),
wherein the drug delivery device (10, 200, 220, 222, 225) comprises an inner housing (180),
wherein the inner housing (180) is permanently rotationally and/or axially fixed relative to the outer housing (3, 211),
wherein the balance weight (160) is located between the outer housing (3, 211) and the inner housing (180).
13. The drug delivery device (10, 200, 220, 222, 225) according to embodiment 12,
wherein the balance weight (160) rests on an outer surface (199) of the inner housing (180).
14. The drug delivery device (10, 200, 220, 222, 225) according to one of the preceding embodiments,
wherein the balancing weight (160) is axially and/or rotationally fixed relative to the housing (3, 43, 210, 221, 223, 226).
15. The drug delivery device (10, 200, 220, 222, 225) according to embodiment 14,
wherein the balancing weight (160) is received in a support (170), the support (170) being configured to axially and/or rotationally fix the balancing weight (160) relative to the housing (3, 43, 210, 221, 223, 226).
16. The drug delivery device (10, 200, 220, 222, 225) of embodiment 15,
wherein the abutment (170) comprises a longitudinal stop element (171, 173), the longitudinal stop element (171, 173) preventing the balance weight (160) from moving along the longitudinal axis (207).
17. The drug delivery device (10, 200, 220, 222, 225) according to one of embodiments 15 and 16,
wherein the abutment (170) comprises a circumferential stop element (172), the circumferential stop element (172) preventing the balancing weight (160) from moving about the longitudinal axis (207).
18. The drug delivery device (10, 200, 220, 222, 225) according to one of embodiments 15 to 17,
Wherein the stop element (171, 172, 173) is configured as a projection on a surface (199) within the housing (3, 43, 210, 221, 223, 226).
19. The drug delivery device (10, 200, 220, 222, 225) according to one of embodiments 15 to 18 and embodiment 13,
wherein the support (170) is disposed at the outer surface (199) of the inner housing (180).
20. The drug delivery device (10, 200, 220, 222, 225) according to one of embodiments 15 to 19,
wherein the housing (3, 43, 210, 221, 223, 226), such as an outer housing (211) of the housing (3, 43, 210, 221, 223, 226), is configured to cover the abutment (170) in a radial direction perpendicular to the longitudinal axis (207) to prevent radial movement of the balance weight (160).
21. The drug delivery device (10, 200, 220, 222, 225) according to one of the preceding embodiments,
wherein the balancing weight (160) has a bottom surface (161), e.g. a curved and/or concave bottom surface,
wherein the bottom surface (161) faces radially towards the longitudinal axis (207),
wherein the bottom surface (161) is formed complementary to a surface of one or more components of the drug delivery device (10, 200, 220, 222, 225) located between the longitudinal axis (207) and the balancing weight (160).
22. The drug delivery device (10, 200, 220, 222, 225) according to one of the preceding embodiments,
wherein the balancing weight (160) has a top surface (162), such as a curved and/or convex top surface,
wherein the top surface (162) faces radially away from the longitudinal axis (207),
wherein the top surface (162) is formed complementary to one or more inner surfaces of the housing (3, 43, 210, 221, 223, 226) of the drug delivery device (10, 200, 220, 222, 225).
23. The drug delivery device (10, 200, 220, 222, 225) according to one of the preceding embodiments,
wherein the shape of the balancing weight (160) is symmetrical with respect to a central plane passing through the balancing weight (160), the central plane being oriented perpendicular to the longitudinal axis (207).
List of reference numerals
1. Cap with cap
2. Cartridge holder
3. Outer housing
3a window
4. Needle
5. Hub
6. Cannula tube
8. Cartridge cartridge
8a sealing device
9. Piston
10. Other drug delivery devices
30. Quantitative dosing mechanism
31. Dose setting member
32. Coupling member
32. Ridge
33. Buckle element
33a coupler element
33c flexible arm
33d projection
33f other projections
34. Connector with a plurality of connectors
34a coupler element
34b ridge
35. Dose selector member
35a dose stop
35b maximum stop feature
35c minimum stop feature
36. Nut
37. Spline connection
38. Dosage sleeve
40. Optical marking
41. Driver(s)
42. Piston rod
42a disc
43. Piston guide
60. External screw thread
61. Dose button
67. Screw thread
63. Stop feature
64. Projection part
81. Medicament compartment
82. Annular edge
83. Distal surface
85. Annular pawl
90. Rotary biasing member
100. Reset mechanism
110. Reset element
111. Gripping zone
112 receiving area
113. Inner surface
114. An opening
115. Cartridge cavity
116. Guide structure
116a front surface
116b rear surface
117 contact structure
119. Stop piece
120 engagement features
130 coupling portion/insert
134 coupling portion
135. Engagement features
136 notch
137. First locking structure
138. Projection part
139. Slot groove
139a recess
140. Second locking structure
150. Biasing element
160. Balance weight
161. Bottom surface
162. Top surface
163. Proximal protruding portion
164. Front face
165. Distal projection
170. Support seat
171. Longitudinal stop element
172. Circumferential stop element
173. Longitudinal stop element
175. Support surface
180. Inner housing
180a window
181. Proximal portion
182. Distal portion
183. Inner sleeve
184 tappet
185. Dose thread
186. Drive screw
187. Groove
188. Other grooves
189. Shell cavity
190. Maximum stop feature
191. Hook
192. Limiting surface
193. Concave part
194. Projection part
195 projection
196 zero stop feature
197 zero stop surface
198. Longitudinal slot
199. Outer surface
200. Drug delivery device
205. Proximal end
206. Distal end
207. Longitudinal axis
208. Centroid of mass
209. Cap with cap
210. Shell body
211. Outer housing
211a window
213. Collar ring
214 pawl
216 pawl
218. Groove
220. First drug delivery device
221. First shell body
222. Second drug delivery device
223. Second shell
225. Third drug delivery device
226. Third shell
230. Quantitative dosing mechanism
232. Dose limiting mechanism
234. Coupling mechanism
235. First part
236. Second part
237. Coupling mechanism
238. First part
239. Second part
240. Piston rod
241. Screw thread
242. Plunger disc
243. Stop feature
244-disc connector
250. Nut
251. Proximal portion
252. Distal portion
253. Proximal protruding portion
254. Longitudinal groove
255. Annular pawl
256. Screw thread
270. Coupling member
271. Longitudinal ridges
273. Coupling element
274. Proximal portion
275. Distal portion
277. Connection
278. Buckle hook
279. First ridge
280. Second ridge
290. Dose setting member
292. Elastic element
294. Coupling element
295. Concave part
296. An opening
297. First longitudinal groove
298. Second longitudinal groove
308. Biasing member
310. Dose selector member
311. Distal portion
312. Functional features
314 contact surface
315. Ridge
316. Other ridges
317. Proximal portion
318. Connector with a plurality of connectors
319. Flexible component
319a projection
320 pawl
322. Inner wall
323. An opening
330. Dosing member
331. Optical marking
332. Proximal portion
333. Distal portion
334. Threaded connection
335. External screw thread
336. Coupling element
337. Maximum dose stop
338. Stop surface
340 zero dose stop
341. Groove
343. Connector with a plurality of connectors
344. Annular ridge
346. Distal end surface
350. Driver(s)
351. Proximal portion
352. Threaded connection
353. Screw thread
354. Connection
356. Flexible arm
358. Front surface
359. Distal portion
360. Spline
370. First bearing element
371. Distal disc
372 keeper
373. Proximal disc
375. Ball bearing
380. Second bearing element
402 pin connector
404. Connector with a plurality of connectors
405. Contact surface
406. Biasing element
407 contact surface
408. Stop piece
409. Ridge
410 dispensing unit
412. Cartridge holder
413. Cartridge cavity
414. Connecting device
420. First dispensing unit
422. First cartridge holder
424. First connecting device
430. Second dispensing unit
432. Second cartridge holder
434. Second connecting device
440. Third dispensing unit
442. Third cartridge holder
444. Third connecting device
450 contact features
501. Ridge
502 cereal
510. Connecting device
511. First connecting device
520. Second connecting device
530. Third connecting device
P 1 First pitch of
w 1 First width of
h 1 First height of
CD 1 First core diameter
D 1 First outer diameter
A 1 First angle of
P 2 Second pitch of
w 2 Second width of
h 2 Second height
CD 2 Second core diameter
D 2 Second outer diameter
A 2 Second angle
P 3 Third pitch of
w 3 Third width
h 3 Third height
CD 3 Third core diameter
D 3 Third outer diameter
A 3 And a third angle.
Claims (24)
1. A drug delivery device (10, 200, 220, 222, 225) having an elongated housing (3, 43, 210, 221, 223, 226) extending along a longitudinal axis (207) between a distal end (206) and a proximal end (205), such as a generally cylindrical housing (3, 43, 210, 221, 223, 226),
wherein the drug delivery device (10, 200, 220, 222, 225) comprises a balancing weight (160) within the housing (3, 43, 210, 221, 223, 226),
wherein a centroid (208) of the drug delivery device (10, 200, 220, 222, 225) is positioned radially offset in a radial direction from the longitudinal axis (207) towards the balance weight (160).
2. The drug delivery device (10, 200, 220, 222, 225) according to claim 1,
wherein the centroid (208) is located between the balance weight (160) and the longitudinal axis (207).
3. Drug delivery device (10, 200, 220, 222, 225) according to one of the preceding claims,
wherein a distance between a radial position of the balance weight (160) and a radial position of the centroid (208) is greater than a distance between a radial position of the centroid (208) and the longitudinal axis (207).
4. Drug delivery device (10, 200, 220, 222, 225) according to one of the preceding claims,
wherein the balance weight (160) and the window (3 a, 211 a) of the housing (3, 43, 210, 221, 223, 226) for showing the optical marker (40, 331) indicative of the set dose are located at different angular positions relative to the longitudinal axis (207), for example at angular positions differing by 180 °.
5. Drug delivery device (10, 200, 220, 222, 225) according to one of the preceding claims,
wherein the material of the balancing weight (160) has a higher density than the material of most components of the dosing mechanism (230) of the drug delivery device (10, 200, 220, 222, 225).
6. Drug delivery device (10, 200, 220, 222, 225) according to one of the preceding claims,
wherein the balancing weight (160) is located at an inner surface of a shell of the housing (3, 43, 210, 221, 223, 226) of the drug delivery device (10, 200, 220, 222, 225).
7. Drug delivery device (10, 200, 220, 222, 225) according to one of the preceding claims,
wherein the balancing weight (160) is configured to be separated from a component of a dosing mechanism (30, 230) of the drug delivery device (10, 200, 220, 222, 225).
8. The drug delivery device (10, 200, 220, 222, 225) according to claim 7,
wherein the balancing weight (160) is located between the housing (3, 43, 210, 221, 223, 226) and the dosing mechanism (30, 230).
9. Drug delivery device (10, 200, 220, 222, 225) according to one of the claims 7 and 8,
wherein the balance weight (160) is located radially outward of the dosing mechanism (30, 230).
10. Drug delivery device (10, 200, 220, 222, 225) according to one of the preceding claims,
wherein the housing (3, 43, 210, 221, 223, 226) comprises an outer housing (3, 211),
Wherein the drug delivery device (10, 200, 220, 222, 225) comprises an inner housing (180),
wherein the inner housing (180) is permanently rotationally and/or axially fixed relative to the outer housing (3, 211),
wherein the balance weight (160) is located between the outer housing (3, 211) and the inner housing (180).
11. The drug delivery device (10, 200, 220, 222, 225) according to claim 10,
wherein the balance weight (160) rests on an outer surface (199) of the inner housing (180).
12. Drug delivery device (10, 200, 220, 222, 225) according to one of the preceding claims,
wherein the balancing weight (160) is axially and/or rotationally fixed relative to the housing (3, 43, 210, 221, 223, 226).
13. The drug delivery device (10, 200, 220, 222, 225) according to claim 12,
wherein the balancing weight (160) is received in a mount (170) configured to axially and/or rotationally fix the balancing weight (160) relative to the housing (3, 43, 210, 221, 223, 226).
14. The drug delivery device (10, 200, 220, 222, 225) according to claim 13,
Wherein the abutment (170) comprises a longitudinal stop element (171, 173) preventing movement of the balancing weight (160) along the longitudinal axis (207).
15. Drug delivery device (10, 200, 220, 222, 225) according to one of the claims 13 and 14,
wherein the abutment (170) comprises a circumferential stop element (172) preventing the balancing weight (160) from moving about the longitudinal axis (207).
16. Drug delivery device (10, 200, 220, 222, 225) according to one of the claims 14 and 15,
wherein the stop element (171, 172, 173) is configured as a protrusion on a surface (199) of the drug delivery device (10, 200, 220, 222, 225).
17. Drug delivery device (10, 200, 220, 222, 225) according to one of the claims 13 to 16, according to claim 10 or 11,
wherein the support (170) is disposed at an outer surface (199) of the inner housing (180).
18. Drug delivery device (10, 200, 220, 222, 225) according to one of the claims 13 to 17,
wherein the housing (3, 43, 210, 221, 223, 226), for example an outer housing (211) of the housing (3, 43, 210, 221, 223, 226), is configured to cover the abutment (170) in a radial direction perpendicular to the longitudinal axis (207) to prevent radial movement of the balance weight (160).
19. Drug delivery device (10, 200, 220, 222, 225) according to one of the preceding claims,
wherein the balancing weight (160) has a bottom surface (161), for example a curved and/or concave bottom surface,
wherein the bottom surface (161) faces radially towards the longitudinal axis (207),
wherein the bottom surface (161) is formed complementary to a surface of one or more components of the drug delivery device (10, 200, 220, 222, 225) located between the longitudinal axis (207) and the balancing weight (160).
20. Drug delivery device (10, 200, 220, 222, 225) according to one of the preceding claims,
wherein the balancing weight (160) has a top surface (162), e.g. a curved and/or convex top surface,
wherein the top surface (162) faces radially away from the longitudinal axis (207),
wherein the top surface (162) is formed complementary to one or more inner surfaces of the housing (3, 43, 210, 221, 223, 226) of the drug delivery device (10, 200, 220, 222, 225).
21. Drug delivery device (10, 200, 220, 222, 225) according to one of the preceding claims,
Wherein the drug delivery device (10, 200, 220, 222, 225) comprises a piston rod (42, 240) configured to move along the longitudinal axis (207) to expel a drug from a drug compartment (81) connected to the housing (3, 43, 210, 221, 223, 226).
22. Drug delivery device (10, 200, 220, 222, 225) according to one of the preceding claims,
wherein the shape of the balancing weight (160) is symmetrical with respect to a central plane passing through the balancing weight (160), the central plane being oriented perpendicular to the longitudinal axis (207).
23. Drug delivery device (10, 200, 220, 222, 225) according to one of the preceding claims,
wherein the drug delivery device (10, 200, 220, 222, 225) is an injection device.
24. Drug delivery device (10, 200, 220, 222, 225) according to one of the preceding claims,
wherein the balance weight (160) is made of metal.
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21167293.6 | 2021-04-07 | ||
| EP21181883.6 | 2021-06-25 | ||
| EP21181887.7 | 2021-06-25 | ||
| EP21184545.8 | 2021-07-08 | ||
| US17/472554 | 2021-09-10 | ||
| US17/472,561 US20220323685A1 (en) | 2021-04-07 | 2021-09-10 | Drug delivery device |
| US17/472561 | 2021-09-10 | ||
| US17/472550 | 2021-09-10 | ||
| US17/472546 | 2021-09-10 | ||
| EP21202384.0 | 2021-10-13 | ||
| PCT/EP2022/059332 WO2022214624A1 (en) | 2021-04-07 | 2022-04-07 | Drug delivery device with balancing weight |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117500543A true CN117500543A (en) | 2024-02-02 |
Family
ID=89525239
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280041046.0A Pending CN117425509A (en) | 2021-04-07 | 2022-04-07 | Drug delivery device |
| CN202280041054.5A Pending CN117425511A (en) | 2021-04-07 | 2022-04-07 | Drug delivery device with keyed connector |
| CN202280041045.6A Pending CN117460551A (en) | 2021-04-07 | 2022-04-07 | Drug delivery device |
| CN202280041055.XA Pending CN117500543A (en) | 2021-04-07 | 2022-04-07 | Drug delivery device with balancing weights |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280041046.0A Pending CN117425509A (en) | 2021-04-07 | 2022-04-07 | Drug delivery device |
| CN202280041054.5A Pending CN117425511A (en) | 2021-04-07 | 2022-04-07 | Drug delivery device with keyed connector |
| CN202280041045.6A Pending CN117460551A (en) | 2021-04-07 | 2022-04-07 | Drug delivery device |
Country Status (1)
| Country | Link |
|---|---|
| CN (4) | CN117425509A (en) |
-
2022
- 2022-04-07 CN CN202280041046.0A patent/CN117425509A/en active Pending
- 2022-04-07 CN CN202280041054.5A patent/CN117425511A/en active Pending
- 2022-04-07 CN CN202280041045.6A patent/CN117460551A/en active Pending
- 2022-04-07 CN CN202280041055.XA patent/CN117500543A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117425509A (en) | 2024-01-19 |
| CN117460551A (en) | 2024-01-26 |
| CN117425511A (en) | 2024-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101551210B1 (en) | Medication delivery device | |
| US9238106B2 (en) | Dose setting mechanism for priming a drug delivery device | |
| KR101558197B1 (en) | Medication delivery device | |
| US8585656B2 (en) | Dose setting mechanism for priming a drug delivery device | |
| RU2382656C2 (en) | Method of assembling devices for delivery of medications | |
| EP0897728B1 (en) | Medication delivery pen | |
| JP2010503433A (en) | Injection device with a dose limiting unit that can be reset automatically | |
| CN117500543A (en) | Drug delivery device with balancing weights | |
| EP4070829A1 (en) | Drug delivery device with balancing weight | |
| US20240189518A1 (en) | Drug delivery device with balancing weight | |
| US11872379B2 (en) | Drug delivery device | |
| CN117425510A (en) | Drug delivery device | |
| JP7349443B2 (en) | Drive mechanism for injection device | |
| WO2024218114A1 (en) | Mechanism for an automatic medicament delivery device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |